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Abstract
It is a generally accepted paradigm that there is a direct link between inflammation and tumor progression.
During inflammation, there is increased formation of lipid hydroperoxides, mediated either non-
enzymatically by reactive oxygen species or enzymatically by lipoxygenases (LOs) or cyclooxygenases
(COXs). Lipid hydroperoxides undergo further oxidation into oxo-eicosatetraenoic acids (oxo-ETEs), which
are produced and released by cells including macrophages and epithelial cells. Therefore, these oxo-ETEs
could potentially mediate biological effects in an autocrine and/or a paracrine manner. In addition, oxo-ETEs
conjugate intracellular glutathione (GSH) to form adducts which could serve as biomarkers of oxo-ETE
formation.
In this study, a targeted lipidomics approach combined with stable isotope dilution methodology was
employed to identify and quantify lipid hydroperoxides and their metabolites formed in 15-LO-expressing
mouse macrophage cell line (R15L cells) and COX-2 expressing cell models (RIES cells and Caco-2 cells) as
well as in mouse hematocytes and primary human monocytes. 15-Oxo-5,8,11,13-(Z,Z,Z,E)-ETE (15-oxo-
ETE) was identified and characterized as a major eicosanoid produced in both mouse and human macrophage
15-LO pathway. 15-Oxo-ETE was shown to be a metabolite of arachidonic acid (AA)-derived 15(S)-
hydroxyeicosatetraenoic acid (15(S)-HETE) by 15-hydroxyprostaglandin dehydrogenase (15-PGDH). A
novel biological activity of 15-oxo-ETE was revealed, which involved inhibition of human umbilical vein
endothelial cell (HUVEC) proliferation by suppressing DNA synthesis, implicating a potential anti-
angiogenic role of 15-oxo-ETE.
In addition to 15-oxo-ETE, another AA-derived eicosanoid 11-oxo-5,8,12,14-(Z,Z,E,Z)-eicosatetraenoic acid
(11-oxo-ETE), was identified as a major metabolite arising from COX-2-derived from 11(R)-
hydroxyl-5,8,12,14-(Z,Z,E,Z)-eicosatetraenoic acid (11(R)-HETE) in both rat (RIES) and human (Caco-2)
epithelial cell lines. A specific liquid chromatography-multiple reaction monitoring mass spectrometry (LC-
MRM/MS) method revealed that both 11-oxo-ETE and 15-oxo-ETE were secreted in nM concentrations
when AA was added to RIES and human Caco-2 cells. Surprisingly, 11(R)-HETE was an excellent substrate
for 15-PGDH, with a catalytic efficiency similar to that found for 15(S)-HETE. In addition, it was
demonstrated that aspirin significantly stimulated the production of 15(R)-HETE, which was then converted
to 15-oxo-ETE by an unknown dehydrogenase (DH). These findings could have significant clinical
implications since 15-PGDH is down-regulated during carcinogenesis, which in addition to increasing the
pro-proliferative activity of PGE2 would prevent the formation of anti-proliferative 15-oxo-ETE from 15(S)-
HETE. However, the formation of 15-oxo-ETE from 15(R)-HETE after aspirin treatment, through a pathway
that does not involve 15-PGDH, could help counteract the increased pro-proliferative activity of PGE2.
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ABSTRACT 
THE ROLE OF 15-LIPOXYGENASE-1- AND CYCLOOXYGENASE-2-DERIVED 
LIPID MEDIATORS IN ENDOTHELIAL CELL PROLIFERATION 
 
Cong Wei 
Ian A. Blair, Ph.D. 
Supervisor of Dissertation 
 
It is a generally accepted paradigm that there is a direct link between 
inflammation and tumor progression.  During inflammation, there is increased formation 
of lipid hydroperoxides, mediated either non-enzymatically by reactive oxygen species or 
enzymatically by lipoxygenases (LOs) or cyclooxygenases (COXs).  Lipid 
hydroperoxides undergo further oxidation into oxo-eicosatetraenoic acids (oxo-ETEs), 
which are produced and released by cells including macrophages and epithelial cells.  
Therefore, these oxo-ETEs could potentially mediate biological effects in an autocrine 
and/or a paracrine manner.  In addition, oxo-ETEs conjugate intracellular glutathione 
(GSH) to form adducts which could serve as biomarkers of oxo-ETE formation. 
In this study, a targeted lipidomics approach combined with stable isotope 
dilution methodology was employed to identify and quantify lipid hydroperoxides and 
their metabolites formed in 15-LO-expressing mouse macrophage cell line (R15L cells) 
and COX-2 expressing cell models (RIES cells and Caco-2 cells) as well as in mouse 
hematocytes and primary human monocytes.  15-Oxo-5,8,11,13-(Z,Z,Z,E)-ETE (15-oxo-
ETE) was identified and characterized as a major eicosanoid produced in both mouse and 
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human macrophage 15-LO pathway.  15-Oxo-ETE was shown to be a metabolite of 
arachidonic acid (AA)-derived 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) by 15-
hydroxyprostaglandin dehydrogenase (15-PGDH).  A novel biological activity of 15-oxo-
ETE was revealed, which involved inhibition of human umbilical vein endothelial cell 
(HUVEC) proliferation by suppressing DNA synthesis, implicating a potential anti-
angiogenic role of 15-oxo-ETE.  
In addition to 15-oxo-ETE, another AA-derived eicosanoid 11-oxo-5,8,12,14-
(Z,Z,E,Z)-eicosatetraenoic acid (11-oxo-ETE), was identified as a major metabolite 
arising from COX-2-derived from 11(R)-hydroxyl-5,8,12,14-(Z,Z,E,Z)-eicosatetraenoic 
acid (11(R)-HETE) in both rat (RIES) and human (Caco-2) epithelial cell lines.  A 
specific liquid chromatography-multiple reaction monitoring mass spectrometry (LC-
MRM/MS) method revealed that both 11-oxo-ETE and 15-oxo-ETE were secreted in nM 
concentrations when AA was added to RIES and human Caco-2 cells.  Surprisingly, 
11(R)-HETE was an excellent substrate for 15-PGDH, with a catalytic efficiency similar 
to that found for 15(S)-HETE.  In addition, it was demonstrated that aspirin significantly 
stimulated the production of 15(R)-HETE, which was then converted to 15-oxo-ETE by 
an unknown dehydrogenase (DH).  These findings could have significant clinical 
implications since 15-PGDH is down-regulated during carcinogenesis, which in addition 
to increasing the pro-proliferative activity of PGE2 would prevent the formation of anti-
proliferative 15-oxo-ETE from 15(S)-HETE.  However, the formation of 15-oxo-ETE 
from 15(R)-HETE after aspirin treatment, through a pathway that does not involve 15-
PGDH, could help counteract the increased pro-proliferative activity of PGE2. 
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CHAPTER 1 
General Introduction 
1.1 Lipid Peroxidation 
Many diseases such as cancer, cardiovascular diseases, diabetes and 
neurodegenerative diseases are associated with cellular oxidative stress as an important 
pathological process (Ames et al., 1993).  During oxidative stress, there is increased 
production of reactive oxygen species (ROS).  Up-regulation of cyclooxygenases (COXs) 
and lipoxygenases (LOs) is also observed (Farrow and Evers, 2002; Tanabe and Tohnai, 
2002; Jang and Surh, 2005; Pathak et al., 2005).  All of these three pathways are involved 
in the formation of lipid hydroperoxides that play pivotal roles in pathological processes.   
Polyunsaturated fatty acid (PUFAs) such as AA and linonic acid (LA) are present 
in many esterified lipid classes.  Free AA and LA can be released from esterified lipid 
pools by the action of specific lipases.  AA and LA, as free fatty acids or as esterified 
lipids, can be oxidized to lipid hydroperoxides either enzymatically by COXs (Blair, 
2008) and LOs (Jian et al., 2009) or non-enzymatically by the action of ROS (Porter et 
al., 1995) (Scheme 1.1). 
1.1.1 LO–Mediated Lipid Peroxidation  
LOs are non-heme iron-containing enzymes that catalyze the stereospeific 
insertion of molecular oxygen into PUFAs to form lipid hydroperoxides (Brash, 1999).  
In the case of mammals, the preferred substrate is most often AA, and the product is 
hydroperoxyeicosatetraenoic acid (HPETE).  HPETEs are subsequently reduced by 
glutathione peroxidase (GSH POX) and/or glutathione-S-transferases (GSTs) into the 
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Scheme 1.1  Lipid peroxidation pathways. 
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corresponding HETEs (Cohen and Hochstein, 1963).  The LOs are classified with respect 
to their positional specificity of AA oxygenation into 5-, 12- and 15-LOs (Bryant et al., 
1982; Brash, 1999). 
5-LO is the enzyme responsible for converting AA into leukotrienes (LTs), which 
are potent inflammatory mediators (Chen and Funk, 2001).  It is expressed mainly in 
inflammatory cells such as polymorphonuclear leukocytes, macrophages and mast cells 
(Werz, 2002).  In resting cells, 5-LO is localized in the cytoplasm and upon stimulation 
of the cells (e.g. by increases in calcium concentration), 5-LO translocates to the outside 
of the nuclear envelope (Woods et al., 1993).  Meanwhile cytosolic phospholipase A2 
(cPLA2) releases AA from phospholipids on the membrane (Six and Dennis, 2000).  5-
LO activating protein (FLAP), which located on the nuclear envelope serves as a 
substrate presenter to provide the AA to 5-LO.  5-LO stereoselectively converts AA into 
5(S)-hydroperoxy-6,8,11,14-(E,Z,Z,Z)-eicosatetraenoic acid [5(S)-HPETE], which is 
further metabolized into LTA4 and other LTs. 
In contrast to 5-LOs, which strongly prefer free AA as substrate (Jian et al., 
2009), mammalian 15-LOs are capable of oxygenating both free and esterified PUFAs 
(Chaitidis et al., 1998; Kuhn et al., 2002; Kuhn and O'Donnell, 2006).  15-LO can also 
oxygenate even more complex lipid protein assemblies such as biomembranes (Kuhn and 
Borchert, 2002) and lipoproteins (Belkner et al., 1993; Brinckmann et al., 1998).  Type 1 
human 15-LO (15-LO-1), mainly expressed by reticulocytes, eosinophils and 
macrophages, is the enzyme responsible for converting AA to 15(S)-hydroperoxy-
5,8,11,13-(Z,Z,Z,E)-eicosatetraenoic acid [15(S)-HPETE] and a small amount of 12(S)-
hydroperoxy-5,8,10,13-(Z,Z,E,Z)-eicosatetraenoic acid [12(S)-HPETE] (Bryant et al., 
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1982).  Type 2 15-LO (15-LO-2), which is mainly expressed in prostate, lung, skin and 
cornea, converts AA into 15(S)-HPETE (Hsi et al., 2002), which is subsequently reduced 
into the corresponding alcohol, 15(S)-HETE.  LA can also serve as a substrate for 15-LO 
to produce 13(S)-hydroperoxy-9,11-(Z,E)-octadecadienoic acid [13(S)-HPODE] 
(Kamitani et al., 1998; Blair, 2008), which is subsequently reduced to the corresponding 
hydroxyoctadecadenoic acid [13(S)-HODE]. 
Several isoforms of 12-LOs have been characterized, including human platelet-
type 12-LO, human leukocyte-type 12-LO and epithelial type 12-LO, all of which 
produce 12(S)-HPETE, which is subsequently reduced to 12(S)-HETE (Shannon et al., 
1993; Rioux and Castonguay, 1998; Raso et al., 2004; Kinder et al., 2010). 
1.1.2 COX–Mediated Lipid Peroxidation  
There are three COX isoforms: COX-1, 2 and 3.  COX-1 is constitutively 
expressed in nearly all tissues in the body and plays a housekeeping role in normal 
physiological process by producing prostaglandins (PGs) and thromboxane A2 (TXA2).  
Besides PGs and TXA2, it also produces 11(R)-hydroperoxy-5,8,12,13-(Z,Z,E,Z)-
eicosatetraenoic acid [11(R)-HPETE], 15(R)-HPETE (30 %) and 15(S)-HPETE (70 %) 
(Hecker et al., 1987).  COX-2 is inducible by various cytokines, growth factors, shear 
stress, inflammation mediators and tumor promoters (Williams and DuBois, 1996; Smyth 
et al., 2009).  It is the more important source of PG and other eicosanoid formation than 
COX-1 in inflammation and perhaps cancer (Smyth et al., 2009).  AA is converted by 
COX-2 into PGs, 11(R)-HPETE and 15(S)-HPETE (Bonazzi et al., 2000; Thuresson et al., 
2002; Lee et al., 2007).  Recently, AA was shown to produce an enantiometric excess of 
33% 15(S)-HETE by COX-2 compared with 15(R)-HETE (Lee et al., 2007).  LA is 
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metabolized by COX-2 into 9(R)-hydroperoxy-10,12-(E,Z)-octadecadienoic acid [9(R)-
HPODE] (52 %), 9(S)-HPODE (11 %), 13(R)-HPODE (35 %), and 13(S)-HPODE (2 %) 
(Hamberg, 1998).  Bioactive lipid mediators are increasingly being recognized as 
important endogenous regulators of angiogenesis (Gonzalez-Periz and Claria, 2007; 
Marks et al., 2007; Kim and Surh, 2008).  One of the major cascades of the bioactive 
lipid mediators production involves the release of AA from membrane phospholipids 
followed by COX-2-mediated formation of eicosanoids (Lee et al., 2007).  COX-3 is an 
alternatively spliced variant of COX-1 found in canine cerebral cortex (Chandrasekharan 
et al., 2002).  Its function is still unresolved.   
1.1.3 ROS–Mediated Lipid Peroxidation  
ROS, including superoxide radical anion (•O2-), hydrogen peroxide and hydroxyl 
radical are generated constantly in biological processes, such as normal mitochondrial 
aerobic respiration, phagocytosis of bacteria or virus-infected cells, peroxisomal-
mediated degradation of fatty acids and cytochrome P450-mediated metabolism (Ames et 
al., 1993).  During mitochondria respiration, the free radical intermediate of coenzyme Q 
can transfer one electron to an oxygen molecule to produce •O2- (Turrens, 1997).  
Previous in vitro studies showed that 1-2% of total consumed oxygen is converted to •O2- 
by mitochondria (Boveris and Chance, 1973).  The •O2- can undergo a 1-electron 
reduction to give rise to hydrogen peroxide (Boveris and Chance, 1973).  Besides 
mitochondria, there are other sources of ROS (Forman and Torres, 2001).  During 
phagocytosis of bacteria or virus-infected cells, nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase can catalyze the reduction of molecular oxygen to •O2- 
(Forman and Torres, 2001).  A body of evidence has emerged to suggest that non-
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phagocyte NADPH oxidase also produces ROS as second messengers to regulate cell 
signaling (Forman and Torres, 2001).  In addition, myeloperoxidase converts hydrogen 
peroxide to hypochlorous acid during neutrophil phagocytosis to help kill bacteria 
(Hampton et al., 1998). 
ROS are normally detoxified by antioxidant defense systems including enzymatic 
systems such as superoxide dismutase, catalase and GSH POX; and small molecule 
antioxidants such as vitamin E, β-carotene, and glutathione (GSH) (Di Mascio et al., 
1991).  Under pathological conditions such as inflammation, infection, radiation or 
metabolism of hormones (estrogens), drugs (etoposides) and environmental toxins 
(polycyclic aromatic hydrocarbons), increased production of ROS overwhelms the 
cellular protection systems and causes damage to cellular components such as lipids 
(Ischiropoulos et al., 1992; Stamler et al., 1992; McCoull et al., 1999; Bolton et al., 2000; 
Lovett et al., 2001).  Fatty acids within phospholipids can be oxidized in situ into 
different regioisomers and enantiomers of HPETEs, HPODEs and isoprostanes (IsoPs), 
which are autooxidation products of AA (Morrow et al., 1992; Spiteller, 2001).  These 
products are reduced and then released by lipases to give rise to a racemic mixture of 
HETEs, HODEs and IsoPs.  In contrast to the LO and COX pathways, ROS-mediated 
lipid peroxidation has no stereoselectivity or enantioselectivity. 
1.2 Eicosanoid Formation 
PGs, prostacyclins, thromboxanes, LTs and HETEs are all considered to be 
eicosanoids.  They are involved in complex signaling pathways involved in normal and 
pathophysiological biological processes including inflammation.  Eicosanoids are derived 
from either omega-3 (ω-3) or omega-6 (ω-6) essential fatty acids.  The amounts and 
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balance of these lipid derivatives will affect numerous signaling pathways in vivo.  Anti-
inflammatory drugs such as aspirin and other non-steroid anti-inflammatory drugs 
(NSAIDs) act by inhibiting eicosanoid synthesis.   
1.2.1 Biosynthesis and Metabolism of Eicosanoids 
Eicosanoids are not stored within cells, but are synthesized as required (Funk, 
2001).  They are derived from the fatty acids that make up the cell membrane and nuclear 
membrane (Funk, 2001).  Increased intracellular calcium triggers the release of a 
phospholipase at the cell membrane.  The phospholipase travels to the nuclear membrane 
or the nearby cell membrane where it catalyzes ester hydrolysis of the phospholipid (by 
cPLA2) or diacylglycerol (by phospholipase C) (Funk, 2001).  This releases a 20-carbon 
essential fatty acid such as AA, and this hydrolysis appears to be the rate-determining 
step for eicosanoid formation.  The fatty acids may be released by any of several 
phospholipases, among which type IV cytosolic phospholipase A2 (cPLA2) is the key 
actor, as cells lacking cPLA2 are generally devoid of eicosanoid synthesis (Funk, 2001).  
The phospholipase cPLA2 is specific for phospholipids that contain AA, eicosapentaenoic 
acid (EPA, 20:5, ω-3) or dihomo-gamma-linolenic acid (DGLA, 20:3, ω-6) at the SN2 
position.   
At the endoplasmic reticulum (ER) and nuclear membrane, arachidonic acid 
released by cPLA2 is presented to prostaglandin H synthase (PGHS; referred to 
colloquially as COX for cyclooxygenase) and is then metabolized to an intermediate 
prostaglandin PGH2 .  PGHS exists as two isoforms referred to as PGHS-1 (COX-1) and 
PGHS-2 (COX-2) (Smith et al., 2000).  COX-1 is the enzyme responsible for basal, 
constitutive prostaglandin synthesis, whereas COX-2 is important in various 
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inflammatory and “induced” settings.  The COX enzymes are monotopically inserted in 
the ER and nuclear membrane with the substrate binding pocket precisely orientated to 
take up released arachidonic acid.  The crystal structures of COX-1 and COX-2 are 
remarkably similar, with one notable amino acid difference that leads to a larger “side-
pocket” for substrate access in COX-2 (Smith et al., 2000). The coupling of PGH2 
synthesis to metabolism by downstream enzymes is intricately orchestrated in a cell-
specific fashion.  Thromboxane synthase is found in platelets and macrophages, 
prostacyclin synthase is found in endothelial cells and prostaglandin F (PGF) synthase in 
uterus, and two types of PGD synthase are found in brain and mast cells. Microsomal 
PGE synthase (mPGES), a member of the MAPEG (membrane-associated proteins in 
eicosanoid and glutathione metabolism) family, is responsible for prostaglandin E2 (PGE2) 
synthesis (Jakobsson et al., 1999).  Coordinate induction of multiple enzymes in the 
prostanoid pathway, in particular mPGES and COX-2, in inflammatory settings is a 
current concept being developed (Mancini et al., 2001).  In contrast to PGs, LTs are made 
predominantly by inflammatory cells like polymorphonuclear leukocytes, macrophages, 
and mast cells (Funk, 2001).  Cellular activation by immune complexes, bacterial 
peptides, and other stimuli elicit a sequence of events that include cPLA2 and 5-LO 
translocations to the nuclear envelope.  5-LO, a nonheme iron dioxygenase, is the key 
enzyme in this cascade and is located in the nucleus in some cell types and the cytosol of 
others (Peters-Golden and Brock, 2001).  5-LO possesses a NH2-terminal domain that 
binds two calcium ions, similar to the β-sandwich C2 domains of cPLA2 and protein 
kinase C, and a large catalytic domain that binds iron (Hammarberg et al., 2000; Chen 
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and Funk, 2001).  It transforms released arachidonic acid to the epoxide LTA4 with the 
concerted efforts of 5-LO-activating protein (FLAP).   
When intracellular calcium concentrations are elevated in macrophages, 15-LO-1 
is recruited to the inner side of the plasma membrane of monocytes/macrophages where it 
converts esterified arachidonic acid to 15(S)-HPETE.  Esterified 15(S)-HPETE is reduced 
to 15(S)-HETE and released as the free acid by cytoplasmic phospholipase A2.  15(S)-
HETE could potentially be further oxidized to form 15-oxo-eicosatetraenoic acid (15-
oxo-ETE) at the C-15 position (Scheme 1.1).  Furthermore, it was demonstrated that upon 
the action of COX-2, arachidonic acid was converted to 15(S)-HPETE and 11(R)-HPETE 
that were further reduced to 15(S)-HETE and 11(R)-HETE, respectively (Lee et al., 
2007).  Our group has recently identified 15-oxo-ETE as a metabolite of 15(S)-HETE 
from COX-2-mediated AA metabolism (Lee et al., 2007) (Scheme 1.1).  15-Oxo-ETE 
was shown to arise from rabbit lung 15-PGDH-mediated oxidation of 15(S)-HETE over 
twenty years ago (Bergholte et al., 1987).  However, this interesting arachidonic acid 
metabolite has remained a pharmacological curiosity for many years.   
In addition, lipid hydroperoxides such as 15(S)-HPETE also undergo homolytic 
decomposition that is mediated by one-electron reductants such as transition metal ions or 
vitamin C (Lee et al., 2001).  13-HPODE, the prototypic ω-6 PUFA-derived lipid 
hydroperoxide, gives rise to 4,5-epoxy-2(E)-decenal (EDE) and 4-hydroperoxy-2-
nonenal (HPNE), which is not stable and is rapidly reduced to 4-hydroxy-2(E)-nonenal 
(HNE) or dehydrated to 4-oxo-2(E)-nonenal (ONE) (Lee et al., 2000) (Scheme 1.2).  13-
HPODE also produces 9,12-dioxo-10(E)-decenoic acid (DODE), which unlike the other 
bifunctional electrophiles, is derived from the α-terminus of the lipid and therefore 
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contains a carboxyl group (Gallasch and Spiteller, 2000) (Scheme 1.2).  They can form 
DNA-adducts by hydroxyl radical attack on the 2’-deoxyriboase DNA backbone (Hecker 
and Ullrich, 1989; Rashid et al., 1999; Zhou et al., 2005).  A recent study by Williams et 
al. on the decomposition of 15(S)-HPETE showed that it formed EDE, HPNE, HNE and 
ONE, but not DODE (Williams et al., 2005) (Scheme 1.2). 
1.2.2 Eicosanoids as Mediators of Cell Signaling  
Eicosanoids are involved in cell signaling cascades that modulate many cellular functions, 
such as cell proliferation, inflammation responses, stimulation of adhesion molecules, 
chemoattractant production, and cell death (Marra et al., 1999; Tanaka et al., 2000; Segui 
et al., 2004; Kabe et al., 2005; Le Bras et al., 2005).  Hydroxyl lipids and oxidized lipids 
(e. g. oxo-ETE family) as well as some aldehydic decomposition products (e. g. HNE and 
ONE) are relatively stable and are able to diffuse into or out of cells (Rossi et al., 2000; 
Straus et al., 2000; Waku et al., 2009).  The aldehydes exhibit facile reactivity towards 
cellular components, and can affect and modulate cellular functions at very low 
concentrations (Jian et al., 2005). 
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 1.2.2.1 Modulation of Cell Proliferation by Eicosanoids  
Many studies have focused on the potential biological roles of the 15-LO-derived 
lipid mediators such as 15(S)-HPETE and 15(S)-HETE which promote recruitment of 
monocytes to endothelium, a key initial step in atherogenesis (Hedrick et al., 1999).  
15(S)-HPETE and 15(S)-HETE were also shown to inhibit cell proliferation and induce 
apoptosis such as on chronic myeloid leukemia cell line (K-562) (Mahipal et al., 2007).  
However, it is not clear whether 15(S)-HPETE and 15(S)-HETE are the biologically 
important 15-LO-1 metabolites involved in modulating cell proliferation, monocyte 
differentiation and macrophage infiltration.  One of the 15-oxo-ETE analogs, 5-oxo-ETE, 
generated by human monocytes, promotes cell survival and acts as a chemo-attractant 
(Sozzani et al., 1996).  The PGD2 decomposition product, 15-deoxy-Δ12,14-PGJ2 (15d-
PGJ2) has unusual properties for a PG – it has anti-inflammatory properties and inhibits 
cell proliferation, causes apoptosis and induces monocyte differentiation (O'Flaherty et 
al., 2005). 
Biological activities of traditional COX-2-derived PGs have been studied 
extensively.  PGE2 is well-known for its pro-proliferation/tumorigenic activity, and it is 
the most abundant PG found in human colorectal cancer (Rigas et al., 1993; Wang et al., 
2004).  A recent study showed that PGE2 treatment dramatically increased both small and 
large intestinal adenoma burden in ApcMin/+ mice and significantly enhanced colon 
carcinogen–induced colon tumor incidence and multiplicity (Kawamori et al., 2003; 
Wang et al., 2004).  Furthermore, PGE2 protects small intestinal adenomas from NSAID-
induced regression in ApcMin/+ mice (Hansen-Petrik et al., 2002).  The central role of 
PGE2 in colorectal tumorigenesis has been further confirmed by evaluating mice with 
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homozygous deletion of PGE2 receptors (Watanabe et al., 1999; Sonoshita et al., 2001; 
Mutoh et al., 2002).   
1.2.2.2 Modulation Mechanisms of Cell Proliferation by Eicosanoids 
Peroxisomal proliferator-activating receptor-γ (PPARγ) can be activated by 
several lipid metabolites, including PUFAs, oxidized fatty acids and nitrated fatty acids 
(Kliewer et al., 1999; Baker et al., 2005; Schopfer et al., 2005; Itoh et al., 2008; Li et al., 
2008).  PPARγ is a member of the nuclear receptor family that has been implicated in cell 
differentiation and proliferation, glucose metabolism, macrophage development, and 
inflammatory responses (Limor et al., 2008).  Both 5-oxo-ETE and 15d-PGJ2 are PPARγ 
agonists (O'Flaherty et al., 2005).  In particular, 15d-PGJ2 is more potent (Forman et al., 
1995; Kliewer et al., 1995; Ricote et al., 1998).  15d-PGJ2 inhibits cell proliferation and 
causes apoptosis, which has been ascribed to its ability to potently activate PPARγ 
(Scheme 1.3) (O'Flaherty et al., 2005; Waku et al., 2009).  Recently, spectroscopic 
analysis of the binding kinetics of 15d-PGJ2 to PPARγ revealed the activating process, 
which involves two distinct steps, termed “dock and lock”: 15d-PGJ2 first enters the 
ligand binding pocket to form a non-covalent intermediate complex (docking step), and 
subsequently this endogenous fatty acid binds covalently to cysteine (Cys285) in the 
PPARγ ligand binding domains (LBD) (Waku et al., 2009).  PPARγ agonists strongly 
inhibit experimental atherosclerosis and formation of macrophage foam cells (Li et al., 
2004).  Sharing the similar chemical structure features, the oxo-ETE family members (5, 
8, 9, 11, 12 and 15-oxo-ETE) have been shown to exhibit transcriptional activity as 
covalent bound ligands to PPARγ (Waku et al., 2009).  Moreover, 15(S)-HETE (0.1 µM) 
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increased the expression of PPARγ messenger RNA (mRNA) by 50% in human vascular 
smooth muscle cells (Limor et al., 2008), which could potentially be ascribed to the 
activity of 15(S)-HETE metabolite 15-oxo-ETE. 
Furthermore, the oxo-ETE moiety can potentially covalently modify cellular 
targets such as nuclear factor kappaB (NF-κB) as well as form adducts with sulfhydryl 
nucleophiles such as glutathione (GSH) (O'Flaherty et al., 2005).  It has been proposed 
that 15d-PGJ2 is an endogenous inhibitor of NF-κB activation, and inhibits cell 
proliferation by covalently binding in a Michael addition reaction to the thiol residues in 
IκB kinase (IKK) or p50 subunit of NF-κB to block the proteins from performing their 
survival function, using a PPARγ independent mechanism (Scheme 1.3) (Rossi et al., 
2000; Straus et al., 2000; Cernuda-Morollon et al., 2001; Ward et al., 2002; Scher and 
Pillinger, 2009).  15d-PGJ2 modulates the NF-κB pathway, which plays an important role 
in gene regulation during inflammation and immune responses.  In endothelial cells, 15d-
PGJ2 inhibited CXC chemokine production, stimulates apoptosis and has variable effects 
on cellular adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) 
(Bishop-Bailey and Hla, 1999; Marx et al., 2000; Chen and Han, 2001).  Cellular 
proteolytic systems, such as the ubiquitin/proteasome system, play an important role in 
the stress response by removing abnormal proteins (Scher and Pillinger, 2009).  15d-PGJ2 
inhibits the proteasome pathway and causes dysregulation of cellular protein turnover, 
leading to cell death (Scheme 1.3) (Okada et al., 1999).  The activation of NF-κB, the 
predominant transcription factor responsible for immune responses, has also been 
increasingly recognized as the key coordinator of the link between the inflammation and 
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cancer.  More specifically, the signal transduction activates IKK which binds to NF-κB 
and keeps it in cytoplasm for not being activated.  The α and/or β subunit of IKK 
complex (IKKα and/or IKKβ) phosphorylates IκB and thus NF-κB is then released to 
nucleus for further gene activation.  Despite the conflicting functions of NF-κB in various 
cell types (either promote or inhibit carcinogenesis), the causative role of NF-κB in 
tumorigenesis has been increasingly revealed by both genetic and biochemical evidence 
(Karin, 2006).  NF-κB is an activator of anti-apoptotic genes.  Both in colitis-associated 
cancer and cholestatic liver cancer, the activation of NF-κB within pre-neoplastic or 
progressing cancer cells is the rate-limiting event, which ensures their survival and 
prevents elimination by pro-apoptotic tumor-surveillance mechanisms. 
The similarity in the structures of 5-oxo-ETE, 15d-PGJ2 and 15-oxo-ETE raises 
the possibility that 15-oxo-ETE might be a PPARγ ligand and so it could modulate cell 
proliferation and apoptosis in a PPARγ-dependent and/or PPARγ-independent 
mechanism (e. g. through NF-κB pathway).  In addition, activation of PPARγ could lead 
to monocyte differentiation (Tontonoz et al., 1998).  Thus if 15-oxo-ETE is a PPARγ 
ligand or it indirectly activates PPARγ, it might stimulate the differentiation of 
monocytes and/or other types of cells. 
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Scheme 1.3 Action of 15d-PGJ2 on receptor-dependent and receptor-independent 
targets (modified from Scher JU and Pillinger MH. J Investig Med. 2009; 57:703). 
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1.3 GSH and Lipid Peroxidation-Derived Eicosanoids 
GSH is a tripeptide (γ-L-Glutamyl-L-cysteinylglycine) with the chemical 
structure (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-
yl]amino]-5-oxo-pentanoic acid, and is the most abundant small molecule thiol in cells 
with concentrations in the millimolar range (Blair, 2006).  It plays an essential role in 
antioxidant defense and in the metabolism of both xenobiotics and endogenous toxins 
(Blair, 2010).  Most of the intracellular GSH (85–90 %) is present in the cytosol at 
concentrations ranging from 3-4 mM, with the remainder being found in the 
mitochondria, nuclear matrix, and peroxisomes (Lu, 2000).  Beside its role in 
detoxification, GSH-adducts may exhibit biological activity and/or provide specific 
biomarkers for specific oxidative stress pathways (Murphy and Zarini, 2002; Blair, 2010).  
The GSH conjugation pathway is the major route of 5-oxo-ETE and 15-oxo-ETE 
metabolism pathway in cells (Schemes 1.4 and 1.7) (Lee et al., 2007).  Cellular GSH 
levels were also modulated during bifunctional electrophile administration and this 
process was involved in apoptosis and other signal transduction pathways (Liu et al., 
2000; Ji et al., 2001; Awasthi et al., 2003; Awasthi et al., 2004).   
1.3.1 GSH Homeostasis 
GSH molecules are in dynamic equilibrium with the extracellular milieu and with 
cellular organelles (Scheme 1.5) (Dickinson and Forman, 2002).  During oxidative stress, 
reduced GSH is converted to GSSG.  In contrast, concentrations of GSSG in mammalian 
cells are usually two orders of magnitude lower (Schafer and Buettner, 2001).  The high  
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  Scheme 1.5  GSH/GSSG homeostasis. 
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abundance of GSH and low abundance of GSSG helps to maintain cells under a reducing 
environment and prevents oxidative damage to cellular macromolecules.  Hydrogen 
peroxide and lipid hydroperoxides undergo GSH POX-mediated reduction to water and 
lipid hydroxides, respectively with GSH providing the reducing equivalents (Arthur, 
2000; Blair, 2010).  GSH also readily forms adducts with a great variety of both 
exogenously- and endogenously-derived electrophilic reactive intermediates (Blair, 2006; 
Doss and Baillie, 2006).  Formation of the GSH-adducts is generally facilitated by GSH 
S-transferases (GSTs) and is normally considered to represent a detoxification of the 
relevant reactive intermediate.  GSH/GSSG homeostasis plays an important role in 
maintaining cellular redox status (Schafer and Buettner, 2001).  Changes in the half-cell 
reduction potential of the 2GSH/GSSG couple correlate with the biological status of the 
cell (Zhu et al., 2008; Blair, 2010). 
GSSG can either be reduced back to GSH at the expense of NADPH by GSH 
reductase (GR), or it can be excreted from cells by transmembrane multidrug resistance 
protein (MRP) (Suzuki and Sugiyama, 1998; Homolya et al., 2003).  GSH itself can be 
transported out of cells through the transmembrane GSH transporter (Rappa et al., 1997; 
Ballatori et al., 2005).  In particular, five of the twelve members of the MRP/cystic 
fibrosis transmembrane conductance regulator (CFTR) family appear to mediate GSH 
export from cells namely, MRP1, MRP2, MRP4, MRP5, and CFTR (Ballatori et al., 2005; 
Ritter et al., 2005).  GSH can also be utilized to form adducts with various xenobiotics 
and with endogeous compounds to form mixed GSH-adducts, which are exported out of 
cells usually by MRPs (Scheme 1.6) (Borst et al., 2000; Kruh et al., 2001; Ritter et al., 
2005).  Once secreted from cells, GSH, GSSG, and GSH-adducts are partially degraded 
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by γ-glutamyltranspeptidase (GGT), an enzyme that resides on the extracellular surface 
of the cell membrane (Griffith et al., 1978; Lieberman et al., 1995; Dalton et al., 2004; 
Blair, 2010), to yield the γ-glutamyl moiety coupled to another amino acid (usually 
cystine) and a dipeptide, which is in turn broken down by external dipeptidase (DP) 
(Scheme 1.6).  Different amino acid transporters bring the free amino acids and the γ-
glutamyl-amino acid complex back to the cells (Dickinson and Forman, 2002).  The γ-
glutamyl-cystine is converted to 5-oxoproline, which is then converted to glutamine (Glu).  
Glu and Cys are conjuagated by Glu-Cys ligase (GCL) to form γ-glutamyl-cysteine, 
which is then conjugated with glycine (Gly) by glutathione synthetase (GS) (Dickinson 
and Forman, 2002; Dalton et al., 2004).  Both steps of the conjugation require ATP. 
 GGT plays an essential role in GSH metabolism.  It is an extracellular enzyme 
that exists on the outside of the plasma membrane.  It is the only enzyme that can break 
the γ-glutamyl amide bond in GSH, GSSG and GSH-adducts.  The importance of GGT 
can be demonstrated by blocking its activity with an inhibitor such as acivicin.  As GSH 
is normally rapidly recycled, acivicin prevents GSH hydrolysis effectively by trapping it 
in the extracellular milieu, which results in intracellular GSH depletion (Capraro and 
Hughey, 1985; Liu et al., 1996).  A decrease in GSH content causes a transient increase 
in the activity of GCL because GCL is feedback inhibited by GSH (Richman and Meister, 
1975).  De novo GSH biosynthesis regulation is mediated by ARE on the Gcl gene 
(Mulcahy and Gipp, 1995).  Numerous conditions can change intracellular GSH levels, 
including heavy metal or GSH-trapping xenobiotics treatment, high glucose 
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concentrations, and exposure to ROS or bifunctional electrophiles such as an α, β-
unsaturated aldehyde genotoxin, HNE (Wild and Mulcahy, 2000). 
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Scheme 1.6 Cellular GSH-adduct transport and metabolism. 
 
1.3.2 GSTs and Other GSH-adduct Metabolizing Enzymes    
 Cytosolic GSTs represent the largest family and comprise seven classes in 
mammalian species.  Isoenzymes within a class typically share more than 40% identity in 
amino acid sequence, while those between classes share more than 25% identity (Hayes 
et al., 2005).  GSTs catalyze the first of the four steps involved in the synthesis of 
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mercapturic acid derivatives of GSH-adducts.  GGTs and DPs then remove the γ-
glutamyl moiety and the Gly, followed by N-acetylation of the resulting Cys conjugate, 
which is catalyzed by the cytosolic enzyme N-acetyl transferase (NAT) (Hinchman and 
Ballatori, 1994) (Schemes 1.6 and 1.7).  In a study of intracellular HNE metabolism, Gly-
Cys-HNE, Cys-HNE and the mercapturic acid derivative from GSH-HNE were detected 
in specific cell types, including kidney cells and neutrophils (Siems and Grune, 2003). 
GSTs catalyze nucleophilic attack by GSH on electrophilic carbon, nitrogen or 
sulphur atoms.  There are three families of GSTs.  Two of these families, the cytosolic 
and mitochondrial GSTs are soluble enzymes and share some similarities in their three-
dimensional folds (Ladner et al., 2004; Robinson et al., 2004).  The third family 
comprises membrane-associated proteins that are involved in eicosanoid and GSH 
metabolism (MAPEG) and bear no structural resemblance to the other two families of 
enzymes (Jakobsson et al., 2000; Lam and Austen, 2002; Murakami and Kudo, 2006).  
The MAPEG family includes six human proteins: 5-LO-activating protein (FLAP), LTC4 
synthase, MGST1, MGST2, MGST3 and PGE synthase, earlier known as microsomal 
glutathione transferase 1-like-1 (MGST1-L-1).  MAPEGs play important roles in 
eicosanoid metabolism, and members of the MAPEG superfamily are involved in the 
transformation of reactive lipid intermediates to bioactive eicosanoids or un-reactive 
products such as lipid alcohols or GSH-adducts.  MGSTs 2 and 3 have both been shown 
to act as GSH peroxidases as well as LTC4 synthases (Jakobsson et al.,2000) (Scheme 
1.7). 
1.3.3 GSH-adduct Transporters 
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GSH-adducts are exported from cells by ATP binding cassette (ABC) transporters 
and/or non-ATP binding cassette transporters (Awasthi et al., 2007; Deeley et al., 2006).  
MRP families are comprised of twelve related ABC proteins that transport structurally-
diverse lipophilic anions and function as drug efflux pumps (Borst et al., 2000; Kruh et 
al., 2001).  Among them, MRP1 functions as the most important and ubiquitous GSH-
adduct pump, and confers drug resistance to anti-cancer drugs (Cole et al., 1994; Chen et 
al., 1999; Diestra et al., 2003).  In spite of the similarity in the resistance profiles of P-
glycoprotein (Pgp) and MRP1, the substrate selectivities of these two kinds of pumps 
differ markedly.  Pgp substrates are neutral or mildly positively charged compounds 
without conjugation, whereas MRP1 substrates include GSH, glucuronate and sulfate 
conjugates (Kruh et al., 2001).  
1.3.4 Biological Effect of GSH-adducts 
Intracellular GSH provides one of the major defenses against oxidative stress in 
mammalian cells (Blair, 2010).  GSH adducts are not merely inactivation products, but 
can also have biological activities.  The best-known examples are the cysteinyl LTs that 
GSH-adducts (LTC4) formed between LTA4 and GSH and act as important inflammation 
mediators (Murphy et al., 1979).  By interacting with cysteinyl leukotreine receptors, 
LTC4 can stimulate proinflammatory activities such as endothelial cell adherence and 
chemokine production (Murphy et al., 1979).  The GSH-adduct with the cyclopentenone 
PGA1 showed a potent inhibitory effect on energy dependent, active export of cAMP 
(Cagen and Pisano, 1979).  Hepoxilins are hydroxy epoxides derived from AA through 
12-LO metabolism, and they induce release of insulin from pancreatic islet cells.  Their 
GSH conjugates retain significant biological activity and can act as hepoxilins themselves 
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Scheme 1.7 Formation of eicosanoids and eicosanoid-derived GSH-adducts (adopted 
from Blair IA Biomed Chromatogr. 2010 Jan; 24(1):29-38).  Abbreviations: 5-HEDH, 
5-hydroxyeicosanoid dehydrogenase; EH, epoxide hydrolase; FLAP, 5- lipoxygenase 
activating protein; FOG-7, 5-oxo-eicosatetraenoic acid GSH-adduct, LTAH, leukotriene 
A4 hydrolase; LTAS, leukotriene A4 synthase; PGS, prostaglandin synthase; TX, 
thromboxane; TXS, thromboxane synthase. 
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 (Pace-Asciak et al., 1989; Laneuville et al., 1990).  A GSH adduct of 5-oxo-
eicosatetraenoic acid (5-oxo-ETE) named as FOG7 (Scheme 1.7) caused a potent 
chemotactic response in human eosinophils and neutrophils, and was also capable of 
initiating actin polymerization  (Bowers et al., 2000).  In addition, the GGT-derived 
cysteinylglycine-adduct (HNE-Cys-Gly) from its corresponding GSH-adduct exhibited 
cytotoxic properties in fibroblast cells (Enoiu et al., 2002).   
1.4 Lipid Peroxidation-Derived Eicosanoids and Disease  
Increased lipid peroxidation accompanied by decreased ability of the body to 
remove its products results in accumulation of lipid peroxidation-derived eicosanoids and 
their metabolites.  The eicosanoids could potentially cause effects on cell proliferation, 
cell differentiation, and other biological effects.  All these processes are thought to be 
involved in the etiology of diseases such as cancer, cancer angiogenesis, and 
cardiovascular diseases. 
1.4.1 Cancer Angiogenesis 
Pro-inflammatory PGs and LTs promote tumor growth by regulating tumor 
epithelial cells themselves and orchestrating the complex interactions between 
transformed epithelial cells and surrounding stromal cells to establish the tumor 
microenvironment that facilitates tumor-associated angiogenesis and evades attack by the 
immune system, while anti-inflammatory eicosanoids oppose this effect (Wang and 
Dubois, 2010).  Among the enzymes known to have increased expression in diseases 
involving integrated action of macrophages and ECs, 15-LO, a cytoplasmic enzyme, 
appears to play a critical pathophysiological role.  This is evidenced by the elevated 
expression of 15-LO-1 in atherosclerotic lesions and its localization at the sites of 
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macrophage accumulation (Yla-Herttuala et al., 1990; Kuhn and Chan, 1997; Kuhn et al., 
1997).  Studies of 15-LO-1 in hematopoietic cells have demonstrated that it is localized 
on the inner cell membrane and other non-nuclear membranes (e.g. sub-mitochondrial 
membranes) after stimulation with calcium (Brinckmann et al., 1997; Walther et al., 
2004).  In mice, endothelial cells are activated by macrophage 12/15-LO activity in the 
presence of low-density lipoprotein (Huo et al., 2004).  It has also been suggested that 15-
LO-1 plays an important role in angiogenesis and carcinogenesis (Harats et al., 2005; 
Furstenberger et al., 2006; Viita et al., 2008).  Human 15-LO-1 is preferentially expressed 
in normal tissues and benign lesions, but not in carcinomas of bladder, breast, colon, 
lung, prostate and skin (Shureiqi et al., 1999).  Angiogenesis and tumor formation in two 
xenograft models are inhibited in transgenic mice over-expressing 15-LO-1 in ECs 
(Harats et al., 2005).  These effects may contribute to the known anti-tumorigenic activity 
of 15-LO-1.  Interestingly, in contrast to inhibiting colorectal cancer cell growth 
(Shureiqi et al., 2003; Hsi et al., 2004), 15-LO-1 stimulates prostate cancer cell growth 
(Belkner et al., 1993; Kelavkar et al., 2001; Kelavkar et al., 2004).  It has also been 
suggested that several possible pro- versus anti-angiogenesis functions are mediated by 
various products of 15-LO-mediated lipid oxidation (Zhang et al., 2005; Viita et al., 
2008).  This is because 15-LO-mediated lipid metabolic pathways have not been fully 
elucidated, and the exact biological role of each of the metabolites has not been 
completely investigated (Weibel et al., 2009).  This is further complicated by the 
observations that 15-LO has pro-inflammatory and anti-inflammatory effects in cell 
cultures and primary cells and even opposite effects on atherosclerosis in two different 
animal species (Wittwer and Hersberger, 2007).  There is also substantial evidence for a 
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pro-atherosclerotic effect of 15-LO including the direct contribution to LDL oxidation 
and to the recruitment of monocytes to the vessel wall, its role in angiotensin II mediated 
mechanisms and in vascular smooth muscle cell proliferation (Wittwer and Hersberger, 
2007). 
1.4.2 Cancer 
Major causes of cancer are chronic infection or inflammation, accompanied by 
increases in lipid peroxidation mediated either by enzymes or ROS (Ames et al., 1993).  
There is increasing evidence that lipid peroxidation products are involved in DNA 
damage and mutagenesis in different cancers.  Unsubstituted etheno-DNA-adducts and 
other DNA-adducts such as M1G have been observed in human and animal tissues 
(Chaudhary et al., 1994; Chaudhary et al., 1994; Burcham, 1998).  They are mutagenic in 
mammalian cells due to error-prone translesion DNA synthesis (Levine et al., 2000; 
Levine et al., 2001). 
Pharmacological inhibition, or genetic deletion of COX-2, reduces tumor 
formation in experimental animal models of colon, breast, lung, and other cancers (Wang 
and Dubois, 2006; Wang et al., 2007).  In mice, targeted overexpression of COX-2 in the 
mammary epithelium is sufficient to induce tumorogenesis (Smyth et al., 2009).  
Epidemiologic studies have shown that regular use of NSAIDs is associated with a 
reduction in the risk of cancers including colorectal cancer (Waddell et al., 1989; Thun, 
1996; Harris et al., 2005).  NSAIDs inhibit both COX-1 and COX-2 (Smith et al., 2000).  
COX inhibitors significantly decrease polyp formation, in patients with familial polyposis 
coli, while a polymorphism in COX-2 has been associated with increased risk of colon 
cancer (Smyth et al., 2009).  Three randomized controlled trials, the Adenoma Prevention 
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with Celecoxib trial, the Prevention of Sporadic Adenomatous Polyps trial, and the 
Adenomatous Polyp Prevention on Vioxx trial, reported a significant reduction in the 
reoccurrence of adenomas in patients receiving either celecoxib or rofecoxib (Bertagnolli, 
2007).  However, this coincided with an increase in risk of cardiovascular events, 
undermining the risk-to-benefit ratio.  Moreover, COX-2 is upregulated in colorectal 
tumor tissue (Eberhart et al., 1994; DuBois et al., 1996).  Substantial evidence suggests 
that PGE2 derived from COX-2 is a primary pro-oncogenic prostanoid, at least in part via 
transactivation of epidermal growth factor receptor (Wang and Dubois, 2006).  PGE2 
facilitates tumor initiation, progression, and metastasis through multiple biological effects, 
including increased proliferation and angiogenesis, decreased apoptosis, augmented 
cellular invasiveness, and modified immunosuppression. Mice lacking the PGE2 receptors 
(EP1, EP2, or EP4) display reduced disease in multiple carcinogenesis models.  By 
contrast, the PGE2 receptor EP3 may play a protective role in some cancers. The pro- and 
anti-oncogenic roles of other prostanoids/eicosanoids remain under investigation, with 
TxA2 emerging as another likely COX-2-derived procarcinogenic mediator (Wang et al., 
2007).  Furthermore, COX-2 derived lipid peroxidation products such as 15(S)-HPETE, 
form heptanone-etheno-DNA-adducts and etheno-DNA-adducts (Williams et al., 2005).  
Heptanone-etheno-2’-deoxyguanosine (H- εdGuo) was formed in rat intestinal epithelial 
cells that stably express COX-2 (Lee et al., 2005).  In addition, there were statistically 
significant increased levels of H-εdGuo and H-εdCyd in a mouse model of colon cancer 
compared with control mice (Williams 2005).  Another study showed that another DNA-
adduct (M1G) formation is correlated with COX-2 expression in human colon cells 
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(Sharma et al., 2001).  These provide substantial evidence that COX-2 mediated DNA 
damage plays a role in carcinogenesis. 
Moreover, significantly elevated levels of LO metabolites have been found in 
lung, prostate, breast, colon, and skin cancer cells, as well as in cells from patients with 
both acute and chronic leukemia (Steele et al., 1999).  For example, 12-LO 
overexpression has been well documented in many types of solid tumor cells, including 
those of the prostate, colon, and epidermoid carcinoma (Chen et al., 1994; Honn et al., 
1994).  In one mouse model of skin cancer, increased etheno-DNA adduct formation was 
correlated to 12-LO-mediated lipid peroxdation (Nair et al., 2000).  In addition, 12-LO 
inhibition was shown to significantly inhibit tumor development in skin (Huang et al., 
1991; Minekura et al., 2001).  Overexpression of 15-LO in human prostate cancer cells 
increases tumorigenesis (Kelavkar et al., 2001; Hsi et al., 2002).  5-LO is expressed in 
many cancer cells and overexpressed in human prostate or pancreatic cancer tissue 
(Goetzl et al., 1995; Gupta et al., 2001; Hennig et al., 2002).  Inhibition of 5-LO activity 
has also been shown to have a chemopreventive effect (Steele et al., 1999; Li et al., 
2005). 
1.4.3 Cardiovascular Disease 
Eicosanoids produced by COX-2 are thought to promote tumorigenesis by 
stimulating angiogenesis (Cha et al., 2006).  However, in atherosclerotic lesions where 
macrophages and ECs are present, COX-2 and LOs can be found suggesting the LO-
derived products might also be involved (Aviram, 1996; Feinmark and Cornicelli, 1997; 
Cornicelli and Trivedi, 1999; Mehrabian and Allayee, 2003; Nie, 2007).  There is also an 
increased level of lipid peroxidation in atherosclerotic lesions as evidenced by the 
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presence of lipid hydroperoxide-derived bifunctional electrophiles such as 
malondialdehyde (Yla-Herttuala et al., 1989) and HNE (as a pyrrole derivative) (McGeer 
et al., 2002), and ROS-derived isoprostanes (IsoPs) (Pratico et al., 1997). 
In atherosclerotic lesions, LOs and COXs are upregulated (Baker et al., 1999; 
Spanbroek et al., 2003).  Lipids are accumulated in the foam cells and necrotic core, 
leading to increased levels of lipid peroxidation.  Expression of 15-LO-1, as a 
cytoplasmic enzyme, is elevated in atherosclerotic lesions and is localized at the sites of 
macrophage accumulation (Yla-Herttuala et al., 1990; Kuhn and Chan, 1997; Kuhn et al., 
1997; Tuomisto et al., 2003).  Studies of 15-LO-1 in 15-LO-expressing mouse 
macrophage (RAW264.7) demonstrated that 15-LO-1 is localized on the inner side of the 
cell membrane and other nonnuclear membranes (e.g. submitochondrial membranes) 
after stimulation with calcium (Brinckmann et al., 1997; Walther et al., 2004).  It has 
been proposed that low-density lipoprotein (LDL), the key component of fatty streak 
atherosclerotic lesion, undergoes modification by lipid peroxidation products before it is 
taken up by macrophages to form foam cells (Steinberg et al., 1989).  The modified apoB 
on LDL gives rise to new epitopes that can be recognized by the scavenger receptor on 
macrophages which would then take away the LDL (Palinski et al., 1989; Rosenfeld et al., 
1990).  It has also been suggested that 15-LO-1 plays an important role in atherogenesis 
by oxidizing LDL (Feinmark and Cornicelli, 1997).  In mice, endothelial cells are 
activated by macrophage 12/15-LO activity in the presence of LDL (Huo et al., 2004).  
Interestingly, in contrast to promoting atherosclerotic lesions in mice and human, 
macrophage-mediated 15-LO expression protects against atherosclerosis development in 
rabbits (Shen et al., 1996).  It has also been suggested that several possible pro- versus 
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anti-atherogenic functions may be mediated by various products of 15-LO-mediated lipid 
oxidation (Cathcart and Folcik, 2000). Therefore, LO- and COX-mediated lipid 
hydroperoxide formation may provide a rich source of endogenous bifunctional 
electrophiles under atherogenic conditions. 
Recently, it was observed that efflux of 15(S)-HETE from cholesteryl ester-
enriched 15-LO-expressing RAW264.7 macrophages, when lipid droplets are present, 
was significantly reduced compared with that from cells enriched with free cholesterol 
(lipid droplets are absent) (Weibel et al., 2009).  It was further proposed that 15-LO-1 is 
present and functional on cytoplasmic neutral lipid droplets in macrophage foam cells, 
and these droplets may act to accumulate the anti-inflammatory lipid mediator 15(S)-
HETE (Weibel et al., 2009).  Moreover, apoptosis may play important roles in different 
stages of cardiovascular disease, especially as apoptosis occur in a variety of cell types 
involved in atherosclerosis, including macrophages, vascular smooth muscle cells, and 
lymphocytes (Kockx and Herman, 2000). 
In cardiovascular ischemia-reperfusion injuries, there is a cycle of ROS bursts and 
lipid peroxidation (Nita et al., 2001; Warner et al., 2004; Fukai et al., 2005; McCord and 
Edeas, 2005; Ozer et al., 2005).  Lipid peroxidation products might also cause oxidative 
injury by inducing apoptosis in the vascular cells (Rittner et al., 1999; Ruef et al., 2001). 
1.5 Lipid Peroxidation Products as Biomarkers of Oxidative Stress 
Small-molecule biomarkers are derived from modifications to GSH, DNA and 
cellular metabolites, such as lipids and folates (Ciccimaro and Blair, 2010).  Intensive 
efforts have been made to search for small-molecule biomarkers that are predictive of 
cancers, cardiovascular disease and neurodegenerative diseases (Blair, 2006; Lee and 
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Blair, 2009; Mesaros et al., 2009; Blair, 2010).  By linking biomarker discovery and 
validation with known pathways of endogenous metabolism, it is possible to rationally 
approach the development of a biomarker for a specific disease (Ciccimaro and Blair, 
2010).   
The primary products in lipid peroxidation are lipid hydroperoxides as well as 
their metabolites.  Lipid peroxidation products provide a rich source of biomarkers, 
including lipid hydroperoxides, hydroxy lipids, MDA, IsoPs, DNA-adducts, protein 
adducts, and GSH adducts (Abuja and Albertini, 2001; Blair, 2010).  Lipid 
hydroperoxides contain a conjugated diene system and strongly absorb light at 234 nm.  
This characteristic absorbance has been employed for continuous monitoring of lipid 
peroxidation in lipoproteins and model membrane system (Esterbauer et al., 1989).  The 
limitation of this method is that it is highly sensitive to UV-absorbing compounds.  Most 
biological systems contain high concentration of such UV-absorbing compounds, which 
makes it almost impossible to monitor lipid peroxidation in biological fluids and tissues 
using this method.  Gas chromatography (GC)-MS and LC-MS methods have also been 
developed to quantify IsoPs (Morrow et al., 1990; Morrow and Roberts, 1994; Pratico et 
al., 1998; Pratico et al., 2004).  The drawback in using IsoPs as biomarkers of oxidative 
stress is that they only reflect the oxidation of AA. 
Lipid hydroperoxides are rapidly reduced to hydroxy lipids in biological systems 
by GSH POX (Cohen and Hochstein, 1963).  Highly specific and accurate stable isotope 
dilution LC-MS methodology has been developed that makes it possible to resolve and 
quantify different regioisomers and enantiomers of hydroxy-lipids that are formed in 
trace amounts in the medium of cultured cells (Lee et al., 2003).  This method has 
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enabled us to elucidate lipid peroxidation mediated by different pathways.  Tissue 
samples such as atherosclerotic plaques and bronchoalveolar lavage (BAL) fluid can also 
be analyzed by this method.  Furthermore, routinely conduct LC-MS assays are being 
developed for analyzing multiple estrogen metabolites in serum and plasma at even lower 
concentrations than the current lower limit of quantitation of 0.4 pg/mL (1.6 pmol/L) 
(Blair, 2010). 
In addition, highly sensitive and specific LC-electrospray ionization (ESI)/ 
MRM/MS methodology has been developed to monitor a variety of etheno-DNA adducts, 
heptanone-etheno-DNA-adducts and other DNA adducts (e. g. 7,8-dihydro-8-oxo-2'-
dGuo) which have been shown to be specifically derived from lipid hydroperoxides in 
human and mouse tissue (Lee et al., 2005; Williams et al., 2005; Williams et al., 2006; 
Mangal et al., 2009).  In addition, an MS-based study showed that urinary etheno-dCyd 
was correlated with cigarette smoking (Chen et al., 2004).   
In the last decade, there has been a fundamental improvement in the analysis of 
protein adducts by mass spectrometry, and in particular by matrix-assisted laser 
desorption ionization (MALDI) and ESI tandem MS.  Until recently, MS approaches 
have been applied, with few exceptions, to characterize protein adducts in in vitro 
systems (incubation of the target peptide/protein with reactive intermediates in buffer), 
often forcing the reaction with large and non-physiological reactive intermediate 
concentrations.  With MS techniques, the  α,β-unsaturated aldehyde HNE mediated 
modification of several groups of proteins has been elucidated, including hemoproteins, 
lipoproteins, insulin, and different enzymes (Carini et al., 2004).  Studies in our group 
have elucidated 4-oxo-2(E)-nonenal (ONE)-mediated modification on hemoglobin and 
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the histone H4 protein (Oe et al., 2003; Yocum et al., 2005).  MS methods have then been 
used to detect bifunctional electrophile-peptide adducts (such as HNE-GSH adducts and 
HNE-carnosine adducts) directly in biological matrices (Aldini et al., 2002; Aldini et al., 
2002).  In one study on oxidative stress-induced lipid peroxidation in rats, HNE-GSH 
levels measured by LC-MS analysis in hepatocytes were shown to be correlated with 
oxidative stress induced by iron nitrilotriacetate (Volkel et al., 2005). More recently, a 
novel GSH adduct derived from lipid peroxidation, thiadiazabicyclo–ONE–GSH-adduct 
(TOG), can provide a specific biomarker of lipid hydroperoxide-derived ONE formation 
(Blair, 2010).   
1.6 Scope of Thesis Research 
Studies on lipid hydroperoxide-mediated formation of eicosanoids have been 
primarily limited to PGs and the prototypic lipid hydroperoxides [e. g. 13(S)-HPODE and 
15(S)-HPETE] and their corresponding alcohols such as 13(S)-HODE and 15(S)-HETE 
(Lee et al., 2001; Williams et al., 2005).  Little is known about the roles of further 
metabolites of lipid hydroperoxides, which may have critical bioactivity and be important 
intermediates in cell signaling.  Also, lack of sensitivity has greatly compromised the 
effectiveness of in vivo detection and analysis of lipid peroxidation products and their 
derivatives.  Once highly sensitive and specific LC-MS methods have been developed, 
suitable cell models can be utilized to elucidate lipid peroxidation pathways in cells and 
to detect cellular components modified by further metabolites of hydroxyl-lipids.  The 
purpose of this study is to identify the in vitro and in vivo metabolites of 15-LO-1- and 
COX-2-derived 15(R,S)-HETE, to examine the biological activity of 15-HETE 
metabolites, to characterize the metabolites of COX-2-derived 11(R)-HETE, and to 
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examine the effect of aspirin on the production and metabolism of COX-2-derived 
15(R,S)-HETE, 11(R)-HETE and their metabolites. 
The first specific aim was to elucidate the 15-LO-1-mediated formation of 15-
oxo-ETE and 15-oxo-ETE-GSH adduct.  A stable isotope dilution LC-MS method was 
established to quantify the formation of 15-oxo-ETE as a metabolite of 15-LO-1 and 15-
PGDH in mouse macrophages and primary human monocytes from both exogenously 
and endogenously AA.  15-oxo-ETE-GSH adduct and –cysteinylglycine adduct 
formation were also monitored.  The biological effect of 15-oxo-ETE on the proliferation 
of human HUVECs was examined.   
The second specific aim was to study COX-2-mediated formation of 11-oxo-ETE 
and 11-oxo-ETE-GSH adduct.  The biosynthesis of 11-oxo-ETE, a novel metabolite of 
COX-2 and 15-PGDH, was revealed in both mouse and human epithelial cell models 
(RIES and Caco-2 cell lines).  The structure of 11-oxo-ETE as well as its GSH-adduct 
structure was confirmed by LC-MS analysis.   
The third specific aim was to study the effect of aspirin on the formation and 
metabolism of 15-oxo-ETE and 11-oxo-ETE as well as their upstream 15(R,S)-HETE and 
11(R)-HETE as COX-2-derived metabolites.  The biosynthesis of 15-oxo-ETE from 
15(R)-HETE was also studied.   
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CHAPTER 2 
15-Oxo-Eicosatetraenoic Acid, a Metabolite of Macrophage 15-
Hydroxyprostaglandin Dehydrogenase That Inhibits Endothelial Cell Proliferation 
Published, Molecular Pharmacology, 2009; 76 (3):516-529 
2.1 Abstract 
The formation of 15-oxo-ETE as a product from rabbit lung 15-PGDH-mediated 
oxidation of 15(S)-HPETE was first reported over 20 years ago.  However, the 
pharmacological significance of 15-oxo-ETE formation has never been established.  We 
have now evaluated 15-LO-1-mediated arachidonic acid (AA) metabolism to 15-oxo-
ETE in human monocytes and mouse RAW macrophages that stably express human 15-
LO-1 (R15L cells).  A targeted lipidomics approach was employed to identify and 
quantify the oxidized lipids that were formed.  15-oxo-ETE was found to be a major AA-
derived 15-LO-1 metabolite when AA was given exogenously or released from 
endogenous esterified lipid stores by calcium ionophore A-23187 (CI).  This established 
the R15L cells as a useful in vitro model system.  Pre-treatment of the R15L cells with 
cinnamyl-3,4-dihydroxycyanocinnamate (CDC), significantly inhibited AA- or CI-
mediated production of 15(S)-HETE and 15-oxo-ETE, confirming the role of 15-LO-1 in 
mediating AA metabolite formation.  Furthermore, 15(S)-HETE was metabolized 
primarily to 15-oxo-ETE.  Pre-treatment of the R15L cells with the 15-PGDH inhibitor, 
5-[[4-ethoxycarbonyl) phenyl]azo]-2-hydroxy-benzeneacetic acid (CAY10397), reduced 
AA- and 15(S)-HETE-mediated formation of 15-oxo-ETE in a dose-dependent manner.  
This confirmed that macrophage-derived 15-PGDH was responsible for catalyzing the 
conversion of 15(S)-HETE to 15-oxo-ETE.  Finally, 15-oxo-ETE was shown to inhibit 
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the proliferation of human vascular vein endothelial cells (HUVECs) by suppressing 
DNA synthesis, implicating a potential anti-proliferative role.  This is the first report 
describing the biosynthesis of 15-oxo-ETE by macrophage/monocytes and its ability to 
inhibit EC proliferation. 
2.2 Introduction 
15-oxo-ETE was originally shown to arise from rabbit lung 15-PGDH-mediated 
oxidation of 15(S)-HETE (Bergholte et al., 1987) (Fig. 2.1).  More recently, 15-oxo-ETE 
was identified as a metabolite of COX-2-mediated-AA metabolism (Lee et al., 2007).  It 
was also observed as an AA metabolite formed in human mast cells (Gulliksson et al., 
2007).  Unlike its 5-LO-derived isomer, 5-oxo-ETE, the pharmacology of 15-oxo-ETE 
has not been explored in detail (Murphy and Zarini, 2002; Powell and Rokach, 2005).  
Therefore, this interesting AA metabolite has remained a pharmacological curiosity for 
many years.  AA is present in many esterified lipid classes and can be released by the 
action of specific lipases.  It can then be oxidized to lipid hydroperoxides either 
enzymatically by COXs (Blair, 2008) and LOs (Jian et al., 2009) or non-enzymatically by 
the action of reactive oxygen species (Porter et al., 1995). 
Bioactive lipid mediators are increasingly being recognized as important 
endogenous regulators of angiogenesis (Gonzalez-Periz and Claria, 2007).  One of the 
major cascades of bioactive lipid mediator production involves the release of AA from  
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Figure 2.1 Chemical structures of AA metabolites with similar structural features. 
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membrane phospholipids followed by COX-2-mediated formation of eicosanoids (Lee et 
al., 2007).  Eicosanoids produced by COX-2 are thought to promote tumorigenesis by 
stimulating angiogenesis (Cha et al., 2006).  It is noteworthy that there is an increased 
level of lipid peroxidation in atherosclerotic lesions as evidenced by the presence of lipid 
hydroperoxide-derived bifunctional electrophiles such as 4-hydroxy-2-nonenal (HNE) (as 
a pyrrole derivative) (Salomon et al., 2000). 
In contrast to 5-LOs, which strongly prefer free AA as substrate (Jian et al., 
2009), mammalian 15-LOs are capable of oxygenating both free and esterified 
polyunsaturated fatty acids (Kuhn and O'Donnell, 2006).  15-LO can also oxygenate even 
more complex lipid-protein assemblies such as biomembranes (Kuhn and Borchert, 2002) 
and lipoproteins (Brinckmann et al., 1998).  Type 1 human 15-LO (15-LO-1), mainly 
expressed by reticulocytes, eosinophils and macrophages, is the enzyme responsible for 
converting AA to 15(S)-HPETE and a small amount of 12(S)-hydroperoxy-5,8,10,14-
(Z,Z,E,Z)-eicosatetraenoic acid (12(S)-HETE) (Bryant et al., 1982).  15-LO-1 is a 
cytoplasmic enzyme with up-regulated expression in atherosclerotic lesions and 
localization at sites of macrophage accumulation (Kuhn and Chan, 1997).  Studies of 15-
LO-1 in hematopoietic cells have demonstrated that it translocates to the inner plasma 
membrane and other non-nuclear membranes (e.g. sub-mitochondrial membranes) after 
stimulation with calcium (Walther et al., 2004). 
Endothelial cells are activated by murine macrophage 12/15-LO activity in the 
presence of low-density lipoprotein (Huo et al., 2004).  Furthermore, it has been 
suggested that 15-LO-1 plays an important role in angiogenesis and carcinogenesis (Viita 
et al., 2008).  Both angiogenesis and tumor formation in two xenograft models were 
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inhibited in transgenic mice over-expressing 15-LO-1 in ECs (Harats et al., 2005).  It has 
been suggested that several possible pro- versus anti-angiogenesis functions are mediated 
by metabolites derived from 15-LO-mediated lipid oxidation (Viita et al., 2008).  These 
issues make it difficult to assess the precise contribution of the 15-LO pathway to 
angiogenesis, atherosclerosis, and tumorigenesis.  For example, 15-LO has pro-
inflammatory and anti-inflammatory effects in cell cultures and primary cells and 
opposite effects on atherosclerosis in two different animal species (Wittwer and 
Hersberger, 2007).  There is also substantial evidence for a pro-atherosclerotic effect of 
15-LO-1 including its direct contribution to LDL oxidation and to the recruitment of 
monocytes to the vessel wall (Wittwer and Hersberger, 2007).  The explanation to these 
conflicting observations might reside in the different biological effects of many lipid 
mediators generated by 15-LO-1 pathway, which have not yet been fully elucidated 
(Weibel et al., 2009).  The present study was designed to elucidate the biosynthesis of 15-
oxo-ETE through the actions of 15-LO-1 and 15-PGDH and to explore its potential 
pharmacological role in angiogenesis, an important mediator of tumorigenesis (Folkman, 
2007). 
2.3 Materials and Methods 
2.3.1 Materials – AA (peroxide-free), 15(S)-HETE, 15-oxo-ETE, [2H8]-15(S)-HETE, 
[2H6]-5-oxo-ETE, CAY10397 were purchased from Cayman Chemical Co. (Ann Arbor, 
MI).  CDC was obtained from BioMol (Plymouth Meeting, PA).  CI, 
diisopropylethylamine (DIPE), 2,3,4,5,6-pentafluorobenzyl bromide (PFB) bromide, fetal 
bovine serum (FBS) and heparin were purchased from Sigma-Aldrich. Dulbecco's 
Modified Eagle's Medium (DMEM), RPMI-1640 media, Medium 199 (M199), phosphate 
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buffered saline (PBS), D-glucose, L-glutamine, penicillin, streptomycin and geneticin 
were supplied by Invitrogen (Carlsbad, CA).  EC growth supplement was purchased from 
Millipore (Temecula, CA).  Collagen I-coated plates for HUVEC cell culture and 
recombinant human interleukin (IL)-4 was obtained from BD Biosciences (San Jose, 
CA).  Nuclear Extract Kit and TransAMTM NF-κB Family Transcription Factor ELISA 
Kit were purchased from Active Motif Co. (Carlsbad, CA).  BCA protein assay reagent 
was obtained from Pierce Biotechnology (Rockford, IL).  High performance LC grade 
water, hexane, methanol, and isopropanol were obtained from Fisher Scientific (Fair 
Lawn, NJ).  Gases were supplied by BOC Gases (Lebanon, NJ). 
2.3.2 Mass spectrometry (MS) - The quantitative targeted lipidomics profile was 
obtained on a triple-quadrupole Finnigan TSQ Quantum Ultra AM mass spectrometer 
(Thermo Scientific, San Jose, CA) equipped for electron capture negative atmospheric 
pressure chemical ionization (ECAPCI) (Lee and Blair, 2007; Mesaros et al., 2009).  
Operating conditions were as follows: spray voltage 4.5 kV, vaporizer temperature at 
450 °C and heated capillary temperature was 350 °C with a discharge current of 30 µA 
applied to the corona needle.  A post column addition of 0.75 ml/min of methanol was 
used to prevent buildup of carbon in the source.  Nitrogen was used as the sheath gas and 
auxiliary gas, set at 60 and 10 (in arbitrary units), respectively.  Collision-induced 
dissociation was performed using argon as the collision gas at 1.5 mTorr in the second 
(rf-only) quadrupole and the collision energy was set at 18 eV.  An additional dc offset 
voltage was applied to the region of the second multipole ion guide (Q0) at 5 V to impart 
enough translational kinetic energy to the ions so that solvent adduct ions dissociate to 
form sample ions.  For multiple reaction monitoring (MRM), unit resolution was 
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maintained for both parent and product ions.  The following MRM transitions were 
monitored: 15-HETEs (m/z 319 → 219), [2H8]-15(S)-HETE (m/z 327 → 226), 15-oxo-
ETE (m/z 317 → 273) and [2H6]-5-oxo-ETE (m/z 323 → 279). 
2.3.3 Liquid Chromatography - Normal phase chiral LC-ECAPCI/MS analyses were 
conducted using a Waters Alliance 2690 high performance LC system (Waters Corp., 
Milford, MA).  A Chiralpak AD-H column (250 x 4.6-mm inner diameter, 5 µm; Daicel 
Chemical Industries, Ltd., West Chester, PA) was employed for gradient 1 with a flow 
rate of 1.0 ml/min.  Solvent A was hexane, and solvent B was methanol/isopropanol (1:1, 
v/v).  Gradient 1 was as follows: 2% B at 0 min, 2% B at 3 min, 3.6% B at 11 min, 8% B 
at 15 min, 8% B at 27 min, 50% B at 30 min, 50% B at 35 min, 2% B at 37 min and 2% B 
at 45 min.  Separations were performed at 30 °C using a linear gradient.   
2.3.4 Cell Culture – Murine macrophage RAW 264.7 cells (obtained from American 
Type Culture Collection, Manassas, VA) were stably transfected with the pcDNA3 
plasmid containing the human 15-LO-1 gene (R15L cells) or an empty pcDNA3 plasmid 
(RMock cells) (Zhu et al., 2008).  Cells were cultured in DMEM supplemented with 10% 
FBS, 4,500 mg/l D-glucose, and 0.5 g/l geneticin.  Before the treatment for lipidomics 
analysis, the culture media was replaced with serum-free DMEM.  HUVECs were a 
generous gift from Dr. Vladimir Muzykantov (University of Pennsylvania).  HUVECs 
were cultured in Medium 199 supplemented with 15% (or 10%) FBS, 110 mg/l L-
glutamine, 100 mg/l heparin, 15 mg/l EC growth supplement, 100,000 units/l penicillin 
and 100,000 μg/l streptomycin.  Primary human monocytes were isolated from the 
peripheral blood of healthy adult donors and purified by the Biomolecular and Cellular 
Resource Center, Department of Pathology and Laboratory Medicine, University of 
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Pennsylvania in accordance with human subject protocols approved by the Internal 
Review Board of the National Institutes of Health.  Cells were cultured in RPMI 1640 
media with 10% FBS, 2 mM L-glutamine, 100,000 units/l penicillin and 100,000 μg/l 
streptomycin for 2 h.  Human IL-4 was added to the cell culture media to reach a final 
concentration of 1000 pM.  Cells were cultured for 40 h at 37 ºC.  Before treatment, cell 
culture media were replaced with serum free RPMI 1640 media containing 2 mM L-
glutamine.  Extraction and incubations of Whole Bone Marrow (WBM) cells from 12/15-
LO deficient mice and wild-type mice were conducted by Michelle Kinder in the 
laboratory of Dr. Ellen Puré at the Wistar Institute.  Cells and media were then harvested 
for further analysis after treatment.  Cell numbers were counted by a hemocytometer. 
2.3.5 AA or CI Treatment of Primary Human Monocytes - Primary human monocytes 
were cultured as described above.  The media was removed and replaced with serum-free 
RPMI-1640 media containing 2 mM L-glutamine.  AA (50 µM final concentration) or CI 
(5 µM final concentration) was added to the media.  The final concentration of ethanol in 
the culture media was less than 0.1%.  Cells were then incubated for 40 min at 37 oC.   A 
portion of cell supernatant (3 ml) was transferred into a glass tube and adjusted to pH 3 
with 2.5 N hydrochloric acid (HCl).  Lipids were extracted with diethyl ether (4 ml x 2) 
and the organic layer was then evaporated to dryness under nitrogen.  100 µl of 
acetonitrile, 100 µl of PFB bromide in acetonitrile (1:19, v/v) and 100 µl of DIPE in 
acetonitrile (1:9, v/v) were added to the residue and the solution was heated at 60 oC for 
60 min.  The solution was allowed to cool down, evaporated to dryness under nitrogen at 
room temperature, dissolved in 100 µl of hexane/ethanol (97:3, v/v) and an aliquot of 20 
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µl was used for normal-phase chiral LC-ECAPCI/MRM/MS analysis using gradient 1 as 
described above.  
2.3.6 AA treatment of R15L and RMock Cells - R15L cells and RMock cells were 
cultured in DMEM supplemented with 10% FBS, 4,500 mg/l D-glucose, and 0.5 g/l 
geneticin.  The media was removed and replaced with serum-free DMEM containing 
peroxide-free AA (10 µM final concentration).  Cells were then incubated for 0 min, 1 
min, 5 min, 10 min, 30 min, 40 min, 1 h, 2 h, 3 h and 24 h at 37 oC.  After each 
incubation, a portion of cell supernatant (3 ml) was transferred into a glass tube and cell 
numbers were counted by a hemocytometer.  Blank media standards (3 ml) were 
prepared, spiked with the following amounts of authentic lipid standards [15(R,S)-
HETEs, 15-oxo-ETE]: 10, 20, 50, 100, 200, 500 and 1000 pg.  A mixture of internal 
standards [2H8]-15(S)-HETE, [2H6]-5-oxo-ETE, 1 ng each was added to each cell 
supernatant sample and standard solution.  The samples and standards were adjusted to 
pH 3 with 2.5 N HCl.  Extraction of 15(R,S)-HETEs and 15-oxo-ETE from cell culture 
media and LC-ECAPCI/MRM/MS analyses were performed as described above.  
Calibration curves were obtained with linear regressions of analyte versus internal 
standard peak-area ratio 15(R,S)-HETEs/[2H8]-15(S)-HETE, 15-oxo-ETE/[2H6]-5-oxo-
ETE against analyte concentrations.  Concentrations of 15(R,S)-HETEs and 15-oxo-ETE 
in the media supernatants were calculated by interpolation from the calculated regression 
lines. 
2.3.7 CI Treatment of R15L Cells - R15L cells were cultured as described above.  The 
media was removed and replaced with serum-free DMEM containing CI (5 µM final 
concentration).  Cells were then incubated for 0 min, 1 min, 5 min, 10 min, 30 min, 40 
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min, 1 h, 2 h, 3 h and 24 h at 37 oC.  Extraction and quantitation of 15(R,S)-HETEs and 
15-oxo-ETE from cell culture media (3 ml) were performed as described above.  
2.3.8 Quantitative Analyses of Eicosanoids from AA or CI Treated Primary Human 
Monocytes – Primary human monocytes were cultured and induced by IL-4 as described 
above.  10 μM of AA or 5 μM of CI in ethanol was added to the media and cells were 
incubated for 40 min at 37 ºC.  The final concentration of ethanol in the culture media 
was less than 0.1%.  Cell media (3 ml) from each treatment were spiked with a mixture of 
internal standards described above.  Extraction and quantitation of 15(R,S)-HETEs and 
15-oxo-ETE from cell culture media were performed as described above.  
2.3.9 Quantitative Analyses of Eicosanoids from Ionomycin- or AA-Treated WBM 
from 12/15-LO Deficient Mice and Wild-Type Mice– WBM containing macrophages 
and hematocyte stem cells were extracted from wild-type (WT) mice and 12/15-LO-
deficient (12/15-LO-/-) mice, and cultured in serum-free RPMI-1640 media.  The mice 
WBM were incubated with 10 μM AA or 5 μM ionomycin for 30 min at 37 ºC.  The 
culture media (3 ml) from each treatment were taken and spiked with a mixture of 
internal standards described above.  Extraction and quantitation of 15(R,S)-HETEs and 
15-oxo-ETE from culture media were performed with the same procedure as that of 
R15L cell media or primary human monocyte media as described above.  
2.3.10 AA or CI Treatment of R15L Cells with LO inhibitor CDC - R15L cells were 
cultured as described above.  Cells were treated with either 10 µM AA for 10 min or 5 
µM CI for 40 min with or without the pretreatment with 20 µM CDC for 40 min.  
Extraction and quantitation of 15-oxo-ETE from cell culture media (3 ml) were 
performed as described above. 
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2.3.11 15(S)-HETE or AA Treatment of R15L Cells with 15-PGDH Inhibitor 
CAY10397 – R15L cells were cultured as described above until almost confluent.  The 
media was removed and replaced with serum-free DMEM containing various doses of 
CAY10397 (0 µM, 5 µM, 10 µM, 15 µM, 25 µM, 50 µM, and 100 µM final 
concentration).  Cells were then incubated for 4 h at 37 oC followed by incubation with 
additional 15(S)-HETE (50 nM final concentration) or AA (10 µM final concentration) 
for 10 min.  Extraction and quantitation of 15(S)-HETE and 15-oxo-ETE from cell 
culture media (3 ml) were performed as described above.  IC50 and EC50 values for 
CAY10397 were calculated from the equation of the non-linear regression dose-response 
curves assuming that the 15(S)-HETE bound to the enzyme following the laws of mass 
action.  
2.3.12 Cell Proliferation 5-Bromo-2’-Deoxyuridine (BrdU) Assay – Equal numbers 
(1000 cells/well) of HUVECs were plated as described above in 24-well collagen I-
coated plates and allowed to attach overnight.  Cells were then treated with 15-oxo-ETE 
dissolved in ethanol (0 µM, 1 µM, 5 µM, 10 µM or 20 µM final concentrations).  The 
final concentration of ethanol in the culture media was less than 0.1%.  Cell proliferation 
was assessed for two days by a commercially available BrdU assay kit according to the 
manufacturer’s protocol [Roche® Cell Proliferation Enzyme-linked immunosorbent assay 
(ELISA) BrdU (colorimetric)].  After the final step of development, the developed 
solution of each well was transferred to 96-well plates to read in a 96-well plate reader at 
the absorbance at 370 nm with 492 nm as reference.  The absorbance at λ = 370 nm 
obtained from the assay was normalized to the cell numbers according to a standard curve 
which was conducted at the same time with various cell numbers (0, 250, 500, 1000, 
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2500 and 5000 cells/well).  Each data point represents the mean value from triplicate 
wells.   
2.3.13 Extraction of Intracellular Eicosanoids in HUVECs after Incubation with 15-
oxo-ETE – HUVECs were cultured as described above.  The media was removed and 
replaced with the media containing 1 µM or 10 µM 15-oxo-ETE.  Cells were then 
incubated for 30 min, 1 h, 4 h, 24 h and 48 h at 37 oC.  After each incubation, cells were 
washed with PBS and re-suspended in 1 ml PBS.  Blank PBS (1 ml) solutions were 
prepared, spiked with the following amounts of authentic lipid standards [15(R,S)-
HETEs, 15-oxo-ETE]: 10, 20, 50, 100, 200, 500 and 1000 pg.  A mixture of internal 
standards [2H8]-15(S)-HETE, [2H6]-5-oxo-ETE, 1 ng each was added to each analytical 
sample and standard solution.  Lipids were extracted with chloroform/methanol (2:1, v/v, 
5 ml x 2).  The organic layer was then washed with 0.9% sodium chloride (1 ml x 2) and 
evaporated to dryness under nitrogen.  Lipid samples were further derivatized with PFB 
bromide, reconstituted in hexane/ethanol and analyzed by LC-ECAPCI/MRM/MS as 
described above. 
2.4 Results 
2.4.1 AA- or CI-Mediated Production of 15(R,S)-HETEs and 15-oxo-ETE in 
Primary Human Monocytes - The cytokine IL-4 induces 15-LO-1 expression in human 
monocytes.  Primary human monocytes were incubated with AA (50 µM) or CI (5 µM) 
for 40 min in serum free RPMI-1640 media following 40 h pretreatment with IL-4 (1 
nM).  Compared to the non-treated IL-4 induced monocytes, the chromatograms from 
LC-ECAPCI/MRM/MS analyses demonstrated the formation of 15(S)-HETE [retention 
time (rt), 15.5 min] in IL-4-induced primary human monocytes treated with exogenous 
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AA or CI (Fig. 2.2A).  There was very little 15(R)-HETE (rt, 15.4 min) compared with 
15(S)-HETE (Fig. 2.2A).  15-oxo-ETE was also identified (rt, 8.10 min) in IL-4-induced 
primary human monocytes with either AA or CI treatment (Fig. 2.2B).  The signal 
intensity of 15-oxo-ETE was approximately 3-fold lower (1.34 x 107) than the intensity 
of 15(S)-HETE (4.35 x 107) in AA-treated cells and approximately 10-fold lower (5.04 x 
105) than the intensity of 15(S)-HETE (4.05 x 106) in CI-treated cells (Figs. 2.2A and 
2.2B).  Quantitative analyses further demonstrated that 303.22 (± 21.69) pmol/106 cells of 
15(S)-HETE (Fig. 2.3A) and 55.61 (± 2.34) pmol/106 cells of 15-oxo-ETE (Fig. 2.3B) 
were produced by IL-4-induced primary human monocytes with AA treatment, and 17.46 
(± 0.52) pmol/106 cells of 15(S)-HETE (Fig. 2.3A) with 4.98 (± 0.21) pmol/106 cells of 
15-oxo-ETE (Fig. 2.3B) was formed by IL-4-induced cells treated with CI, while cells 
with no treatment (NT) or cells only induced with IL-4 did not produce AA-derived 
eicosanoids (Fig. 2.3). 
2.4.2 AA-Mediated Production of 15(R,S)-HETEs and 15-oxo-ETE in R15L Cells - 
R15L cells and RMock cells were incubated with 10 µM AA for a time-course of 24 h.  
LC-ECAPCI/MRM/MS analyses of the R15L cell supernatants demonstrated the 
production of 15-oxo-ETE (rt, 8.67 min) and 15(S)-HETE (rt, 16.15 min) within 5 min 
treatment of AA (Fig. 2.4A).  Extracted chromatograms for 15-oxo-ETE, [2H6]-5-oxo-
ETE, 15(R)-HETE, 15(S)-HETE and [2H8]-15(S)-HETE are shown in Fig. 2.4A.  [2H6]-5-
oxo-ETE and [2H8]-15(S)-HETE were used as internal standards to quantify 15-oxo-ETE 
and 15(R,S)-HETEs, respectively.  Fig. 2.4B displays the production of 15(R)- and 15(S)-
HETE by R15L and RMock cells upon AA treatment.  15(S)-HETE was the predominant 
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eicosanoid isomer released by R15L cells, with negligible amounts of 15(R)-HETE 
produced in response to AA treatment.  Furthermore, 15(S)-HETE level peaked within 5  
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Figure 2.2 LC-MRM/MS analysis of 15-LO-derived eicosanoids from primary 
human monocytes treated with AA and CI.  Primary human monocytes were isolated 
and stimulated with IL-4 for 40 h (NT) followed by 40 min treatment with 50 µM AA 
(AA) or 5 µM CI (CI A-23187).  Cell supernatant in each treatment group was collected.  
Lipid metabolites in the cell supernatant were extracted, derivatized with PFB, and 
analyzed by stable isotope dilution LC-ECAPCI/MRM/MS analysis.  MRM 
chromatograms are shown for (A) 15(R,S)-HETE-PFB (m/z 319 → 219) and (B) 15-oxo-
ETE-PFB (m/z 317 → 273).  
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Figure 2.3 Quantatitive analyses of 15-LO-derived eicosanoids from primary human 
monocytes treated with AA and CI.  (A) 15(S)-HETE formation by primary human 
monocytes that were treated with 10 μM AA or 5 μM CI for 40 min following IL-4 (1 
nM) stimulation.  (B) 15-oxo-ETE formation by primary human monocytes that were 
treated with 10 μM AA or 5 μM CI for 40 min following IL-4 (1 nM) stimulation.  Cells 
with no treatment (NT) or only IL-4 treatment were used as controls.  Lipid metabolites 
in the cell media were extracted and derivatized with PFB.  15(S)-HETE and 15-oxo-ETE 
concentrations were determined in triplicate by stable isotope dilution by LC-
ECAPCI/MRM/MS analysis of PFB derivatives.  Values presented in bar graphs are 
means ± S.E.M. 
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min treatment of AA (500 pmol/106 cells) (Fig. 2.4B).  In contrast, both 15(R)- and 
15(S)-HETE production in RMock cells were close to limit of detection (Fig. 2.4B).  The 
time course of 15-oxo-ETE produced in R15L cells upon AA treatment were similar to 
15(S)-HETE with maximum level of 15-oxo-ETE observed (120 pmol/106 cells) within 5 
min of AA treatment, then continuing to diminish over the remainder of the 24 h 
treatment period (Fig. 2.4C).  Again, there was very little production of 15-oxo-ETE in 
RMock cells (Fig. 2.4C). 
2.4.3 CI-Mediated Production of 15(R,S)-HETEs and 15-oxo-ETE in R15L Cells - CI 
increases the intracellular calcium concentration, which recruits 15-LO from the cytosol 
to the inner side of the plasma membrane, oxidizes AA to 15(S)-HPETE, which is 
subsequently reduced and released as 15(S)-HETE.  The chromatograms of LC-
ECAPCI/MRM/MS analyses demonstrated the production of the endogenous 15-oxo-
ETE (rt, 8.31 min) and 15(S)-HETE (rt, 15.93 min) after 40 min treatment of 5 µM CI 
(Fig. 2.5A).  Maximum synthesis of 15(S)-HETE was observed at 18 pmol/106 cells 
within 1 h of the CI treatment,  and decreased  to limit of detection after 3 h, while there 
was very little production of 15(R)-HETE (rt, 12.60 min) throughout the time course of 
the treatment (Fig. 2.5B).  Similarly, 15-oxo-ETE production peaked at 2 pmol/106 cells 
after 40 min of the CI treatment, and declined to limit of detection after 3 h (Fig. 2.5C). 
2.4.4 Effect of CDC on 15-oxo-ETE Production in R15L Cells - CDC is a LO inhibitor 
that inhibits the production of 15-LO-mediated lipid metabolites (Cho et al., 1991).  
R15L cells were treated with 10 µM AA for 10 min or 5 µM CI for 40 min, with or 
without 40 min pretreatment with 20 µM CDC.  AA treatment alone of R15L cells led to 
the production of 15-oxo-ETE (40 pmol/106 cells) as well as 15(S)-HETE (420 pmol/106 
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cells) (Fig. 2.6A and 2.6C, respectively).  Pretreatment with CDC resulted in significant 
inhibition of 15-oxo-ETE production by almost 70% (12 pmol/106 cells), and 15(S)-
HETE production by almost 95% (20 pmol/106 cells) (Figs. 2.6A and 2.6C. respectively).  
CDC treatment by itself did not lead to 15-oxo-ETE or 15(S)-HETE generation (Figs. 
2.6A and 2.6C respectively).  CI treatment generated 2 pmol/106 cells of 15-oxo-ETE 
(Fig. 2.6B) and 35 pmol/106 cells of 15(S)-HETE (Fig. 2.6D) in R15L cells.  CDC 
pretreatment completely abolished both the CI-mediated 15-oxo-ETE and 15(S)-HETE 
production (Figs. 2.6B and 2.6D, respectively).  CDC treatment alone had no effect on 
15-oxo-ETE or 15(S)-HETE generation (Figs. 2.6B and 2.6D, respectively).  These data 
further confirmed that both 15(S)-HETE and 15-oxo-ETE were 15-LO-derived 
metabolites of endogenous AA. 
2.4.5 Quantitative Analyses of 15(S)-HETE and 15-oxo-ETE from Mice Whole Bone 
Marrow (WBM) by LC-ECAPCI/MS –WBM containing macrophages and hematocyte 
stem cells were extracted from wild-type (WT) mice and 12/15-LO-deficient (12/15-LO-/-
) mice.  The mice WBM were incubated with 10 μM AA or 5 μM ionomycin for 30 min.  
AA led to the formation of 15(S)-HETE [224.90 (±4.35) pmol/106] in WT mice while 
only 1.14 (±0.07) pmol/106 in 12/15-LO-/- mice (Fig. 2.7A).  AA also generated 31.64 
(±1.94) pmol/106 of 15-oxo-ETE in WT mice and 0.07 (±0.00) pmol/106 of 15-oxo-ETE 
in 12/15-LO-/- mice (Fig. 2.7B).  Ionomycin increased the intracellular Ca2+ level leading 
to the endogenous formation of 33.99 (±0.77) pmol/106 15(S)-HETE in WT mice while 
only 1.42 (±0.07) pmol/106 in 12/15-LO-/- mice (Fig. 2.7A).  Endogenous 15-oxo-ETE in 
WBM induced by ionomycin was 7.70 (±0.34) pmol/106 in WT mice and only 0.09 
(±0.00) pmol/106 which was under the limit of detection in 12/15-LO-/- mice (Fig. 2.7B).  
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These data confirmed 15-oxo-ETE production in vivo with animal models and this 
production is through 15-LO pathway. 
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Figure 2.4 LC-MRM/MS analysis and quantitation of 15-LO-derived eicosanoids 
from R15L cells and RMock cells treated with AA.  (A) Representative 
chromatograms of 15-LO-derived lipid metabolites released by R15L cells following 5 
min treatment with 10 µM AA.  MRM chromatograms are shown for (a) 15-oxo-ETE-
PFB (m/z 317 → 273), (b) [2H6]-5-oxo-ETE-PFB internal standard (m/z 326 → 279), (c) 
15-(R,S)-HETE-PFB (m/z 319 → 219), and (d) [2H8]-15-(S)-HETE-PFB internal standard 
(m/z 327 → 226); (B) Concentration-time graph of 15-HETE (R and S-form) released by 
R15L or RMock cells treated with 10 µM AA for 24 h; (C) Concentration-time graph of 
15-oxo-ETE released by R15L or RMock cells treated with 10 µM AA for 24 h.  Cell 
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supernatants were collected at each time point.  Lipid metabolites in the cell supernatants 
were extracted and derivatized with PFB.  Determinations were conducted in triplicate 
(means ± S.E.M.) by stable isotope dilution chiral LC-ECAPCI/MRM/MS analyses of 
PFB derivatives. 
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Figure 2.5 LC-MRM/MS analysis and quantitation of 15-LO-derived eicosanoids 
from R15L cells treated with CI.  (A) Representative chromatograms of endogenous 
15-LO-derived lipid metabolites released by R15L cells following 40 min treatment with 
5 µM CI.  MRM chromatograms are shown for (a) 15-oxo-ETE-PFB (m/z 317 → 273), 
(b) [2H6]- 5-oxo-ETE-PFB internal standard (m/z 326 → 279), (c) 15-(R,S)-HETE-PFB 
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(m/z 319 → 219), and (d) [2H8]-15-(S)-HETE-PFB internal standard (m/z 327 → 226); 
(B) Concentration-time graph of 15-HETE (R and S-form) released by R15L treated with 
5 µM CI for 24 h; (C) Concentration-time graph of 15-oxo-ETE released by R15L cells 
treated with 5 µM CI for 24 h.  Cell supernatants were collected at each time point.  Lipid 
metabolites in the cell supernatants were extracted and derivatized with PFB.  
Determinations were conducted in triplicate (means ± S.E.M.) by stable isotope dilution 
chiral LC-ECAPCI/MRM/MS analyses of PFB derivatives. 
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Figure 2.6 Effect of LO inhibitor (CDC) on formation of 15-oxo-ETE and 15(S)-
HETE by R15L cells.  (A) 15-Oxo-ETE formation by cells that were treated with 10 µM 
AA or pre-treated with 20 µM CDC for 40 min prior to vehicle or 10 µM AA treatment. 
(B) 15-Oxo-ETE formation by cells that were treated with 5 µM CI or pre-treated with 20 
µM CDC for 40 min prior to vehicle or 5 µM CI treatment.  (C) 15(S)-HETE formation 
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by cells that were treated with 10 µM AA or pre-treated with 20 µM CDC for 40 min 
prior to vehicle or 10 µM AA treatment. (D) 15(S)-HETE formation by cells that were 
treated with 5 µM CI or pre-treated with 20 µM CDC for 40 min prior to vehicle or 5 µM 
CI treatment.  Lipid metabolites in the cell media were extracted and derivatized with 
PFB.  15-Oxo-ETE and 15(S)-HETE concentrations were determined in triplicate by 
stable isotope dilution LC-ECAPCI/MRM/MS analyses of PFB derivatives.  Values 
presented in bar graphs are means ± S.E.M. 
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Figure 2.7 Quantitative analyses of 15(S)-HETE and 15-oxo-ETE released from 
ionomycin- or AA-treated whole bone marrow (WBM) from 12/15-LO deficient 
(12/15-LO-/-) mice and wild-type (WT) mice by LC-ECAPCI/MS.  (A) 15(S)-HETE 
formation by whole bone marrow from 12/15-LO-/- mice and WT mice that were treated 
with 10 μM AA or 5 μM ionomycin for 30 min.  (B) 15-oxo-ETE formation by whole 
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bone marrow from 12/15-LO-/- mice and WT mice that were treated with 10 μM AA or 5 
μM ionomycin for 30 min.  Lipid metabolites in the cell media were extracted and 
derivatized with PFB.  15(S)-HETE and 15-oxo-ETE concentrations were determined in 
triplicate by stable isotope dilution by LC-ECAPCI/MRM/MS analysis of PFB 
derivatives.  Values presented in bar graphs are means ± S.E.M.  
 
2.4.6 Kinetics of 15(S)-HETE Metabolism to 15-oxo-ETE by R15L Cells – To study 
the kinetics of 15(S)-HETE metabolism in R15L cells, R15L cells were incubated with 
15(S)-HETE (0.9 µM) for 3 h.  The level of 15(S)-HETE in the cell media declined from 
0.9 µM to being close to the limit of detection in 3 h (Fig. 2.8A).  The half-life of 15(S)-
HETE was determined to be 21 min and the pseudo first-order rate constant (k) was 
0.0331 min-1 (Fig. 2.8B).  Concomitantly, the level of 15-oxo-ETE in the cell media was 
observed to peak within 5 min of 15(S)-HETE treatment with the concentration of 0.022 
(± 0.002) µM, and declined to being close to the limit of detection in 3 h (Fig. 2.8C).  The 
half-life of 15-oxo-ETE was determined to be 11 min and the pseudo first-order rate 
constant (k) was 0.0643 min-1 (Fig. 2.8D). 
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Figure 2.8 Kinetics of 15(S)-HETE metabolism by R15L cells.  R15L cells were 
incubated with 15(S)-HETE (1 µM) for a period of 360 min.  Supernatant was collected 
at different time points.  Lipid metabolites [15(S)-HETE and 15-oxo-ETE] in the cell 
supernatant were extracted and derivatized with PFB and their concentrations were 
determined in triplicate (means ± S.E.M.) by LC-ECAPCI/MRM/MS analysis.  (A) 
Concentration-time plot of 15(S)-HETE (µM) remaining un-metabolized in R15L cell 
culture media; (B) Kinetic plot of 15(S)-HETE metabolism by R15L cells (t1/2=21 min 
and k=0.0331 min-1); (C) Concentration-time plot of 15-oxo-ETE (µM) produced in 
R15L cell culture media. (D) Kinetic plot of 15-oxo-ETE metabolism by R15L cells 
(t1/2=11 min and k=0.0643 min-1). 
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2.4.7 Effect of CAY10397 on 15-oxo-ETE and 15(S)-HETE in R15L Cells - 
CAY10397 is a selective inhibitor of the 15-PGDH that oxidizes 15-hydroxyl group of 
prostaglandins (PGs) to a 15-oxo-group (Berry et al., 1983; Quidville et al., 2006).  To 
determine the effect of CAY10397 on AA-derived 15(S)-HETE and 15-oxo-ETE, R15L 
cells were treated with 10 µM AA for 10 min, with or without the pretreatment with 
various doses of CAY10397 (0-100 µM) for 4 h.  This resulted in a significant inhibition 
of the production of 15-oxo-ETE (Fig. 2.9A) and a simultaneous accumulation of 15(S)-
HETE in a dose-dependent manner (Fig. 2.9B).  To confirm that 15-PGDH was the 
enzyme that oxidized 15(S)-HETE to 15-oxo-ETE, R15L cells were treated with 50 nM 
15(S)-HETE for 10 min, with or without the pretreatment with various doses of 
CAY10397 (0-100 µM) for 4 h.  15(S)-HETE treatment alone gave rise to the production  
of 15-oxo-ETE (3 pmol/106 cells).  CAY10397 pretreatment resulted in dose dependent 
inhibition of 15-oxo-ETE production.  The inhibition reached 80% in the presence of 100 
µM CAY10397 (Fig. 2.9C).  CAY10397 also caused a concomitant dose-dependent 
increase in 15(S)-HETE concentrations after the addition of exogenous 15(S)-HETE (Fig. 
2.9D).  CAY10397 treatment by itself in the absence of AA did not lead to 15-oxo-ETE 
generation (data not shown).  The IC50 of CAY10397 on AA-mediated (Fig. 2.9A) or 
15(S)-HETE-mediated (Fig. 2.9C) 15-oxo-ETE production were very similar at 17.3 µM 
and 13.2 µM, respectively.  The Hill coefficient for the inhibition of 15(S)-HETE-derived 
15-oxo-ETE was -1.2 indicating that the 15(S)-HETE and CAY10397 were binding at the 
same site (Fig. 2.9C).  However, a Hill coefficient of -2.2 was obtained for the inhibition 
of AA-derived 15-oxo-ETE indicating that there was cooperativity in the inhibition of 
these more complex ligand/binding site interactions (Fig. 2.9A).  The EC50 for 
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CAY10397-induced increase in AA-mediated 15(S)-HETE formation was 19.6 µM (Fig. 
2.9B), which was similar to the IC50 of 17.3 µM for inhibition of AA-mediated 15-oxo-
ETE formation (Fig. 2.9A).  As expected, the Hill coefficient (-3.0) deviated from -1.0 
because of cooperativity effects.  The effect of CAY10397 on 15(S)-HETE 
concentrations after the addition of exogenous 15(S)-HETE was too complex to analyze 
using conventional non-linear binding models (Fig. 2.9D).  This suggested that 
conversion of 15(S)-HETE to 15-oxo-ETE is more complex than simple 15-PGDH-
mediated metabolism. 
2.4.8 Effect of 15-oxo-ETE on Proliferation on HUVECs - In order to examine the 
effect of 15-oxo-ETE on cell proliferation, colorimetric BrdU ELISA assays were 
performed on HUVECs treated with different concentrations (1-20 µM) of 15-oxo-ETE 
for a 48 h period (Fig. 2.10A).  BrdU incorporation was analyzed and the corresponding 
cell number was determined from a standard curve (Fig. 2.10B).  DNA synthesis in the 
HUVECs (as measured by BrdU incorporation) was inhibited by 15-oxo-ETE (Fig. 
2.10A).  This resulted in a dose-dependent decrease in cellular proliferation as reflected 
by the cell count determined from the BrdU standard curve (Fig. 2.10C).   
2.4.9 15-oxo-ETE Uptake into HUVECs - Cells were incubated with 1 µM or 10 µM of 
15-oxo-ETE for 48 h.  For 1 µM 15-oxo-ETE incubation, the intracellular concentrations 
of 15-oxo-ETE were measured during the time course.  The intracellular concentrations 
of 15-oxo-ETE increased from below the limit of detection at 0 min to 408.08 (± 12.13) 
nM at 30 min, 154.18 (± 14.91) nM at 1 h, 70.18 (± 9.85) nM at 4 h and below the limit 
of detection after 24 h (Fig. 2.11A).  In HUVECs incubated with 10 µM of 15-oxo-ETE, 
the intracellular concentrations of 15-oxo-ETE were measured at 3.19 (± 1.10) µM at 30 
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min, 2.48 (± 0.21) µM at 1 h, 2.42 (± 0.52) µM at 4 h and below the limit of detection 
after 24 h (Fig. 2.11B). 
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Figure 2.9 Dose-dependent effects of CAY10397 on the levels of 15-oxo-ETE and 
15(S)-HETE released by R15L cells. (A) Dose-dependent inhibition curve of 
CAY10397 on 15-oxo-ETE released by R15L cells treated with 10 µM AA for 10 min 
following the pretreatment with CAY10397 for 4 h; (B) Dose-dependent curve of 
CAY10397 on 15(S)-HETE accumulation by R15L cells treated with 10 µM AA for 10 
min following the pretreatment with CAY10397 for 4 h; (C) Dose-dependent inhibition 
curve of CAY10397 on 15-oxo-ETE released by R15L cells treated with 50 nM 15(S)-
HETE for 10 min following the pretreatment with CAY10397 for 4 h; (D) Dose-
dependent curve of CAY10397 on 15(S)-HETE accumulation by R15L cells treated with 
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50 nM 15(S)-HETE for 10 min following the pretreatment with CAY10397 for 4 h.  Cell 
supernatants were collected at each time point.  Lipid metabolites in the cell supernatants 
were extracted and derivatized with PFB.  Determinations were conducted in triplicate 
(means ±S EM) by stable isotope dilution chiral LC-ECAPCI/MRM/MS analyses of PFB 
derivatives. 
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Figure 2.10 Effect of 15-oxo-ETE on cell proliferation of HUVECs.  Determinations 
were conducted in triplicate (means ± S.E.M.).  Concentrations of 15-oxo-ETE were 
determined by LC-ECAPCI/MS. (A) HUVECs were treated with various doses (0-20 
µM) of 15-oxo-ETE for a period of 48 h.  Cell proliferation in terms of DNA synthesis 
was determined by colorimetric BrdU ELISA assays.  Absorbance was measured in 
triplicate at 370 nm with 492 nm as reference.  (B)  A standard curve of corrected 
OD370nm was determined with the various numbers of cells by the BrdU ELISA assay. 
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(C) The corresponding cell numbers with 15-oxo-ETE treatment were determined from 
the standard curve. (D) Inhibition constant of 15-oxo-ETE (IC50=8.1 μM). 
   
 
 
 
 
 
Figure 2.11 15-oxo-ETE uptake into HUVECs.  (A) Intracellular levels of 15-oxo-ETE 
in HUVECs incubated with 1 µM 15-oxo-ETE for 48 h. (B) Intracellular levels of 15-
oxo-ETE in HUVECs incubated with 10 µM 15-oxo-ETE for 48 h. 
 
2.5 Discussion 
IL-4 stimulated human monocytes were found to secrete primarily 15(S)-HETE 
and 15-oxo-ETE when treated with exogenous AA or with CI (Fig. 2.2).  Brinckmann et 
al. reported that 15-LO-1 translocated to plasma membrane in a calcium-dependent 
manner in rabbit hematopoietic cells and that the translocation activated the oxygenase 
activity of the enzyme (Brinckmann et al., 1998).  It is known that 15-LO-1 has a broad  
substrate specificity so that it can oxidize esterified lipids as well as protein-lipid 
assemblies (Kuhn and O'Donnell, 2006).  Furthermore, Maskrey et al. showed that when 
(A) (B) 
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IL-4-treated monocytes were stimulated with CI, they generated predominantly esterified 
15-HETE; with many fold less free 15-HETE (Maskrey et al., 2007).  These studies 
suggest that CI treatment of the monocytes resulted in translocation of 15-LO-1 to the 
plasma membrane so that it was no longer present the cytosol.  15(S)-HPETE was then 
formed primarily on esterified AA rather than from free of AA released by CI-mediated 
translocation of cytosolic phospholipase A2 (cPLA2) to the membrane.  The resulting 
esterified 15(S)-HPETE was then reduced to 15(S)-HETE (Schnurr et al., 1999) and a 
significant amount then released by cPLA2-mediated hydrolysis of the esterified 15(S)-
HETE and released from the cells as suggested previously by Chaitidis et al. (Chaitidis et 
al., 1998).  Indeed, CI or ionomycin treatment of R15L cells and mice WBM led to the 
production of 15(S)-HETE and 15-oxo-ETE (Figs. 2.2 and 2.7), confirming that they are 
metabolites of endogenously-derived AA.  These data also suggest that 15(S)-HETE is 
the predominant precursor of 15-oxo-ETE in 15-LO-1 mediated metabolism of 
endogenously-derived AA.  This contrasts with COX-2-mediated formation of 15-oxo-
ETE, which could be derived from 15(S)-HPETE, 15(S)-HETE, or the corresponding 
15(R)-enantiomers (Lee et al., 2007). 
A targeted quantitative chiral lipidomics analysis showed that 15(S)-HETE and 
15-oxo-ETE were also major metabolites derived from exogenous and endogenous AA in 
R15L cells (Figs. 2.4 and 2.5).  Moreover, the RMock cells that do not express any 
human 15-LO-1 failed to generate these metabolites (Figs. 2.4 and 2.5).  Pre-treatment of 
R15L cells with CDC, a LO inhibitor, led to a significant reduction in 15-oxo-ETE and 
15(S)-HETE levels that were produced by AA treatment alone (Fig. 2.6A and 2.6C 
respectively).  CDC pre-treatment also led to complete inhibition of 15-oxo-ETE and 
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15(S)-HETE production by CI treatment in R15L cells (Fig. 2.6B and 2.6D respectively).  
CDC treatment by itself did not generate any 15(S)-HETE and 15-oxo-ETE in R15L 
cells.  Thus, these data provide further evidence that 15(S)-HETE and 15-oxo-ETE are 
15-LO-specific metabolites of AA.  15(S)-HETE was found to be rapidly converted into 
15-oxo-ETE, with approximately 90% conversion occurring within 3 h in the R15L cells 
(Fig. 2.8A).  A kinetic plot (Fig. 2.8B) revealed that the half-life of 15(S)-HETE in R15L 
cells was 21 min with a pseudo first-order rate constant of 0.0331 min-1.  These data are 
consistent with findings from a similar study involving COX-2 expressing RIES cells 
(Lee et al., 2007). 
15-PGDH catalyzes NAD+-mediated oxidation of 15(S)-hydroxyl group of PGs 
and lipoxins (Quidville et al., 2006; Tai et al., 2007).  It is a key PG catabolism enzyme, 
converting (for example) PGF2α to 15-oxo-PGF2α (Fig. 2.1).  Our previous studies had 
established 15-oxo-ETE as a downstream metabolite of 15(S)-HETE (Lee et al., 2007); 
however, the enzyme responsible for this oxidation was not identified.  In the present 
study we have shown that the specific 15-PGDH inhibitor (CAY10397) significantly 
decreased the production of 15-oxo-ETE and the metabolism of 15(S)-HETE in the 
macrophages treated with either AA (Fig. 2.9A) or 15(S)-HETE (Fig. 2.9C).  The IC50 
values for CAY10397-mediated 15-oxo-ETE inhibition were determined to be 17.3 and 
13.2 µM, respectively.  There was a concomitant increase in 15(S)-HETE concentrations 
after inhibition of AA- (Fig. 2.9B) and 15(S)-HETE-mediated (Fig. 2.9D) 15-oxo-ETE 
formation.  These data clearly show that 15-oxo-ETE arose through the oxidation of 
15(S)-HETE by murine 15-PGDH.  Mouse 12/15-LO, which is the counterpart of human 
15-LO-1, produces both 12-LO- and 15-LO-derived lipid metabolites (Fig. 2.7) (Kuhn 
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and O'Donnell, 2006; Middleton et al., 2006).  Mouse WBM were found to produce 
15(S)-HETE, 15-oxo-ETE (Figure 2.7) and 12(S)-HETE (data not shown).  Additional 
studies will be required to determine whether 12-oxo-ETE is also formed and the 
potential biological consequences.  Thus, it is not clear that the phenotypes in 12/15-LO-
deficient mice are due to lack of 12-LO- or 15-LO-derived lipid mediators.  In this 
regard, the mouse R15L macrophage cell line, which expresses human 15-LO-1, 
provided an excellent model to identify 15-LO-derived lipid metabolites. 
15-oxo-ETE was rapidly cleared from the R15L cells, with a half-life of only 11 
min, indicating that it underwent further metabolism (Fig. 2.8D).  We showed previously 
that 15-oxo-ETE forms a GSH-adduct through GSH S-transferase-mediated Michael 
addition (Lee et al., 2007).  Other studies have shown that AA-derived metabolites such 
as leukotriene C4 and 5-oxo-ETE can also form GSH-adducts (Murphy and Zarini, 2002; 
Blair, 2006).  This suggests and indeed that 15-oxo-ETE is also metabolized to a GSH-
adduct in the R15L cells (Fig. 2.12A) and the GSH-adduct is then cleaved by GGTP on 
the cell membrane to form a cysteinylglycine adduct extracellularly (Fig. 2.12B), which 
would account in part for its rapid clearance. 
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Figure 2.12 LC-MRM/MS analysis of GSH and cysteinylglycine adducts after 
incubation of R15L cells with 15-oxo-ETE (30 μM).  (A) Intracellular formation and 
the representative chromatogram of 15-oxo-ETE-GSH adducts (15-OEG) in R15L cells 
after incubated with 15-oxo-ETE for 5 min. (B) Formation and the representative 
chromatogram of 15-oxo-ETE-cysteinylglycine (15-OEC) adduct in the extracellular 
milieu of R15L cells after cells were incubated with 15-oxo-ETE for 3 h. 
 
A previous study reported that 15-oxo-ETE has very low but detectable 
chemotactic activity in human monocytes in vitro (Sozzani et al., 1996).  Another study 
reported that 15-oxo-ETE can inhibit proliferation in breast cancer cell lines, however, 
only at concentrations exceeding 100 µM (O'Flaherty et al., 2005).  The present study has 
shown that 15-oxo-ETE inhibits BrdU incorporation and HUVEC proliferation in a time-
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dependent manner at much lower concentrations (down to 1 µM) than reported for breast 
cancer cells (Fig. 2.10).  Rapid 15-oxo-ETE uptake in R15L cells was quantified in order 
to confirm that this pharmacological effect was in fact due to the presence of intracellular 
15-oxo-ETE.  Rapid uptake was observed at extra-cellular concentrations of 1 µM (Fig. 
2.11A) and 10 µM (Fig. 2.11B) showing that 15-oxo-ETE can readily cross the plasma 
membrane. 
The 15-oxo-ETE analogs, 5-oxo-ETE and 15d-PGJ2, (15-deoxy-Δ12,14-
prostaglandin J2, Fig. 2.1) modulate cell proliferation and apoptosis as peroxisome 
proliferator-activated receptor (PPAR)γ agonists (O'Flaherty et al., 2005).  PPARγ 
agonists inhibit experimental models of atherosclerosis and the formation of macrophage 
foam cells (Li et al., 2004).  It has been proposed that 15d-PGJ2 inhibits proliferation by 
covalently binding to the thiol residues in IκB kinase or p50 subunit of NF-κB through a 
Michael addition reaction to block the proteins from performing their survival function, 
using a PPARγ independent mechanism (Cernuda-Morollon et al., 2001).  The similar 
structural features present in 5-oxo-ETE, 15d-PGJ2 and 15-oxo-ETE (Fig. 2.1) suggest 
that 15-oxo-ETE might also modulate cell proliferation and apoptosis through PPARγ-
dependent and/or PPARγ-independent mechanism.   
Our observation that 15-oxo-ETE can inhibit HUVEC proliferation provides a 
novel mechanism that could promote endothelial dysfunction (Carmeliet, 2005).  It is 
interesting to note that 15-PGDH is down-regulated in vivo in colorectal cancer 
(Backlund et al., 2005).  In view of our new findings, it is intriguing to speculate that 
down-regulation of 15-PGDH inhibits the production of 15-oxo-ETE and suppresses the 
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anti-proliferative effect of 15-oxo-ETE on ECs, thus potentially exacerbating colorectal 
cancer.  Moreover, the capability of 15-oxo-ETE to inhibit EC proliferation suggests that 
it might be involved in other conditions where macrophage and/or endothelial cell 
dysfunction play a role such as in chronic inflammation, atherosclerosis, leukemia, and 
asthma.  Chronic inflammation is known to be involved as a critical component in 
angiogenesis as well as cancer (Fierro et al., 2002).  Therefore, depending on the location 
and the local environment in vivo, reduction of EC proliferation and migration in 
response to 15-oxo-ETE treatment might also be responsible for anti-inflammatory 
activity.  Previous studies have demonstrated that overexpression of 15-LO-1 is 
associated with an anti-inflammatory response in both rabbit and murine models 
(Merched et al., 2008).  Furthermore, aspirin-triggered 15-LO-1 metabolites of AA 
(lipoxins) have an anti-inflammatory activity through inhibition of EC proliferation 
(Fierro et al., 2002).  Lipoxins have also been shown to promote resolution, a process 
known to involve active biochemical programs that enables inflamed tissues to return to 
homeostasis (Serhan et al., 2008).  15-LO-1 activation during the process of 
inflammation has also been correlated with switching the metabolism of AA and other ω-
3 polyunsaturated fatty acids to produce pro-resolving lipid mediators such as resolvins 
and protectins.  Taken together, 15-LO-1 up-regulation can result in the production of 
anti-inflammatory as well as pro-resolving activities (Serhan et al., 2008).  Localized 
formation of 15-oxo-ETE production in vivo could be involved in both of these processes. 
In summary, our studies have provided additional insight into IL-4-induced 15-
LO-1 signaling in monocyte/macrophages and potential cell-cell interactions (Fig. 2.13).  
After IL-4 binds to its receptor, 15-LO-1 expression is induced via Janus kinase 1 (JAK1) 
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activation, followed by dimerization and nuclear trans-localization of signal transducer 
and activator of transcription 6 (Stat6) (Chatila, 2004).  With elevated intracellular 
calcium concentrations, 15-LO-1 is recruited to the inner side of the plasma membrane 
where it converts esterified AA to 15(S)-HPETE.  Esterified 15(S)-HPETE is reduced to 
15(S)-HETE and released as the free acid by c-PLA2.  The 15(S)-HETE is then oxidized 
to 15-oxo-ETE by 15-PGDH, and 15-oxo-ETE is conjugated to form a 15-oxo-ETE-
GSH-adduct (OEG), which is then hydrolyzed by γ-glutamyltranspeptidase (GGTP) to a 
15-oxo-ETE-cysteinylglycine-adduct (OEC) by R15L cells (Figs. 2.12 and 2.13) (Lee et 
al., 2007).  Released 15-oxo-ETE can inhibit EC proliferation which could further 
prevent EC growth and that in turn could lead to the inhibition of angiogenesis.  In the 
absence of 15-PGDH (Backlund et al., 2005), no 15-oxo-ETE would be formed and 
therefore the anti-angiogenesis activity on ECs would be lost.  This could then lead to 
increased tumor growth and metastasis.  Therefore, these studies provide a 
pharmacological basis for the design of new targeted therapeutic strategies to inhibit 
angiogenesis. 
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Figure 2.13 Formation and action of 15-LO-1-derived eicosanoids in a 
monocyte/macrophage cell model.  IL-4 binds to its receptor, and activates JAK1, 
which causes dimerization and nuclear trans-localization of transcription 6 (Stat6).  The 
dimerized Stat6 binds to DNA stimulating the production of 15-LO-1.  When 
intracellular calcium concentrations increase, 15-LO-1 is recruited to the inner side of the 
cell membrane where metabolizes AA to 15(S)-HPETE and 15(S)-HETE which is 
released by c-PLA2 from the plasma membrane.  15(S)-HETE is then oxidized to 15-oxo-
ETE by intracellular 15-PGDH and 15-oxo-ETE is conjugated to form OEG, which is 
released and hydrolyzed by GGTP to give OEC.  Released intact 15-oxo-ETE can 
participate in cell-cell interactions such as with ECs to inhibit proliferation. 
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CHAPTER 3 
11-Oxo-Eicosatetraenoic Acid is a Novel Cyclooxygenase-2/15-
Hydroxyprostaglandin Dehydrogenase-Derived Endogenous Arachidonic Acid 
Metabolite  
3.1 Abstract 
Previous studies have shown that COX-2 is up-regulated during carcinogenesis 
while 15-PGDH is down-regulated.  11(R)-HETE is a major eicosanoid formed from 
arachidonic acid metabolism in both rat (RIES) and human (Caco-2) epithelial cell lines 
that express COX-2.  11(R)-HETE was metabolized primarily to 11-oxo-ETE.  11-oxo-
ETE as well as 15-oxo-ETE was revealed by a specific LC-MRM/MS method to be 
secreted in nM concentrations when AA was added to RIES and Caco-2 cells.  Pre-
treatment of the RIES cells with the 15-PGDH inhibitor (CAY10397) decreased AA- and 
11(R)-HETE-mediated formation of 11-oxo-ETE in a dose-dependent manner.  We have 
also made the surprising observation that 11(R)-HETE is an excellent substrate for 15-
PGDH, with a catalytic efficiency similar to that found for 15(S)-HETE.  This confirmed 
that epithelial cell-derived 15-PGDH was responsible for catalyzing the conversion of 
11(R)-HETE to 11-oxo-ETE.  In comparison to the rat cell line (RIES cells), 11(S)-HETE 
and 15(R)-HETE were observed in the human cell line (Caco-2 cells), which was most 
likely due to the back reduction of 11-oxo-ETE and 15-oxo-ETE by aldo-keto reductases 
(AKRs) in the human Caco-2 cells with increased reductase activity when compared with 
the RIES cells.  Furthermore, the formation of 11-oxo-ETE-GSH adduct (11-OEG) and 
its corresponding cysteinylglycine adduct were also identified in RIES cells by LC-MS.   
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3.2 Introduction 
Endogenous factors such as COX-derived PGE2 can increase the proliferation of 
tumor cells through multiple mechanisms including activation of plasma membrane G-
protein-coupled receptors and nuclear PPARγ receptors (Wang and Dubois, 2010) up to 
the point where they need a new blood supply (Folkman, 1995).  Tumors accomplish this 
goal through the release of bioactive substances such as vascular endothelial growth 
factor (VEGF) that stimulate angiogenesis by increasing endothelial cell proliferation 
(Breen, 2007).  The concept has evolved that there is an “angiogenic switch” from 
endogenous substances produced by normal physiological processes such as angiostatin 
(O'Reilly et al., 1994) that inhibit endothelial cell proliferation and so prevent the 
progression of cancer; and pro-proliferative substances such as VEGF produced by the 
tumor that aid in progression (Bergers and Benjamin, 2003).  Some 27 different 
endogenous proteins and small molecules have been identified that can inhibit 
angiogenesis in vitro (Ribatti, 2009).  As a result, numerous therapeutic strategies have 
been developed to inhibit angiogenesis and modulate tumor cell proliferation (Fujita et 
al., 2008). 
COX-2, an immediate-early inducible gene that is involved in inflammation, 
mitogenesis, and signal transduction pathways is up-regulated in many tumor types 
(Wang and Dubois, 2010).  Traditional non-steroidal anti-inflammatory drugs (NSAIDs), 
which inhibit both COX-1 and COX-2 were shown in an observational study to be 
associated with a decreased risk for colon cancer (Thun et al., 1991).  A steady-state level 
of PGE2 is maintained in tumors from PGE-synthase-mediated metabolism of COX-2-
derived PGH2 and a catabolic pathway involving 15-PGDH-mediated inactivation to the 
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15-oxo-PGE2 metabolite (Fig. 3.1) (Tai et al., 2007; Hughes et al., 2008).  The 15-oxo-
PGE2 is then converted to 15-oxo-13,14-dihydro-PGE2 by 15-oxo-prostaglandin-Δ13 
reductase (Chou et al., 2007).  Loss of 15-PGDH expression correlates with tumor 
formation in bladder, breast, colon, intestine, kidney, lung, pancreas, stomach, and skin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              
 
 
 
 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 The formation of 15-oxo-PGE2 from PGE2, 15-oxo-PGD2 and 15d-PGJ2 
from PGD2, and 11-oxo-ETE from 11(R)-HETE. 
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cancer (Backlund et al., 2005; Tai et al., 2007; Celis et al., 2008; Hughes et al., 2008; 
Thiel et al., 2009; Pham et al., 2010; Tseng-Rogenski et al., 2010).  Thus, up-regulation 
of COX-2 (Wang and Dubois, 2010) and down-regulation of PGDH (Backlund et al., 
2005) provides endogenous oncogenic mediators that are significant contributors to 
cancer progression (Markowitz and Bertagnolli, 2009). 
PGD2, another COX-derived metabolite is also metabolized by 15-PGDH to form 
15-oxo-PGD2, which is then converted to the corresponding inactive 13,14-dihydro-
derivative (Rangachari and Betti, 1993), most likely by a 15-oxo-prostaglandin-Δ13 
reductase (Fig. 3.1) (Chou et al., 2007).  Alternatively PGD2 undergoes albumin-
mediated dehydration to give PGJ2, followed by a further dehydration to give 15d-PGJ2 
(Fig. 3.1) (Fitzpatrick and Wynalda, 1983).  Previous studies have shown that 15d-PGJ2 
is a PPARγ receptor agonist that induces adipogenesis (Forman et al., 1995) and inhibits 
the proliferation of HUVECs in culture (Xin et al., 1999).  However, 15d-PGJ2 is known 
to have multiple activities including its ability to induce endothelial cell apoptosis and 
inhibit the NF-κB pathway (Bishop-Bailey and Hla, 1999; Scher and Pillinger, 2009).  In 
contrast to the anti-proliferative macrophage/monocyte-derived 15-oxo-ETE that we 
identified recently (Wei et al., 2009) there is little evidence to show that 15d-PGJ2 can be 
formed in concentrations commensurate with an in vivo anti-proliferative role (Ide et al., 
2003). 
There has been enormous interest in the potential activity of COX-derived PGs as 
mediators of cell proliferation and tumorigenesis (Wang and Dubois, 2010).  In contrast, 
COX-derived lipid hydroperoxides have been largely ignored in spite of their importance 
as initial products of COX-mediated arachidonic acid metabolism (Lee et al., 2007).  
77 
 
Numerous studies of purified COX-1 and COX-2 enzymes from sheep, mouse and 
humans have shown that 11(R)-HETE, 15(S)-HETE, and 15(R)-HETE metabolites are 
formed in relatively high amounts (Lee et al., 2005).  The HETEs arise from reduction of 
the corresponding HPETEs either through the peroxidase activity of COX enzymes or 
through the action of cytosolic peroxidases (Blair, 2008).  We showed that 11(R)-HETE 
is a major eicosanoid secreted at early time-points by arachidonic acid-treated rat 
intestinal epithelial cells that stably express COX-2 (RIES cells) but that it is rapidly 
metabolized so that PGE2 becomes the major metabolite at later time-points (Lee et al., 
2007).  The second most abundant metabolite (15(S)-HETE) is metabolized to 15-oxo-
ETE as would be anticipated from its configuration at C-15 and the known substrate 
specificity of 15-PGDH (Wei et al., 2009).  In our earlier study (Lee et al., 2007), we 
were unable to identify the metabolites of 11(R)-HETE that were secreted by the RIES 
cells.  We have now synthesized 11-oxo-ETE and developed a LC-MRM/MS method for 
its analysis.  This method was then used to determine whether 11-oxo-ETE is secreted 
from COX-2 expressing RIES cells and human Caco-2 cells (Lee et al., 2005; Kamitani 
et al., 1998) and to identify the dehydrogenase responsible for its formation.   
3.3 Materials and Methods 
3.3.1 Materials – Arachidonic acid (peroxide-free), [2H6]-5-oxo-ETE, 11(R,S)-HETE, 
[2H8]-12(S)-HETE, 15(R,S)-HETE, [2H8]-15(S)-HETE, 15-oxo-ETE, 15-oxo-PGE2, 
CAY10397, recombinant human 15-PGDH, murine COX-2 polyclonal antibody and 
horseradish peroxidase conjugated anti-rabbit monoclonal IgG (mIgG) were purchased 
from Cayman Chemical Co. (Ann Arbor, MI).  The Dess-Martin reagent [periodinane; 
1,1,1-Tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one], PFB bromide, Trizma-
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HCl, lipoxidase from Glycine max (soybean), sodium borohydride, β-Nicotinamide 
adenine dinucleotide hydrate (NAD+) and FBS were purchased from Sigma-Aldrich (St. 
Louis, MO).  RPMI-1640 media, Medium 199 (M199), D-glucose, L-glutamine, 
penicillin, streptomycin, pre-cast 4-12% NuPAGE Novex Bis-Tris gels, 0.45 μM 
nitrocellulose membranes and protease inhibitor cocktail were supplied by Invitrogen 
(Carlsbad, CA).  BCA protein assay reagent was obtained from Pierce Biotechnology 
(Rockford, IL).  Caco-2 cells and Eagle’s minimum essential medium (EMEM) were 
obtained from American Type Culture Collection (ATCC) (Manassas, VA).  High 
performance LC grade water, hexane, methanol, isopropanol and dichloromethane were 
obtained from Fisher Scientific (Fair Lawn, NJ).  Gases were supplied by BOC Gases 
(Lebanon, NJ).  [13C20]-AA was obtained from Spectra Stable Isotopes (Columbia, MD).  
Pure 15(S)-HPETE was prepared by soybean oxidation of AA using standard procedures.  
11(R)-HPETE was a kind gift from Dr. Alan Brash (Vanderbilt University, Nashville, 
TN).  RIES cells were a kind gift from Dr. Raymond N. DuBois (University of Texas M. 
D. Anderson Cancer Center, Houston, TX), and HCT-116 cells were a generous gift from 
Dr. Thomas Eling, National Institute of Environmental Health Sciences, NIH, Research 
Triangle Park, NC).  The final concentration of ethanol in the culture media was less than 
0.1 %.  Cell numbers (typically 106/plate) were counted by a hemocytometer.   
3.3.2 Mass Spectrometry - The quantitative targeted lipidomics profile was obtained on 
a TSQ Quantum Ultra AM mass spectrometer (Thermo Scientific, San Jose, CA) as 
described in Chapter 2.  The following MRM transitions were monitored with PFB-
derivatized eicosanoids: 11-oxo-ETE (m/z 317 → 165), 15-oxo-ETE (m/z 317 → 113), 
[2H6]-5-oxo-ETE (m/z 323 → 279), 15-HETEs (m/z 319 → 219), [2H8]-15(S)-HETE (m/z 
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327 → 226), 11-HETEs (m/z 319 → 167), and [2H8]-12(S)-HETE (m/z 327 → 184).  An 
ion trap LTQ mass spectrometer (Thermo Fisher, San Jose, CA) equipped with 
electrospray ionization (ESI) source was to acquire the complete product ion spectra for 
structural confirmation of 11- and 15-oxo-ETE.  Operating conditions were as follows: 
spray voltage at 4 kV and capillary temperature at 220 °C.  Nitrogen was used as the 
sheath gas and auxiliary gas, set at 35 and 18 (in arbitrary units), respectively.  The 11-
oxo-ETE (m/z 341, [M+Na]+), 15-oxo-ETE (m/z 341, [M+Na]+) and 13C20-15-oxo-ETE 
(m/z 361, [M+Na]+) were monitored in the full scan positive mode.  For the analysis of 
sulfhydryl adducts formed in 11(R,S)-HETE-treated RIES cells, an ion-trap Finnigan 
LTQ XL mass spectrometer (Thermo Scientific, San Jose, CA) was equipped with an ESI 
source and operated in the positive ion mode.  Operating conditions were as follows: The 
spray voltage was 5000 V, the capillary voltage was 46 V, the capillary temperature was 
275 oC and the tube lens was at 50 V.  Nitrogen was used for the sheath gas and auxillary 
gas set at 30 and 10 (in arbitary units), respectively.  The MS/MS spectrum for 11-OEG 
was acquired by CID of MH+ at m/z 626 (collision energy, 20 eV).  Accurate mass 
measurements were obtained using ESI on a Thermo LTQ-FT mass spectrometer at a 
resolution of 100,000 and NMR spectra were obtained on a Bruker 500 MHz NMR 
instrument.   
3.3.3 Liquid Chromatography - Normal phase chiral LC-ECAPCI/MS analyses for 
PFB-derivatized lipidomics profile were conducted using a Waters Alliance 2690 high 
performance LC system (Waters Corp., Milford, MA).  A Chiralpak AD-H column (250 x 
4.6-mm internal diameter (id), 5 µm; Daicel Chemical Industries, West Chester, PA) was 
employed for LC system 1 with a flow rate of 1.0 ml/min.  Solvent A was hexane, and 
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solvent B was methanol/isopropanol (1:1, v/v).  The linear gradient for LC system 1 was 
as follows: 2 % B at 0 min, 2 % B at 3 min, 3.6 % B at 11 min, 8 % B at 15 min, 8 % B at 
27 min, 50 % B at 30 min, 50 % B at 35 min, 2 % B at 37 min and 2 % B at 45 min.  
Separations were performed at 30 °C.  Reversed phase LC-ESI/MS analyses were 
conducted using LC system 2 with a Waters Alliance 2690 high-performance LC system 
and a Chiralpak AD-RH column (150 x 4.6-mm id, 5 μm; Daicel Chemical Industries)) at 
a flow rate of 0.5 ml/min.  Solvent A was 0.1 % formic acid in water, and solvent B was 
0.1 % formic acid in methanol.  LC system 2 was isocratic using a mobile phase of 95 % 
B for 15 min.  LC-UV chromatography for synthetic 11-oxo-ETE purification was 
conducted using LC system 3 on a Hitachi L-6200A Intelligent Pump equipped with a 
Hitachi L4000 UV detector (Hitachi, San Jose, CA).  The separation employed a 
Beckman ultrasphere normal phase column (250 x 10 mm id; 5μm).  LC system 3 was 
isocratic with a mobile phase of hexane/isopropanol (197:3) containing 0.1 % acetic acid.  
Separations were conducted at a flow rate 2.5 ml/min and at ambient temperature.  
Reverse phase LC-ESI/MS analyses for GSH-adducts were conducted using LC system 4.  
This employed an Eksigent Express LCTM-100 high performance LC system coupled 
with CTC Analytics HTC PAL autosampler system (Leap Technologies, Carrboro, NC).  
Gradient elution of GSH-adducts was performed in the linear mode employing a YMC 
J’sphere M18S column (150 x 1.0-mm inner id, 4 μm; Phenomenex, Torrance, CA) at a 
flow rate of 20 μl/min.  Solvent A was 10 mM ammonium acetate and 0.1% 
trifluoroacetic acid (TFA) in water, and solvent B was 10 mM ammonium acetate and 
0.1% TFA in acetonitrile.  LC system 4 was as follows: 20 % B at 0 min, 20 % B at 5 
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min, 60 % B at 10 min, 60 % B at 20 min, 90 % B at 22 min, 90 % B at 33 min, 20 % B 
at 35 min.   
3.3.4 Eicosanoid Analyses – A portion of the cell media (3 ml) was transferred into a 
glass tube and adjusted to pH 3 with 2.5 N HCl.  Lipids were extracted with diethyl ether 
(4 ml x 2) and the organic layer was then evaporated to dryness under nitrogen.  
Eicosanoids PFB derivatization was conducted by dissolving the residue in 100 µl of 
acetonitrile, 100 µl of PFB bromide in acetonitrile (1:19, v/v) and 100 µl of DIPE in 
acetonitrile (1:9, v/v) and the solution was heated at 60 oC for 60 min.  The solution was 
allowed to cool down, evaporated to dryness under nitrogen at room temperature, 
dissolved in 100 µl of hexane/ethanol (97:3, v/v) and an aliquot of the final solution (20 
µl) was used for normal-phase chiral LC-ECAPCI/MS analysis using LC system 1.  
Blank media standards (3 ml) were prepared, spiked with the following amounts of 
authentic lipid standards [11(R,S)-HETEs, 15(R,S)-HETEs, 11-oxo-ETE, and 15-oxo-
ETE]: 10, 20, 50, 100, 200, 500 and 1000 pg.  A mixture of internal standards [2H6]-5-
oxo-ETE, [2H8]-12(S)-HETE, and [2H8]-15(S)-HETE (1 ng of each) was added to cell 
supernatant samples and standard solutions.  Calibration curves were obtained with linear 
regressions of analyte versus internal standard peak-area ratio 11(R,S)-HETEs/[2H8]-
12(S)-HETE,15(R,S)-HETE/[2H8]-15(S)-HETE, and 11-oxo-ETE and 15-oxo-ETE/[2H6]-
5-oxo-ETE against analyte concentrations.  Concentrations of HETEs and oxo-ETEs in 
the media supernatants were calculated by interpolation from the calculated regression 
lines.  The limit of detection for each HETE and oxo-ETE was 0.1 nM. 
3.3.5 Synthesis and Purification of 11-oxo-ETE – This was performed by Dr. Suhong 
Zhang in the Blair laboratory.  Dess-Martin regent (1 mg, 2.36 μmol) was added to a 
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solution of 11(R,S)-HETE (2 mg, 6.2 mmol) in dichloromethane (0.5 ml) and stirred for 2 
h at room temperature.  Analysis by LC-MS after PFB derivatization using LC system 1 
revealed there was no starting material left and that there was one major product 
corresponding to 11-oxo-ETE.  The reaction mixture was centrifuged twice at 3,400 rpm 
(10 min) and the supernatant was evaporated ready for LC purification.  The residue was 
dissolved in the mobile phase (200 μl) and preparative LC separation conducted using LC 
system 3 monitoring the UV absorbance at 236 nm.  The retention time for 11-oxo-ETE 
was 15.0 min and for 15-oxo-ETE was 12.7 min.  High resolution electrospray 
ionization-MS of 11-oxo-ETE revealed accurate masses of m/z 319.2263 and m/z 
341.2079 for the protonated and sodiated molecules, respectively [calculated accurate 
mass measurements for protonated (C20H31O3) and sodiated (C20H30O3Na) molecules, m/z 
319.2273 and m/z 341.2093, respectively].  500 MHz 1H-NMR (δH, CDCl3; Fig. 3.2) 
7.55 (dd, J1 = 11.5 Hz, J2 =15.5, 1H), 6.21(d, J =15.5Hz, 1H),  6.15-6.11 (m, 1H), 5.97-
5.92 (m, 1H), 5.60-5.58 (m, 2H), 5.41-5.38 (m, 2H), 3.35 (d, J =4.5Hz , 2H), 2.83-2.81 
(m, 2H), 2.38-2.31 (m, 4H), 2.17-2.12 (m, 2H), 1.74-1.25 (m, 8H), 0.89 (t, J = 7.0 Hz, 
3H).  Analysis of purified 11-oxo-ETE as its PFB derivative was conducted using LC 
system 1.  A single peak was observed at a retention time of 7.5 min with an intense 
negative ion at m/z 317 corresponding to [M-PFB]-.  CID of [M-PFB]- (m/z 317) and 
MS/MS analysis revealed major product ions at m/z 123, 149, 165, 219, and 273 (Fig. 
3.3a).  The UV spectrum was consistent with the presence of a conjugated dienone with a 
UV λmax at 279 nm and molecular extinction coefficient (ε) of 18,985 M-1cm-1.  11-Oxo-
ETE was identified previously as an endogenous fatty acid oxidation product that was 
present in human atherosclerotic plaques (Waddington et al., 2001).   
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Figure 3.2 1H NMR spectrum for 11-oxo-ETE. 
 
3.3.6 Preparation and Purification of 15(S)-HETE and 11(R)-HETE – This was 
performed by Dr. Suhong Zhang in the Blair laboratory.  15(S)-HPETE and 11(R)-
HPETE were reduced in 4 ml methanol containing NaBH4 (4 mg) at room temperature 
for 1 h to give rise to 15(S)-HETE and 11(R)-HETE.  The reaction was quenched by 
adding 4 ml water on ice and adjusted pH to 3 with 3 N HCl.  15(S)-HETE and 11(R)-
HETE were extracted by hexane (2 x 4 ml).  The upper organic layer was taken and 
evaporated to dryness under nitrogen.  The concentrations of 11(R)-HETE of 15(S)-
HETE and were confirmed by UV spectroscopy (λmax 236 nm, ε=27000 M-1cm-1).  The 
purities of 11(R)-HETE and 15(S)-HETE were established as > 99 % by reversed-phase 
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chiral LC-electrospray ionization/MS analysis using LC system 2, eluting respectively at 
retention time of 6.1 min and 13.2 min with ammoniated molecules at m/z 338 
([M+NH4]+). 
3.3.7 Preparation of [13C20]-15-oxo-ETE - This was performed by Dr. Jasbir Arora in 
the Blair laboratory.  [13C20]-AA was converted to [13C20]-15(S)-HPETE using soybean 
lipoxygenase.  The labeled HPETE was then reduced to [13C20]-15(S)-HETE with 
NaBH4, which was then oxidized to [13C20]-15-oxo-ETE using the Dess-Martin reagent as 
described above.  There was < 0.5 % of [12C20]-15-oxo-ETE present in the [13C20]-15-
oxo-ETE.  
3.3.8 Preparation of 11-Oxo-ETE-Glutathione-Adduct (OEG) – This was performed 
by Dr. Jasbir Arora in the Blair laboratory. 11-oxo-ETE and glutathione (GSH) was 
converted to 11-OEG by incubating in 100 mM phosphate buffer (pH 6.5) for 5 h at 37 
oC, or by incubating with glutathione-S-transferase (GST) in 100 mM phosphate buffer 
(pH 6.5) for 5 h at 37 oC.  The reaction mixture was then spinned to evaporate traces of 
ehanol in speed vac.  11-OEG extraction was performed by solid phase extraction (SPE) 
using pre-conditioned Waters Oasis HLB cartridges (6 ml, 200 mg).  The cartridges were 
washed with 3 ml water and 11-oxo-ETE-GSH was eluted with 3 ml acetonitrile/water 
(80:20).  The eluted extraction was evaporated under nitrogen to dryness and 
reconstituted in CH3CN/water (20:80) for LC-MS analysis. 
3.3.9 Cell Culture - RIES cells were cultured in RPMI 1640 media with 10 % FBS, 2 
mM L-glutamine, 100,000 units/l penicillin and 100,000 μg/l streptomycin.  Before the 
treatment for lipidomics analysis, the culture media was replaced with serum-free RPMI 
1640 media.  Caco-2 cells were cultured in cell culture dishes precoated with FNC-
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coating mix (AthenaES, Baltimore, MD) and maintained in EMEM supplemented with 
10 % FBS, 100,000 units/l penicillin and 100,000 μg/l streptomycin.  Before treatment, 
cell culture media were replaced with serum-free EMEM containing a balanced salt 
solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, and 
1500 mg/L sodium bicarbonate.  HCT-116 cells were cultured in cell culture dishes 
precoated with FNC-coating mix (AthenaES, Baltimore, MD) and maintained in 
McCoy’s 5A Medium supplemented with 10 % FBS, 100,000 units/l penicillin and 
100,000 μg/l streptomycin.   
3.3.10 Metabolism of Arachidonic Acid by RIES Cells - RIES cells were cultured as 
described above until 90% confluent.  The media was replaced with serum-free RPMI 
1640 and cells were treated with AA (10 µM final concentration).  Incubations were then 
conducted for 5 min, 15 min, 30 min, 40 min, 1 h, 3 h and 6 h at 37 oC.  Lipid extractions 
from cell culture media (3 ml) were performed as described above.  
3.3.11 Inhibition of RIES cell 15-PGDH with CAY10397 – RIES cells were cultured as 
described above until 90% confluent.  The media was replaced with serum-free RPMI-
1640 containing CAY10397 (100 µM final concentration).  Cells were then incubated for 
4 h at 37 oC followed by incubation with AA (10 μM final concentration) for 10 min.  In 
separate experiments the media was replaced with serum-free RPMI-1640 containing 
various doses of CAY10397 (0 µM, 5 µM, 10 µM, 15 µM, 25 µM, 50 µM, and 100 µM 
final concentration).  Cells were then incubated for 4 h at 37 oC followed by incubation 
with additional 11(R)-HETE (50 nM final concentration) or AA (10 µM final 
concentration) for 10 min.  
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3.3.12 Western Blot Analysis of Caco-2 Cells and HCT-116 Cells – Cells were 
cultured as described above, and washed with PBS.  Lysis buffer containing protease 
inhibitor cocktail were then added cells to lyse the cells.  Cells were then collected and 
centrifuged at 13,000 rpm for 10 min.  Protein concentration was determined by BCA 
assay.  12 micrograms of heat-inactivated protein were loaded and analyzed on 4-12% 
SDS/PAGE.  For Western blot analysis fractionated proteins were electrotransferred onto 
a nitrocellulose membrane (Invitrogen, Carlsbad, CA) and unspecific binding was 
blocked with tris(hydroxymethyl)aminomethane (Tris)-buffered saline containing 10% 
non-fat milk powder and 0.1% Tween-20.  A rabbit antibody against murine COX-2 
(Cayman Chemical Co., Ann Arbor, MI) served as the primary antibody. The secondary 
antibody was conjugated with peroxidase (Jackson Immunoresearch Laboratories, West 
Grove, PA) and the antigen-antibody complex was detected with ECL Plus (Amersham 
Biosciences, Piscataway, NJ). 
3.3.13 Metabolism of Arachidonic Acid by Caco-2 Cells – Caco-2 cells were cultured 
as described above until 90% confluent.  The media was replaced with serum-free 
EMEM.  AA (10 μM final concentration) in ethanol was added to the media and cells 
were incubated for 5 min at 37 ºC. In separate experiments, the media was replaced with 
serum-free EMEM containing CAY10397 (100 µM final concentration).  Cells were then 
incubated for 4 h at 37 oC followed by incubation with additional AA (10 µM final 
concentration) for 10 min. 
3.3.14 Analysis of 11-Oxo-ETE-Glutathione-Adduct (OEG) and its Cysteinylglycine 
Metabolite in 11(R,S)-HETE-Treated-RIES Cells – The media was replaced with 
serum-free RPMI-1640 containing 11(R,S)-HETE (1 μM final concentration).  Cells were 
87 
 
then incubated for 30 min at 37 oC.  The cell culture medium was loaded on a solid phase 
extraction column (C18, 3 ml), which was preconditioned with acetonitrile and water.  
After they were washed with 3 ml of water, OEG and the cysteinylglycine-adduct were 
eluted with 6 ml of 50 % acetonitrile in water.  The solution was evaporated to dryness 
under nitrogen, and reconstituted in 100 μl methanol which was then diluted by 1000 
times.  An aliquot of 20 μl was used for reversed-phase LC-electrospray ionization/MS 
analysis using LC system 4. 
3.3.15 Metabolism of 11(R)-HETE and 15(S)-HETE by 15-PGDH – This was 
performed by Ms. Xiaojing Liu in the Blair laboratory. Various concentrations of 11(R)-
HETE (0, 2.3 μM, 4.6 μM, 6.9 μM, 9.2 μM and 23 μM) were incubated with 9.0 nM of 
recombinant 15-PGDH (50 ng, 1.8 pmol) and cofactor NAD+ (400 μM) in 50 mM Tris-
Cl (pH 7.9) for 3.5 min at 37 oC.  Similarly, various concentrations of 15(S)-HETE (0, 
0.92 μM, 1.84 μM, 2.76 μM, 3.68 μM, 4.6 μM, 9.2 μM and 23 μM) were incubated with 
2.25 nM (13 ng, 0.45 pmol) of recombinant 15-PGDH and cofactor NAD+ (400 μM) in 
500 mM Tris-Cl (pH 7.9) for 3 min at 37 oC.  Each total reaction volume was 200 μl.  
After a 3 min incubation, the enzymatic reaction was quenched with 400 μl of ice cold 
methanol and [13C20]-15-oxo-ETE (8 ng) added as the internal standard.  Eicosanoids 
were extracted with dichloromethane/methanol (1.2 ml; 8:1, v/v).  The lower organic 
layer was then evaporated to dryness under nitrogen and reconstituted in methanol (100 
μl).  An aliquot (25 µl) was used for reversed-phase chiral LC-electrospray 
ionization/MS analysis using LC system 2.  The retention times for 11-oxo-ETE and 15-
oxo-ETE were 8.7 min and 9.3 min, respectively.  In separate experiments, the formation 
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of 11-oxo-ETE and 15-oxo-ETE were found to be linear for the first 5 min.  Eicosanoids 
were quantified by interpolation from a standard curve prepared with 15-oxo-ETE and 
11-oxo-ETE using [13C20]-15-oxo-ETE as the internal standard. 
3.3.16 Statistical Analyses – All experiments were conducted in triplicate.  Statistical 
significance (p value < 0.05) was determined using a two-tailed unpaired t-test employing 
GraphPad Prism software (v 5.01, GraphPad Software Inc., La Jolla). 
3.4 Results 
3.4.1 LC-MS and MS/MS Analysis of 11-oxo-ETE and 15-oxo-ETE - RIES cells were 
incubated with 1 µM 11(R)-HETE for 5 min.  LC-MS analysis of PFB derivatives of 
lipids extracted from the RIES cell media showed that there was a single major 
metabolite, which eluted at 7.4 min (data not shown).  The full scan mass spectrum of 
this metabolite had only one major ion at m/z 317 corresponding to [M-PFB]-.  CID and 
MS/MS analysis revealed the formation of intense product ions at m/z 123, 149, 165, 219, 
and 273 (Fig. 3.3b).  The MS/MS spectrum was identical with that obtained from 
authentic synthetic 11-oxo-ETE-PFB (Fig. 3.3a), which confirmed the identity of 11-oxo-
ETE from RIES cells.  In comparison, CID and MS/MS analysis of authentic 15-oxo-
ETE-PFB standard showed major product ions at m/z 113, 139, 147, 219, and 273 (Fig. 
3.3c).  The product ion at m/z 165 in RIES cell-derived and synthetic 11-oxo-ETE-PFB 
corresponded to cleavage between C-9 and C-10 and m/z 123 was formed from cleavage 
between C-11 and C-12 (Figs. 3.3a and 3.3b).  In contrast, the specific product ion of 15-
oxo-ETE-PFB at m/z 113 was formed from the cleavage of the double bond between C-
13 and C-14 (Fig. 3.3c).     
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Figure 3.3 MS/MS analyses of 11-oxo-ETE and 15-oxo-ETE. A. Product ion spectra 
for (a) synthetic 11-oxo-ETE-PFB standard, (b) 15-PGDH-derived 11-oxo-ETE-PFB 
from RIES cells treated with 1 μM 11(R)-HETE, and (c) synthetic 15-oxo-ETE-PFB 
standard. B. Structure of 11-oxo-ETE [(a) and (b)] and 15-oxo-ETE (c) along with the 
specific product ions observed by CID of [M-PFB]- (m/z 317) and MS/MS analysis of 11- 
and 15-oxo-ETE-PFB. 
3.4.2 Arachidonic Acid-Mediated Formation of HETEs in RIES Cells - RIES cells 
were incubated with 10 µM AA for 6 h and RIES cell supernatants were analyzed by LC-
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MS.  This demonstrated the secretion of 11-oxo-ETE (retention time 7.4 min) and 11(R)-
HETE (retention time, 10.4 min) within 5 min of AA addition (Figs. 3.4Aa and 3.4Af).  
The chromatograms also revealed the presence of 15-oxo-ETE (retention time, 7.5 min) 
as well as its potential precursors 15(R)-HETE (retention time, 11.7 min) and 15(S)-
HETE (retention time, 15.2 min) (Figs. 3.4Ab and 3.4Ad).  Quantification of 15(R)- and 
15(S)-HETE revealed a 20 % enantiomeric excess of 15(S)-HETE (Fig. 3.4Ad).  11(R)-
HETE was the most abundant metabolite of AA secreted by cells at the early time points 
(< 1 h), as we had observed previously (Lee et al., 2007).  The maximum 11(R)-HETE 
concentrations was observed within 5-min of AA addition (Fig. 3.5A).  11(R)-HETE was 
then rapidly metabolized over 3 h (Fig. 3.5A).  11-Oxo-ETE in the cell media was also 
observed to peak within 5 min of AA addition and declined to a steady state after 3 h 
(Fig. 3.5B).  Only trace amounts of 11(S)-HETE were observed after the addition of AA 
(Fig. 3.4Af) or 11(R)-HETE (data not shown) to the RIES cells.  Pre-treatment with 
CAY10397 resulted in increased levels of 15(S)-HETE (Fig. 3.7A) and decreased levels 
of 15-oxo-ETE (Fig. 3.7B).  This suggested that CAY10397-mediated inhibition of 15-
PGDH led to a modest accumulation of 15(S)-HETE (Fig. 3.7A) and a simultaneous 
inhibition of 15-oxo-ETE formation (Fig. 3.7B).  The level of 15(R)-HETE was almost 
identical after the addition of AA alone when compared with the presence of CAY10397 
(Fig. 3.7A). Pre-treatment of CAY10397 also resulted in a substantial increase in 11(R)-
HETE concentrations (Fig. 3.8A) together with a reduction in 11-oxo-ETE concentrations 
(Fig. 3.8B).   
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Figure 3.4 Targeted chiral lipidomics analysis of COX-2 derived AA metabolites 
from RIES and Caco-2 cells. MRM chromatograms are shown for (a) 11-oxo-ETE-PFB 
(m/z 317 → 165), (b) 15-oxo-ETE-PFB (m/z 317 → 113), (c) [2H6]-5-oxo-ETE-PFB 
internal standard (m/z 326 → 279), (d) 15-(R,S)-HETE-PFB (m/z 319 → 219), (e) [2H8]-
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15(S)-HETE-PFB internal standard (m/z 327 → 226), (f) 11(R,S)-HETE-PFB (m/z 319 → 
167), (g) [2H8]-12(S)-HETE-PFB internal standard (m/z 327 → 184). (A) RIES cells. (B) 
Caco-2 cells. 
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Figure 3.5 Kinetics of 11(R)-HETE and 11-oxo-ETE by RIES cells.  RIES cells were 
incubated with AA (10 μM) or 11(R)-HETE (1 µM) for a period of 360 min.  Supernatant 
was collected at different time points.  Lipid metabolites [11(R)-HETE and 11-oxo-ETE] 
in the cell supernatant were extracted and derivatized with PFB and their concentrations 
were determined in triplicate (means ± S.E.M.) by LC-ECAPCI/MRM/MS analysis.  (A) 
Kinetic plot of 11(R)-HETE metabolism by RIES cells treated with AA (10 µM) 
(t1/2=21.6 min and k=0.0321 min-1); (B) Kinetic plot of 11-oxo-ETE metabolism by RIES 
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cells treated with AA (10 µM) (t1/2=32.2 min and k=0.0215 min-1); (C) Kinetic plot of 
11-oxo-ETE metabolism by RIES cells treated with 11(R)-HETE (1 µM) (t1/2=29.2 min 
and k=0.0237 min-1).   
 
 
COX-2 (72 kDa)
HCT-116        Caco-2 
β-actin (43 kDa)
 
 
Figure 3.6 Western blot analysis of COX-2 in human epithelial colorectal 
adenocarcinoma cells (HCT-116 and Caco-2).  Western blot analysis are shown for 
COX-2 (72 kDa) in HCT-116 cells and Caco-2 cells, with β-actin (43 kDa) as a loading 
control. 
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Figure 3.7 Inhibition of 15-HETE metabolism to 15-oxo-ETE by 15-PGDH inhibitor 
CAY 10397.  (A) 15(S)-HETE and 15(R)-HETE formation by RIES cells that were 
treated with 10 μM AA or pretreated with 100 μM CAY10397 for 4 h before 10 μM AA 
treatment.  (B) 15-oxo-ETE formation by RIES cells that were treated with 10 μM AA or 
pretreated with 100 μM CAY10397 for 4 h before 10 μM AA treatment.  (C) 15(S)-
HETE and 15(R)-HETE formation by Caco-2 cells that were treated with 10 μM AA or 
pretreated with 100 μM CAY10397 for 4 h before 10 μM AA treatment.  (D) 15-oxo-
ETE formation by Caco-2 cells that were treated with 10 μM AA or pretreated with 100 
μM CAY10397 for 4 h before 10 μM AA treatment. Lipid metabolites in the cell media 
were extracted and derivatized with PFB.  11(S)-HETE, 11(R)-HETE, and 11-oxo-ETE 
concentrations were determined in triplicate by stable isotope dilution by LC-
95 
 
ECAPCI/MRM/MS analysis of PFB derivatives.  Values presented in bar graphs are 
means ± S.E.M. 
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Figure 3.8 Inhibition of 11-HETE metabolism to 11-oxo-ETE by 15-PGDH inhibitor 
CAY 10397.  (A) 11(R)-HETE formation by RIES cells that were treated with 10 μM 
AA or pretreated with 100 μM CAY10397 for 4 h before 10 μM AA treatment.  (B) 11-
oxo-ETE formation by RIES cells that were treated with 10 μM AA or pretreated with 
100 μM CAY10397 for 4 h before 10 μM AA treatment.  (C) 11(S)-HETE and (R)-
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HETE formation byCaco-2 cells that were treated with 10 μM AA or pretreated with 100 
μM CAY10397 for 4 h before 10 μM AA treatment.  (D) 11-oxo-ETE formation by 
Caco-2 cells that were treated with 10 μM AA or pretreated with 100 μM CAY10397 for 
4 h before 10 μM AA treatment. Lipid metabolites in the cell media were extracted and 
derivatized with PFB.  11(S)-HETE, 11(R)-HETE, and 11-oxo-ETE concentrations were 
determined in triplicate by stable isotope dilution by LC-ECAPCI/MRM/MS analysis of 
PFB derivatives.  Values presented in bar graphs are means ± S.E.M.      
 
3.4.3 Dose-dependent Effect of CAY10397 on 11-oxo-ETE and 11(R)-HETE in RIES 
Cells - AA (10 µM) was added to the RIES cells for 10 min, with or without the pre-
treatment with various doses of CAY10397 (0-100 µM) for 4 h.  This resulted in a 
significant inhibition of 11-oxo-ETE formation (Fig. 3.9A) and a simultaneous 
accumulation of 11(R)-HETE in a dose-dependent manner (Fig. 3.9C).  To confirm that 
15-PGDH was the enzyme that oxidized 11(R)-HETE to 11-oxo-ETE, RIES cells were 
treated with 50 nM 11(R)-HETE for 10 min, with or without the pre-treatment with 
various doses of CAY10397 (0-100 µM) for 4 h.  Addition of 11(R)-HETE alone resulted 
in the formation of 11-oxo-ETE, whereas CAY10397 pre-treatment resulted in a dose 
dependent inhibition of 11-oxo-ETE formation (Fig. 3.9B).  Inhibition of 11-oxo-ETE 
formation reached 70 % in the presence of 100 µM CAY10397 (Fig. 3.9B).  CAY10397 
also caused a dose-dependent increase in 11(R)-HETE concentrations after the addition 
of exogenous 11(R)-HETE (Fig. 3.9D).  In the absence of AA, CAY10397 did not lead to 
11-oxo-ETE generation (data not shown), whereas there was significant inhibition of AA-
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mediated (Fig. 3.9A) and 11(R)-HETE-mediated (Fig. 3.9B) formation of 11-oxo-ETE.  
The EC50 for CAY10397-induced increase in AA-mediated 11(R)-HETE formation (Fig. 
3.9C) was significantly higher than the IC50 of CAY10397 on AA-mediated 11-oxo-ETE 
formation (Fig. 3.9C).  In contrast, EC50 for 11(R)-HETE concentration after the addition 
of exogenous 11(R)-HETE (Fig. 3.9D), which was similar to the IC50 for inhibition of 
11(R)-HETE-mediated 11-oxo-ETE formation (Fig. 3.9C).  This is most likely because of 
the complexity of the pathways involved in AA-mediated 11-oxo-ETE formation 
compared with its direct formation from 11(R)-HETE. 
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Figure 3.9 Dose-dependent effects of CAY 10397 on the levels of 11-oxo-ETE and 
11-HETEs released by RIES cells.  (A) Dose-dependent inhibition curve of CAY 10397 
on 11-oxo-ETE released by RIES cells treated with 10 µM AA for 10 min following the 
4 h pretreatment with CAY 10397; (B) Dose-dependent inhibition curve of CAY 10397 
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on 11-oxo-ETE released by RIES cells treated with 50 nM 11(R)-HETE for 5 min 
following the 4 h pretreatment with CAY 10397; (C) Dose-dependent curve of CAY 
10397 on 11(R)-HETE accumulation by RIES cells treated with 10 µM AA for 10 min 
following the 4 h pretreatment with CAY 10397;  (D) Dose-dependent curve of CAY 
10397 on 11(R)-HETE accumulation by RIES cells treated with 50 nM 11(R)-HETE for 
5 min following the 4 h pretreatment with CAY 10397.  Cell supernatant was collected at 
each time point.  Lipid metabolites in the cell supernatant were extracted and derivatized 
with PFB.  Determinations were conducted in triplicate (means ± S.E.M.) by stable 
isotope dilution LC-ECAPCI/MRM/MS analyses of PFB derivatives. 
 
3.4.4 Formation of 11-OEG-adduct in RIES Cell Culture - Secretion of 11-OEG and 
its conversion to the corresponding cysteinylglycine-adduct were monitored in the media 
after the addition of 11(R, S)-HETE to the RIES cells.  11-OEG was detected by specific 
LC-MS monitoring as significant metabolites after 30 min incubation.  The OEG 
(retention time = 13.1 min) (Fig. 3.10Ac) and its cysteinylglycine metabolite (11-oxo-
ETE-cysteinylglycine-adduct) (data not shown) were also observed as intense speaks in 
the chromatogram when analyzed by LC system 4 coupled with electrospray 
ionization/MS.  The 11-OEG observed from RIES cells shared the same chromatograms 
with the authentic 11-OEG synthesized with GST (Fig. 3.10Aa) or synthesized without 
GST at pH 6.5 (Fig. 3.10Ab).  The full scan mass spectrum of this metabolite had only 
one major ion at m/z 626 corresponding to [M+H]+.  CID and MS/MS analysis revealed 
the formation of intense product ions at m/z 497, 479, 394, 319 and 301 (Fig. 3.10Bb).  
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The MS/MS spectrum was identical with that obtained from authentic synthetic 11-OEG 
(Fig. 3.10Ba and 3.10Bb), which confirmed the identity of 11-OEG from RIES cells.  
3.4.5 Arachidonic acid-Mediated Formation of HETEs in Caco-2 Cells Analysis – In 
order to examine the formation of COX-2-derived HETEs in human epithelial cells, the 
Caco-2 colorectal carcinoma cell line was employed.  Caco-2 cells were reported 
previously to constitutively express COX-2 (Kamitani et al., 1998).  This was confirmed 
by Western blot analysis before AA was added to the cells (Fig. 3.6).  A very similar 
product and kinetic profile was observed as for the RIES cells (Figs. 3.4B and 3.5) with 
11-oxo-ETE (Fig. 3.4Ba), 15-oxo-ETE (Fig. 3.4Bb), 15(R)-HETE (Fig. 3.4Bd), 15(S)-
HETE (Fig. 3.4Bd), and 11(R)-HETE (Fig. 3.4Bf) as the major AA-derived metabolites.  
A significant amount of 11(S)-HETE was secreted from the cells (Fig. 3.4Bf).  AA (10 
µM) was added to the Caco-2 for 10 min, with or without the pre-treatment with 
CAY10397 (100 µM) for 4 h.  Unlike the RIES cells, CAY10397 caused an increase of 
both 15(S)-HETE and 15(R)-HETE (Fig. 3.7C).  There was a concomitant reduction in 
15-oxo-ETE levels (Fig. 3.7D).  This suggested that there was some inter-conversion 
between 15-oxo-ETE and 15(R)-HETE.  Pre-treatment of CAY10397 also resulted in a 
substantial increase in 11(R)-HETE concentrations (Fig, 3.8C) together with a reduction 
in 11-oxo-ETE (Fig. 3.8D).  Again, unlike the RIES cells, there was a substantial increase 
in 11(S)-HETE concentrations (Fig. 3.8C).  This suggested that there was also some inter-
conversion between 11-oxo-ETE and 11(S)-HETE in the Caco-2 cells. 
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Figure 3.10 LC-MS analysis and MS/MS spectrums of the formation of 11-oxo-ETE-
GSH adduct (11-OEG).  (A) Representative LC-MS chromatograms of reaction 
products between 11-oxo-ETE and GSH incubated with 4 nM glutathione-S-transferases 
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(GST) (a), without GST in the chemical condition of pH 6.5 (b), and 11-OEG derived 
from 11(R,S)-HETE by RIES cells (c).  The reconstituted ion chromatograms for MH+ of 
the major adduct (m/z 626, 13.1 min) are shown.  (B) Product ion spectra for (a) GST-
mediated synthetic 11-OEG standard, (b) chemically synthetic 11-OEG standard without 
enzyme. (c) 11-OEG from RIES cells treated with 1 μM 11(R,S)-HETE.  (C) Structure of 
11-OEG along with the specific product ions observed by CID of [M+H]+ (m/z 626) and 
MS/MS analysis of 11-OEG. 
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Figure 3.11 Kinetic plot of the formation of 11-oxo-ETE and 15-oxo-ETE by 15-
PGDH.  Various concentrations of (A) 11(R)-HETE or (B) 15(S)-HETE, were incubated 
with 4 nM 15-PGDH and cofactor NAD+. Determinations were conducted in triplicate 
(means ± S.E.M.) by stable isotope dilution LC-ESI/MRM/MS analyses.  (A) 11-oxo-
ETE. (B) 15-oxo-ETE. 
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3.4.6 15-PGDH-Mediated Formation of 11-oxo-ETE and 15-oxo-ETE - Various 
concentrations of 11(R)-HETE and 15(S)-HETE were incubated with recombinant human 
15-PGDH and NAD+ at 37 oC.  A Michaelis-Menton kinetic analysis of 11-oxo-ETE 
formation revealed that the Vmax, Km, and kcat values for oxidation of 11(R)-HETE (Fig. 
3.11A) and 15(S)-HETE (Fig. 3.11B) were similar.  Therefore, the catalytic efficiency 
(Kcat/Km) for 15-PGDH-mediated oxidation of 11(R)-HETE (2.5 x 103 min-1mM-1) and 
15(S)-HETE were similar (6.9 x 103 min-1mM-1). 
3.5 Discussion  
Eicosanoids secreted from RIES and human Caco-2 cells were analyzed as PFB 
derivatives by chiral LC-ECAPCI/MS methodology (Lee and Blair, 2007; Mesaros et al., 
2009).  This revealed the presence of 11-oxo-ETE, 15-oxo-ETE, 15(R)-HETE, 15(S)-
HETE, and 11(R)-HETE (Fig. 3.3).  The product ion mass spectrum of 11-oxo-ETE 
secreted from the RIES cells was identical with the product ion mass spectrum of an 
authentic 11-oxo-ETE standard that we had synthesized (Fig. 3.3).  Importantly, there 
were significant differences between the product ion spectra of 11-oxo-ETE and 15-oxo-
ETE.  The ions at m/z 113, 139, and 147 in 15-oxo-ETE were completely absent in the 
spectrum from 11-oxo-ETE.  Conversely, ions at m/z 123, 149, and 165 in the spectrum 
from 11-oxo-ETE were completely absent in the spectrum from 15-oxo-ETE.  This made 
it possible to analyze the two oxo-ETE PFB derivatives using specific LC-MRM/MS 
transitions even though their LC retention times were very similar (Fig. 3.3).  These 
studies confirmed our previous finding that 11(R)-HETE was the major HETE secreted 
from RIES cells (Lee et al., 2007).  They also showed that 11(R)-HETE was cleared 
rapidly (t1/2 of 21.6 min, Fig. 3.5B).  The 11-oxo-ETE that was formed from 11(R)-HETE 
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was metabolized at a similar rate (Fig. 3.5C).  This was due in part to the rapid 
intracellular inactivation to 11-OEG through GST-mediated metabolism as we observed 
previously for 15-oxo-ETE (Lee et al., 2007).  The inactive 11-OEG was then secreted 
and converted to the corresponding cysteinylglycine-adduct by γ-glutamyltranspeptidase 
analogous to 15-OEG (Lee et al., 2007).  Similar results were obtained with Caco-2 cells, 
except that the 15-oxo-ETE and 11-oxo-ETE were converted to 15(R)-HETE and 11(S)-
HETE, respectively (Fig. 3.4B).  Formation of these HETEs became much more apparent 
when 15-PGDH was inhibited, which resulted in an almost three-fold increase in both 
15(R)-HETE (Fig. 3.7C) and 11(S)-HETE (Fig. 3.8C) concentrations.  This might arise 
from AKRs in the human Caco-2 cells which have increased activity when compared 
with the RIES cells (Penning and Byrns, 2009).  Subsequent 15-PGDH-mediated oxo-
ETE formation would lead to redox cycling between the oxo-ETEs and HETEs.  AKR-
mediated metabolism of the oxo-ETEs could then compete with GST-mediated 15-OEG 
formation (Fig. 3.12).  This might explain why secreted 11-oxo-ETE concentrations 
reached a low steady state of 0.23 nM in the RIES cells rather than being completely 
metabolized to the corresponding 11-OEG (Figs. 3.5B and 3.5C).  Reductive metabolism 
of the oxo-ETEs could also provide an endogenous pathway for decreasing the in vivo 
concentrations of anti-proliferative 11- and 15-oxo-ETE as has been suggested previously 
for 15d-PGJ2 (Penning and Byrns, 2009). 
15-PGDH catalyzes NAD+-mediated oxidation of the 15(S)-hydroxyl moiety of 
PGs and other eicosanoids (Fig. 3.1) (Wei et al., 2009).  It is a key PG catabolism enzyme 
that converts PGE2 and PGD2 to inactive 15-oxo-metabolites (Figs. 3.1 and 3.13) 
(Backlund et al., 2005; Rangachari and Betti, 1993).  Our previous studies established 
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that 15-oxo-ETE was formed from 15-LO-1-derived 15(S)-HETE in macrophages and 
monocytes and that its biosynthesis was reduced by CAY10397, a 15-PGDH inhibitor 
(Wei et al., 2009).  Surprisingly, CAY10937 had even greater effects on the 11(R)-HETE 
pathway.  Thus, there was an almost three-fold increase in 11(R)-HETE concentrations 
after CAY10937-mediated inhibition of 11-oxo-ETE formation in both RIES cells and 
human Caco-2 cells (Figs. 3.7A and 3.7C).  There was also a significant decrease in 11-
oxo-ETE levels (Figs. 3.7B and 3.7D).  IC50 values for inhibition of 15-PGDH-mediated 
11-oxo-ETE formation by CAY10937 from either AA-derived 11(R)-HETE (Fig. 3.8A) 
or from added 11(R)-HETE (Fig. 3.8B) were similar.  The corresponding EC50 vales for 
inhibition of 15-PGDH-mediated oxidation of AA-derived 11(R)-HETE (Fig. 3.8C) or 
added 11(R)-HETE (Fig. 3.8D) were similar to those found in mouse macrophages and 
human monocytes for inhibition of 15(S)-HETE oxidation (Wei et al., 2009).  These 
results were very surprising in view of the lack of a 15(S)-hydroxyl group on 11(R)-
HETE and suggested that perhaps the CAY10397 could be inhibiting another 
dehydrogenase.  This was shown not to be the case because the catalytic activity of 
human 15-PGDH for oxidation of 11(R)-HETE was less than a factor of three lower than 
that observed for 15-oxo-ETE (Fig. 3.11).  These data clearly show that 11(R)-HETE is 
an excellent substrate for 15-PGDH in spite of its lack of an appropriate functional group 
at C-15 and incorrect 11(R)-stereochemistry (Fig. 3.1). 
We realized that when compared to 15-oxo-ETE, its isomer, 11-oxo-ETE, is very 
similar in structure to 15d-PGJ2.  It only differs in the lack of a C-8 to C-12 bond, in 
having a cis-8,9- rather than cis-9,10-double bond, and a cis- rather than trans-14,15-
double bond (Fig. 3.1).  This suggested that 11-oxo-ETE might be a more effective 
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inhibitor of HUVEC proliferation than 15-oxo-ETE (Wei et al., 2009) with a potency 
similar to that observed for 15d-PGJ2 (Xin et al., 1999).  Ground-breaking experiments 
conducted in 1994 by M. O’Reilly in the Folkman group had revealed that angiostatin, a 
kringle-containing internal fragment of plasminogen, was a potent inhibitor of endothelial 
cell proliferation (O'Reilly et al., 1994).  
As noted above, inhibition of 15-PGDH resulted in significant decreases in 11-
oxo-ETE formation in both RIES and human Caco-2 cells (Figs. 3.8B and 3.8D).  15-
PGDH is down-regulated in numerous cancers (Celis et al., 2008; Tai et al., 2007; Pham 
et al., 2010; Thiel et al., 2009; Backlund et al., 2005; Tseng-Rogenski et al., 2010), which 
would cause a decrease in 11-oxo-ETE biosynthesis by preventing the in vivo conversion 
of 11(R)-HETE to 11-oxo-ETE (Fig. 3.1).  This could potentially be devastating as COX-
2 becomes up-regulated during tumorigenesis because the decreased 15-PGDH-mediated 
inactivation of PGE2 through its conversion to 15-oxo-PGE2 would result in increased in 
PGE2-mediated pro-proliferative activity (Markowitz and Bertagnolli, 2009; Wang and 
Dubois, 2010) without the counter effect of anti-proliferative oxo-ETEs.  Increased PGE2 
activity can also arise through up-regulation of the efflux ATP binding cassette (ABC) 
C4 transporter and down-regulation of the influx PG transporter - the organic anion 
transporter polypeptide (OATP) 2A1 (Fig. 3.12) (Holla et al., 2008; Meijerman et al., 
2008). 
Major metabolic pathways involved in 11-oxo-ETE inactivation involve GST-
mediated formation of 11-OEG and a pathway that could involve AKRs (Fig. 3.12) 
(Penning and Byrns, 2009).  Up-regulation of these metabolic pathways, which is often 
observed in cancer patients (Pompella et al., 2007; Meijerman et al., 2008; Penning and 
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Lerman, 2008), would reduce the amount of endogenous anti-proliferative 15-oxo-ETE 
and/or 11-oxo-ETE.  Increased metabolism of 11-oxo-ETE and 15-oxo-ETE, together 
with reduced biosynthesis through down-regulation of 15-PGDH could then potentially 
result in increased endothelial cell proliferation (Bergers and Benjamin, 2003).  The 
inhibition of endothelial cell proliferation could arise by a mechanism involving 
inhibition of the NF-κB pathway as has been suggested for 15d-PGJ2 (Scher and 
Pillinger, 2009).  It is noteworthy that 11-oxo-ETE can activate the nuclear receptor 
PPARγ (Waku et al., 2009).  PPARγ is a ligand-dependent transcription factor 
responsible for the regulation of a number of cellular events ranging from lipid 
metabolism to apoptosis (Wang and Dubois, 2008).  15d-PGJ2 is also a PPARγ agonist, 
which might account for its ability to inhibit endothelial cell proliferation (Forman et al., 
1995; Xin et al., 1999).  However, this effect is only observed with pharmacological 
amounts of 15d-PGJ2 rather than endogenous concentrations (Ide et al., 2003).  In view of 
the ability of COX-2/15-PGDH to rapidly metabolize AA to nM amounts of oxo-ETEs, 
together with the structural similarity of oxo-ETEs and 15d-PGJ2 (Fig. 3.1), it will be 
important to determine which of these activities are shared by both classes of eicosanoids. 
In summary, our studies have revealed that down-regulation of 15-PGDH inhibits 
the formation of 11-oxo-ETE and 15-oxo-ETE (an endogenous anti-proliferative 
eicosanoid).  Therefore, 15-PGDH has two quite distinct properties; it can either 
inactivate PGs or activate HETEs to oxo-ETEs that potentially exert a paracrine effect on 
endothelial cells (Fig. 3.12).  11-oxo-ETE, a member of the oxo-ETE family, (O'Flaherty 
et al., 1994; Grant et al., 2009), was observed previously as an endogenously-derived 
lipid in human atherosclerotic plaques (Waddington et al., 2001).  In that earlier study, 
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the biosynthesis of 11-oxo-ETE was not evaluated.  Furthermore, there does not appear to 
be any subsequent reports of its formation either in vitro or in vivo.  In this study, 11-oxo-
ETE was identified to be derived from COX-2/15-PGDH-mediated AA metabolism, and 
it could potentially have similar activity as 15-oxo-ETE and 15d-PGJ2 (Xin et al., 1999; 
Waku et al., 2009).  There is some evidence 11-oxo-ETE is an activator of PPARγ similar 
to 15d-PGJ2 (Forman et al., 1995; Waku et al., 2009), which suggests it could have anti-
proliferative activity similar to 15-oxo-ETE and 15d-PGJ2 (Ondrey, 2009).  Finally, 
biologically active stable analogs of 15-oxo-ETE, could potentially have efficacy as anti-
cancer agents. 
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Figure 3.12 Formation and action of COX-2-derived eicosanoids in epithelial cell 
models.  AA is released from membrane phospholipids by calcium-dependent cytosolic 
cPLA2.  The released AA undergoes COX-2-mediated metabolism to PGs or forms the 
LOX products 15(R)-HPETE, 15(S)-HPETE and 11(R)-HPETE, which are reduced to the 
corresponding HETEs.  PGE2 and PGD2 are inactivated by 15-PGDH-mediated 
conversion to their 15-oxo-metabolites.  PGE2 released from the epithelial cells can 
initiate tumor cell proliferation.  In contrast to PGE2 and PGD2, 15(S)-HETE and 11(R)-
HETE are activated by 15-PGDH-mediated oxidation to 15-oxo-ETE and 11-oxo-ETE, 
respectively.  15(R)-HETE is oxidized by an unknown DH to 15-oxo-ETE.  The oxo-
ETEs are conjugated to form OEGs, which are secreted and hydrolyzed by γ-
glutamyltranspeptidase to OECs.  15-oxo-ETE and 11-oxo-ETE are reduced back to 
HETEs in the mammalian epithelial cells (most likely by AKRs) and re-oxidized by DHs.  
Secreted 15-oxo-ETE can inhibit EC proliferation.  Therefore, down-regulation of 15-
PGDH would result in increased tumor cell proliferation and increased endothelial cell 
proliferation. 
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CHAPTER 4 
Novel Aspirin Effect on COX-2-Mediated Formation and Metabolism of 15-Oxo-
Eicosatetraenoic Acid and 11-Oxo-Eicosatetraenoic Acid 
4.1 Abstract 
COX-2 expression is upregulated in many cancers.  Inhibition of COXs by 
nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin has been recognized to 
reduce the risk of colon and breast cancers.  However, the mechanism of the anti-
tumorigenesis effect of aspirin is still uncertain.  Our previous studies showed that aspirin 
significantly induced the production of 15(R)-HETE even after 24 h of treatment with 
AA.  The present study was to determine the potential effect of aspirin on the formation 
and metabolic kinetics of AA metabolites in colorectal cancer cell models by LC-MS.  
Rat (RIES) and human epithelial cells (Caco-2) that expressed COX-2 were employed to 
study the effect of aspirin on the formation and metabolic kinetics of AA metabolites.  
RIES cells were treated with AA following the pretreatment with aspirin in comparison 
with no aspirin pretreatment, to determine the effect of aspirin on the production of 11-
HETE, 15-HETE enantiomers, 15-oxo-ETE and 11-oxo-ETE formation and metabolism.  
Quantification of AA metabolites was performed using stable isotope dilution chiral LC 
coupled with ECAPCI/MS.  The quantitative analysis revealed that aspirin pretreatment 
increased the 15(R)-HETE enantiomeric excess to 61%, comparing to the 15(S)-HETE 
enantiomeric excess of 19% with only AA treatment, indicating aspirin switched the 
15(S)-lipoxygenase activity of COX-2 to 15(R)-lipoxygenase activity.  The analysis also 
demonstrated that aspirin significantly accelerated the metabolism of 11(R)-HETE, 15(S, 
R)-HETEs, 11-oxo-ETE and 15-oxo-ETE.  15-oxo-ETE generation following 15(R)-
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HETE treatment as well as 11-oxo-ETE generation following 11(R)-HETE treatment was 
also monitored by LC-EPAPCI/MS. The pretreatment of 11-hydroxysteroid-
dehydrogenase (11-HSD) inhibitor, carbenoxolone, followed by AA treatment in RIES 
cells significantly inhibited the 15(R)-HETE-mediated production of 15-oxo-ETE in a 
dose-dependent manner, indicating 11-HSD is the enzyme catalyzing the metabolism of 
15(R)-HETE to 15-oxo-ETE.  These data also established that the formation of 15-oxo-
ETE as a downstream metabolite of 15(R)-HETE in the AA metabolic pathway, and also 
suggests 11-HSD as the enzyme responsible for its biosynthesis from 15(R)-HETE.  The 
formation of 15-oxo-ETE from 15(R)-HETE after aspirin treatment, through a pathway 
that does not involve 15-PGDH, could potentially help counteract the increased pro-
proliferative activity of PGE2 in cancer. 
4.2 Introduction 
PUFAs such as AA and LA are present in many esterified lipid classes.  Free AA 
and LA can be released from esterified lipid pools by the action of specific lipases.  AA 
and LA, as free fatty acids or as esterified lipids, can be oxidized to lipid hydroperoxides 
either enzymatically by COXs (Blair, 2008) and LOs (Jian et al., 2009) or non-
enzymatically by the action of ROS (Porter et al., 1995).  The inducible COX isoenzyme, 
COX-2, is overexpressed in precursor lesions in colorectum (adenomatous polyps), breast 
(ductal carcinoma in situ), and lung (Eberhart et al., 1994; Hwang et al., 1998; Wolff et 
al., 1998; Half et al., 2002; Thun et al., 2002; Zhang and Sun, 2002; Brown and DuBois, 
2005).  Bioactive lipid mediators are increasingly being recognized as important 
endogenous regulators and biomarkers of cancer and cancer angiogenesis (Gonzalez-
Periz and Claria, 2007; Marks et al., 2007; Wang and DuBois, 2007; Kim and Surh, 
111 
 
2008; Wang and Dubois, 2010).  One of the major cascades of bioactive lipid mediator 
production involves the release of AA from membrane phospholipids followed by COX-
2-mediated formation of eicosanoids, leading to the formation of bioactive prostaglandins 
(PGs) as well as HPETEs, HETEs and thromboxanes (Jones et al., 2003; Chen et al., 
2006; Lee et al., 2007).  Eicosanoids produced by COX-2 are thought to promote 
tumorigenesis by stimulating angiogenesis such as PGE2 (Cha et al., 2006).  The roles 
and the metabolism pathways of COX-2-mediated lipid hydroperoxide formation of 
HETEs as well as the novel bioactive family of oxo-ETEs in colon cancer progression 
have been largely ignored.   
Although NSAIDs, which target COX enzymes, are still among the most 
promising chemopreventive agents for cancer, cardiovascular and gastrointestinal side 
effects have dampened enthusiasm for their use as chemopreventive agents (Wang and 
Dubois, 2010).  Aspirin, also known as acetylsalicylic acid, is a widely used anti-
infammatory drug for more than 100 years, and is the only treatment combining the 
benefit of protection against cardiovascular disease with the potential to reduce the risk of 
some types of cancer (Cuzick et al., 2009).  Aspirin is a non-selective COX-1/COX-2 
inhibitor, which acetylates the enzymes and inhibits the conversion of AA to 
thromboxanes and PGs.  Clinical studies showed that low dose aspirin (e.g. 100 mg) 
selectively inhibits thromboxane synthesis in platelets where COX-1 is constitutively 
expressed, and only small amounts of the drug survive reach the systemic circulation 
(Cuzick et al., 2009).  Higher doses of aspirin (e. g. 500 mg) were shown to reach the 
systemic circulation and inhibit PGE2 production in gastric epithelium and PGI2 synthesis 
in vascular endothelial cells (Cuzick et al., 2009).  A large body of evidence supports an 
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antitumor effect of aspirin on colorectal cancer (Cuzick et al., 2009), including two 
random trials of 300 mg, 500 mg, or 1200 mg daily, which showed a decrease in cancer 
incidence (Flossmann and Rothwell, 2007).  Additionally, observational evidence of a 
chemopreventive effect of aspirin has been reported for esophageal, gastric, lung, breast, 
and prostate cancer (Schreinemachers and Everson, 1994; Bosetti et al., 2006).  The aim 
of the present study was to determine whether could modulated the formation of HETEs 
and oxo-ETEs in rat and human colon cancer cell lines that expressed COX-2. 
4.3 Materials and Methods 
4.3.1 Materials – AA (peroxide-free), 15(S)-HPETE, 15(S)-HETE, 15-oxo-ETE, [2H8]-
15(S)-HETE, [2H6]-5-oxo-AA (peroxide-free), 11(R)-HPETE, 11(R)-HETE, 15-oxo-ETE, 
[2H8]-15(S)- HETE, [2H6]-5-oxo-ETE, [2H8]-12(S)-HETE, and [2H4]-PGE2 were 
purchased from Cayman Chemical Co. (Ann Arbor, MI).  All chemicals, PFB bromide, 
aspirin, carbenoxolone disodium salt, and FBS were purchased from Sigma-Aldrich (St. 
Louis, MO).  RPMI-1640 media, EMEM, D-glucose, L-glutamine, penicillin, and 
streptomycin were supplied by Invitrogen (Carlsbad, CA).  High performance LC grade 
water, hexane, methanol, isopropanol and dichloromethane were obtained from Fisher 
Scientific (Fair Lawn, NJ).  Gases were supplied by BOC Gases (Lebanon, NJ).  Caco-2 
cells were purchased from ATCC (Manassas, VA).  RIES cells were a kind gift from Dr. 
Raymond N. DuBois (University of Texas M. D. Anderson Cancer Center, Houston, TX).  
Statistical analyses and kinetic plots were performed using GraphPad software (v5.01, 
GraphPad Software Inc., La Jolla, CA).  BCA protein assay reagent was obtained from 
Pierce Biotechnology (Rockford, IL).   
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4.3.2 LC-MS Analysis of Eicosanoids - Normal phase chiral LC-ECAPCI/MS analyses 
for PFB-derivatized eicosanoids were conducted using a Finnigan TSQ Quantum Ultra 
AM spectrometer (Thermo Electron, San Jose, CA) as described in Chapter 2.  The 
following MRM transitions were monitored with PFB-derivatized eicosanoids: 11-oxo-
ETE (m/z 317 → 165), 15-oxo-ETE (m/z 317 → 113), [2H6]-5-oxo-ETE (m/z 323 → 
279), 15-HETEs (m/z 319 → 219), [2H8]-15(S)-HETE (m/z 327 → 226), 11-HETEs (m/z 
319 → 167), and [2H8]-12(S)-HETE (m/z 327 → 184). 
4.3.3 Cell Culture and Treatment - RIES cells and Caco-2 cells were cultured and 
maintained as described in Chapter 3.   
4.3.4 AA Treatment of RIES cells – RIES cells were cultured as described above.  The 
media was removed and replaced with serum-free RPMI 1640 containing peroxide-free 
AA (10 µM final concentration).  The final concentration of ethanol in the culture media 
was less than 0.1 %.  Cells were then incubated for 5 min, 15 min, 30 min, 40 min, 1 h, 3 
h and 6 h at 37 oC.  After each incubation, the extraction, analysis and concentration 
calculations of eicosanoids were performed following the procedures as described in 
Chapter 3.  
4.3.5 AA Treatment of RIES Cells with Aspirin - RIES cells were cultured as 
described above until almost confluent.  The media was removed and replaced with 
serum-free RPMI-1640 containing aspirin (200 µM final concentration).  The final 
concentration of ethanol in the culture media was less than 0.1 %.  Cells were then 
incubated for 3 h at 37 oC followed by incubation with additional AA (10 μM final 
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concentration) for 5 min, 15 min, 30 min, 1 h, 3 h and 6 h at 37 oC. Lipid extractions 
from cell culture media (3 ml) were performed as described in Chapter 3.  
4.3.6 15(R)-HETE Treatment of RIES Cells - RIES cells were cultured as described 
above until almost confluent.  The media was removed and replaced with serum-free 
RPMI-1640 containing 15(R)-HETE (100 nM final concentration).  The final 
concentration of ethanol in the culture media was less than 0.1 %.  Cells were then 
incubated for 5 min, 15 min, 30 min, 1 h, 3 h and 6 h at 37 oC.  Cells and media were then 
harvested for further analysis.  Extraction and quantitation of 15(R)-HETE and 15-oxo-
ETE from cell culture media (3 ml) were performed as described in Chapter 3. 
4.3.7 15(R)-HETE of RIES Cells with 11-HSD Inhibitor Carbenoxolone - RIES cells 
were cultured as described above until almost confluent.  The media was removed and 
replaced with serum-free RPMI-1640 containing various doses of carbenoxolone (0 µM, 
10 µM or 100 µM final concentrations).  Cells were then incubated for 3 h or 24 h at 37 
oC followed by incubation with additional 15(R)-HETE (50 nM final concentration) for 
10 min.  Extraction and quantitation of 15(R)-HETE and 15-oxo-ETE from cell culture 
media (3 ml) were performed as described in Chapter 3.  
4.3.8 AA or 11(R)-HETE Treatment of Caco-2 Cells - Caco-2 cells were cultured as 
described above.  AA (10 μM final concentration) and 11(R)-HETE (50 nM final 
concentration) in ethanol was added to the media and cells were incubated for 5 min, 15 
min, 30 min, 1 h, 3 h and 6 h at 37 ºC.  The final concentration of ethanol in the culture 
media was less than 0.1 %.  Cells and media were then harvested for further analysis.  A 
portion of cell supernatant (3 ml) was transferred into a glass tube and adjusted to pH 3 
with 2.5 N HCl.  Extraction of 15(R,S)-HETEs, 15-oxo-ETE, 11(R,S)-HETEs and 11-
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oxo-ETE from cell culture media and LC-ECAPCI/MRM/MS analyses were performed 
as described in Chapter 3.  Cell numbers were counted by a hemocytometer. 
4.4 Results 
4.4.1 Effect of Aspirin on AA-mediated Production of HETEs in RIES Cells - RIES 
cells were incubated with 10 µM AA for 6 h and LC-ECAPCI/MRM/MS analyses of the 
RIES cell supernatants was conducted.  This demonstrated the secretion of 15-oxo-ETE 
(rt 7.7 min) as well as its potential precursors 15(R)-HETE (rt, 11.8 min) and 15(S)-
HETE (rt, 15.1 min) within 5 min of AA treatment (Fig. 4.1A).  The chromatograms also 
revealed the presence of 11-oxo-ETE (rt, 7.6 min) and 11(R)-HETE (rt, 10.6 min) (data 
not shown).  When RIES cells were incubated with 10 µM AA for a period of 6 h 
following 200 µM aspirin pretreatment, the LC-ECAPCI/MRM/MS analyses of the RIES 
cell supernatants demonstrated the secretion of 15-oxo-ETE (rt 7.8 min) as well as its 
potential precursors 15(R)-HETE (rt, 11.9 min) and 15(S)-HETE (rt, 15.2 min) within 5 
min of AA treatment (Fig. 4.1B).  The chromatogram showed that the ratio of 15(R)-
HETE to 15(S)-HETE in the cells with aspirin pretreatment was much higher than that in 
only AA treatment.  The chromatograms also revealed the presence of 11-oxo-ETE (rt, 
7.6 min) and 11(R)-HETE (rt, 10.6 min) (data not shown).  
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 Figure 4.1 LC-MRM/MS analysis of 15(R,S)-HETE and 15-oxo-ETE derived from 
AA in RIES cells.  (A) Representative chromatograms of COX-2-derived 15(R,S)-HETE 
and 15-oxo-ETE released by RIES cells after 5-min treatment with 10 μM AA.  (B) 
Representative chromatograms of 15(R,S)-HETE and 15-oxo-ETE released by RIES cells 
treated with 10 μM AA for 5 min following the treatment with 200 μM aspirin for 3 h.  
MRM chromatograms are shown for (a) 15-oxo-ETE-PFB (m/z 317 → 113), (b) 15-
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(R,S)-HETE-PFB (m/z 319 → 219), and (c) [2H8]-15(S)-HETE-PFB internal standard 
(m/z 327 → 226). 
 
4.4.2 Kinetics of 15(R, S)-HETE and 15-oxo-ETE Metabolism by RIES Cells and 
Aspirin-Treated RIES Cells - RIES cells were incubated with AA (10 µM) for 6 h.  
15(R, S)-HETE was one of the abundant metabolites of AA released by cells, as we had 
observed previously (Lee et al., 2007).  The maximum 15(R,S)-HETE concentrations was 
15.73 (± 0.55) nM within 5-min treatment of AA (Fig. 4.2A).  15(R, S)-HETE was then 
rapidly metabolized over 6 h with a half-life (t1/2) of 29.6 min and a pseudo first-order 
rate constant (k) of 0.0234 min-1 (Fig. 4.2A).  The area under curve (AUC) of 15(R, S)-
HETE metabolism was determined to be 1254.6 nmol.min/L (Fig. 4.2A).  Concomitantly, 
15-oxo-ETE in the cell media was observed to peak within 5 min of AA treatment with 
the concentration of 2.66 (± 0.03) nM, and a pseudo first-order rate constant (k) of 0.0235 
min-1 and AUC of 196.0 nmol.min/L (Fig. 4.2B).  Quantification of 15(R)- and 15(S)-
HETE revealed a 19 % enantiomeric excess of 15(S)-HETE (Fig. 4.2A). 
When RIES cells were incubated with AA (10 µM) for 6 h, with the pre-treatment 
with aspirin (200 µM) for 3 h, the maximum 15(R)-HETE concentrations was 38.69 (± 
1.90) nM within 5-min treatment of AA (Fig. 4.2C).  15(R)-HETE was then rapidly 
metabolized over 3 h with a half-life (t1/2) of 2.48 min and a pseudo first-order rate 
constant (k) of 0.2798 min-1 (Fig. 4.2C).  The area under curve (AUC) of 15(R)-HETE 
metabolism was determined to be 1428.6 nmol.min/L (Fig. 4.2C).  Concomitantly, 15-
oxo-ETE in the cell media was observed to peak within 5 min of AA treatment with the 
concentration of 7.32 (± 0.37) nM, and declined to a steady state of 0.29 (± 0.05) nM 
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after 1 h (Fig. 4.2D).  The half-life (t1/2) of 15-oxo-ETE was determined to be 3.72 min 
and the pseudo first-order rate constant (k) was 0.1862 min-1 with AUC of 186.1 
nmol.min/L (Fig. 4.2D).  Aspirin significantly accelerated the initial rate of 15(R,S)-
HETE and 15-oxo-ETE metabolism and made 15-oxo-ETE reach a steady concentration 
after 1 h.  Quantification of 15(R)- and 15(S)-HETE revealed a 61 % enantiomeric excess 
of 15(R)-HETE in the aspirin-treated RIES cells (Fig. 4.2C), compared with 19 % 
enantiomeric excess of 15(S)-HETE in only AA-treated RIES cells (Fig. 4.2A). 
        
 
 
Figure 4.2 Kinetics of 15(R, S)-HETE and 15-oxo-ETE by RIES cells.  RIES cells 
were incubated with 10 μM AA for a period of 360 min (A, B) or with 200 μM aspirin 
for 3 h followed by 10 μM AA treatment for a period of 360 min (C, D).  The media were 
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collected at different time points.  Secreted lipid metabolites present in the media were 
extracted, converted to PFB derivative, and their concentrations were determined in 
triplicate (means±S.E.M.) by stable isotope dilution chiral LC-ECAPCI/MRM/MS 
analysis. (A) Kinetic plot of 15(S, R)-HETE metabolism by RIES cells to which only AA 
was added (t1/2=29.6 min); (B) Kinetic plot of 15-oxo-ETE metabolism by only AA-
treated RIES cells (t1/2=29.5 min); (C) Kinetic plot of 15(R)-HETE metabolism by aspirin 
treated-RIES cells followed by AA treatment (t1/2=2.48 min); (D) Kinetic plot of 15-oxo-
ETE metabolism by aspirin treated-RIES cells followed by AA treatment (t1/2=3.72 min). 
 
4.4.3 Kinetics of 11(R)-HETE and 11-oxo-ETE Metabolism by RIES Cells and 
Aspirin-Treated RIES Cells - RIES cells were incubated with AA (10 µM) for 6 h.  
11(R)-HETE was the most abundant metabolite of AA released by cells at the early time 
points (< 1 h), as we had observed previously (Lee et al., 2007).  The maximum 11(R)-
HETE concentrations was 15.13 (± 0.43) nM within 5-min treatment of AA (Fig. 4.3A).  
11(R)-HETE was then rapidly metabolized over 3 h with a half-life (t1/2) of 21.6 min and 
a pseudo first-order rate constant (k) of 0.0321 min-1 (Fig. 4.3A).  The area under curve 
(AUC) of 11(R)-HETE metabolism was determined to be 904.8 nmol.min/L (Fig. 4.3A).  
Concomitantly, 11-oxo-ETE in the cell media was observed to peak within 5 min of AA 
treatment with the concentration of 1.42 (± 0.17) nM, and declined to a steady state of 
0.23 (± 0.03) nM after 3 h (Fig. 4.3B).  The half-life (t1/2) of 11-oxo-ETE was determined 
to be 32.2 min and the pseudo first-order rate constant (k) was 0.0215 min-1 with AUC of 
135.2 nmol.min/L (Fig. 4.3B).  Only trace amounts of 11(S)-HETE were observed after 
the addition of AA (Fig. 3.4Af) or 11(R)-HETE (data not shown) to the RIES cells. 
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When RIES cells were incubated with AA (10 µM) for 6 h, with the pre-treatment 
with aspirin (200 µM) for 3 h, the maximum of 11(R)-HETE concentrations was 4.07 (± 
0.16) nM within 5-min treatment of AA (Fig. 4.3C).  11(R)-HETE was then rapidly 
metabolized over 3 h with a half-life (t1/2) of 3.72 min and a pseudo first-order rate 
constant (k) of 0.1862 min-1 (Fig. 4.3C).  The area under curve (AUC) of 11(R)-HETE 
metabolism was determined to be 447.1 nmol.min/L (Fig. 4.3C).  Concomitantly, 11-oxo-
ETE in the cell media was observed to peak within 5 min of AA treatment with the 
concentration of 1.06 (± 0.34) nM, and declined to a steady state of 0.24 (± 0.03) nM 
after 1 h (Fig. 4.3D).  The half-life (t1/2) of 11-oxo-ETE was determined to be 10.72 min 
and the pseudo first-order rate constant (k) was 0.0647 min-1 with AUC of 110.1 
nmol.min/L (Fig. 4.3D).  These data suggested that besides the effect on 15(R,S)-HETE 
and 15-oxo-ETE metabolism, aspirin also caused significant acceleration of 11(R)-HETE 
and 11-oxo-ETE metabolism. 
4.4.4 Kinetics of 15(R)-HETE to 15-oxo-ETE Metabolism by RIES Cells - RIES cells 
were incubated with 15(R)-HETE (100 nM) for 6 h.  The t1/2 of 15(R)-HETE metabolism 
in the cells was determined to be 42.5 min and the pseudo first-order rate constant (k) 
was 0.0163 min-1 with an AUC of 5455.8 nmol.min/L (Fig. 4.4A).  Concomitantly, 15-
oxo-ETE in the cell media was observed to peak within 5 min of 15(R)-HETE treatment 
with the concentration of 5.56 nM, and declined to a steady state of 0.51 nM after 6 h 
(Fig. 4.4B).   The t1/2 of 15-oxo-ETE derived from the addition of 15(R)-HETE to the 
cells was determined to be 40.0 min and k was 0.0173 min-1 with an AUC of 513.5 
nmol.min/L (Fig. 4.4B).  Only trace amounts of 15(S)-HETE were observed after the 
addition 15(R)-HETE to the RIES cells (data not shown). 
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Figure 4.3 Kinetics of 11(R)-HETE and 11-oxo-ETE by RIES cells. RIES cells were 
incubated with 10 μM AA for a period of 360 min (A, B) or with 200 μM aspirin for 3 h 
followed by 10 μM AA treatment for a period of 360 min (C, D).  The media were 
collected at different time points. Secreted lipid metabolites present in the media were 
extracted, converted to PFB derivative, and their concentrations were determined in 
triplicate (means±S.E.M.) by stable isotope dilution chiral LC-ECAPCI/MRM/MS 
analysis.  (A) Kinetic plot of 11(R)-HETE metabolism by RIES cells only incubated with 
AA (t1/2=21.6 min); (B) Kinetic plot of 11-oxo-ETE metabolism by only AA-treated 
RIES cells (t1/2=32.2 min); (C) Kinetic plot of 11(R)-HETE metabolism by aspirin 
treated-RIES cells followed by AA treatment (t1/2=3.72 min); (D) Kinetic plot of 11-oxo-
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ETE metabolism by aspirin treated-RIES cells followed by AA treatment (t1/2=10.72 
min). 
 
Figure 4.4 Metabolism of 15(R)-HETE to 15-oxo-ETE by RIES cells.  RIES cells 
were incubated with 15(R)-HETE (100 nM) for a period of 360 min.  The media was 
collected at different time points.  Lipid metabolites [15(R)-HETE and 15-oxo-ETE] in 
the cell supernatant were extracted and derivatized with PFB and their concentrations 
were determined in triplicate (means ± S.E.M.) by LC-ECAPCI/MRM/MS analysis.  (A) 
Kinetic plot of 15(R)-HETE metabolism by RIES cells treated with 15(R)-HETE (100 
nM) (t1/2=42.5 min and k=0.0163 min-1); (B) Kinetic plot of 15-oxo-ETE metabolism by 
RIES cells treated with 15(R)-HETE (100 nM) (t1/2=40.0 min and k=0.0173 min-1).  
 
4.4.5 Effect of Carbenoxolone on 15(R)-HETE and 15-oxo-ETE in RIES Cells – 
Carbenoxolone (CBX) is a selective inhibitor of the 11β-HSD that oxidizes 11(S)-
hydroxyl group of prostaglandins (PGs) and 11(S)-HETE to a 11-oxo-group (Duax et al., 
2000).  RIES cells were treated with 50 nM 15(R)-HETE for 10 min, with or without the 
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15(R)-HETE was determined to be 18.48 (± 0.38) nM in the absence of carbenoxolone; 
whereas pre-treatment with 10 µM or 100 µM CBX for 24 h resulted in an increased 
level of 15(R)-HETE to 27.21 (± 1.46) nM or 32.67 (± 0.77) nM, respectively (Fig. 
4.5A).  Conversely, the level of 15-oxo-ETE was determined to be 0.86 (± 0.05) nM in 
the absence of CBX; whereas pre-treatment with CBX resulted in a decreased level of 15-
oxo-ETE to 0.54 (± 0.08) nM for 10 µM CBX and 0.33 (± 0.03) nM for 100 µM CBX 
(Fig. 4.5B).  This suggested CBX led to an increase of 15(R)-HETE (Fig. 4.5A) and a 
simultaneous inhibition of the production of 15-oxo-ETE (Fig. 4.5B), which was also 
observed when cells were pretreated with CBX for 3 h (Fig. 4.5C and D).  These data 
revealed that 15(R)-HETE was oxidized to 11-oxo-ETE by 11β-HSD in RIES cells. 
4.4.6 AA-mediated Production of HETEs in Caco-2 cells - The Caco-2 cells were 
incubated with AA as described for the Caco-2 cells for 6 h (Fig. 4.6).  A similar product 
profile was observed as for the RIES cells (Figs. 4.3A and 4.3B) with 11-oxo-ETE, 15-
oxo-ETE, 15(R)-HETE, 15(S)-HETE and 11(R)-HETE as the major AA-derived 
metabolites in human Caco-2 cells (Fig. 4.6).  However, unlike the RIES cells, a 
significant amount of 11(S)-HETE was secreted from the cells (Fig 4.6B).  The t1/2 of 
AA-derived 11(S)-HETE metabolism in Caco-2 cells was 62.0 min and the pseudo first-
order rate constant (k) was 0.0164 min-1 with AUC of 128.2 nmol.min/L (Fig. 4.6B).   
The t1/2 of 11-oxo-ETE metabolism in Caco-2 cells was 21.1 min and k was 0.0328 min-1 
with AUC of 69.1 nmol.min/L (Fig. 4.6C).  The t1/2 (=39.2 min) of AA-derived 11(R)-
HETE metabolism in Caco-2 cells (Fig. 4.6A) was longer than that in RIES cells (Fig. 
4.3A).  The k was 0.0258 min-1 and the AUC of 11(R)-HETE was 286.0 nmol.min/L 
(Fig. 4.3A). 
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4.4.7 Kinetic Analysis of 11(R)-HETE to 11-oxo-ETE Metabolism by Caco-2 Cells - 
Caco-2 cells were incubated with 11(R)-HETE (50 nM) as described above for 6 h.  The 
t1/2 of 11(R)-HETE metabolism in the cells was determined to be 27.6 min and k was 
0.00254 min-1 with AUC of 1884.0 nmol.min/L (Fig. 4.7A).  Concomitantly, 11-oxo-ETE 
in the cell media was observed to peak within 5 min of 11(R)-HETE treatment with the 
concentration of 0.10 nM, and declined to a steady state of 0.031 nM after 6 h (Fig. 
4.4B).   The t1/2 of 11-oxo-ETE derived from the addition of 11(R)-HETE to the cells was 
determined to be 19.3 min and k was 0.0360 min-1 with an AUC of 13.9 nmol.min/L (Fig. 
4.7C).  11(S)-HETE was also observed after the addition 11(R)-HETE to the Caco-2 
cells.  The maximum of 11(S)-HETE production was 2.5 nM at 5 min after addition of 
11(R)-HETE (Fig. 4.7B).  The t1/2 of 11(S)-HETE to the cells was determined to be 28.0 
min and k was 0.0248 min-1 with anAUC of 121.1 nmol.min/L (Fig. 4.7B).  These data 
suggested that there was a conversion of 11-oxo-ETE to 11(S)-HETE during the 6-h-
time-course in human epithelial colorectal adenocarcinoma Caco-2 cells.  
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Figure 4.5 Inhibition of 15(R)-HETE metabolisim to 15-oxo-ETE by 11-HSD 
inhibitor carbenoxolone (CBX) in RIES cells.  (A) Increased 15(R)-HETE level by 
RIES cells that were pretreated with 10 μM or 100 μM CBX for 24 h before the addition 
of 15(R)-HETE (50 nM) for 10 min.  (B) Inhibition of 15-oxo-ETE formation by RIES 
cells that were pretreated with 10 μM or 100 μM CBX for 24 h before the addition of 
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15(R)-HETE (50 nM) for 10 min.  (C) Increased 15(R)-HETE level by RIES cells that 
were pretreated with 10 μM or 100 μM CBX for 3 h before the addition of 15(R)-HETE 
(50 nM) for 10 min.  (D) Inhibition of 15-oxo-ETE formation by RIES cells that were 
pretreated with 10 μM or 100 μM CBX for 3 h before the addition of 15(R)-HETE (50 
nM) for 10 min.  Lipid metabolites in the cell media were extracted and derivatized with 
PFB.  15(R)-HETE and 15-oxo-ETE concentrations were determined in triplicate by 
stable isotope dilution by LC-ECAPCI/MRM/MS analysis of PFB derivatives.  Values 
presented in bar graphs are means ± S.E.M. 
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Figure 4.6 Metabolism of AA to 11(R,S)-HETE and 11-oxo-ETE by Caco-2 cells.  
(A) 11(R)-HETE formation by cells that were treated with 10 µM AA for a period of 6 h.  
(B) 11(S)-HETE formation by cells that were treated with 10 µM AA for a period of 6 h.  
(C) 11-Oxo-ETE formation by cells that were treated with 10 µM AA for a period of 6 h.  
Lipid metabolites in the cell media were extracted and derivatized with PFB.  11-Oxo-
ETE and 11(R,S)-HETE concentrations were determined in triplicate by stable isotope 
dilution LC-ECAPCI/MRM/MS analyses of PFB derivatives.  Values presented in bar 
graphs are means ± S.E.M. 
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Figure 4.7 Kinetics of 11(R, S)-HETE and 11-oxo-ETE by Caco-2 cells.  Caco-2 cells 
were incubated with 11(R)-HETE (50 nM) for a period of 6 h. (A) Kinetic plot of 11(R)-
HETE metabolism by Caco-2 cells treated with 11(R)-HETE (100 nM) (t1/2=27.3 min and 
k=0.0163 min-1); (B) Formation and metabolism of 11(S)-HETE metabolism by Caco-2 
cells treated with 11(R)-HETE (50 nM) (t1/2=28 min and k=0.0248 min-1); (C) Kinetic 
plot of 11-oxo-ETE metabolism by Caco-2 cells treated with 11(R)-HETE (50 nM) 
(t1/2=19.3 min and k=0.0360 min-1).  Lipid metabolites in the cell media were extracted 
and derivatized with PFB.  11(R,S)-HETE and 11-oxo-ETE concentrations were 
determined in triplicate by stable isotope dilution by LC-ECAPCI/MRM/MS analysis of 
PFB derivatives.  Values presented in bar graphs are means ± S.E.M.  
 
4.5 Discussion 
COX-2 is the enzyme responsible for the formation of PGs in vivo.  However, it 
also has 15-LO activity for 15(R,S)-HETE biosynthesis and 11-LO activity for the 
biosynthesis of 11(R)-HETE (Lee et al., 2007).  The enzyme expression is elevated in 
most human colorectal cancer (CRC) and is associated with worse survival among CRC 
patients (Wang and Dubois, 2010).  In addition, numerous studies have implicated the 
COX-2 pathway as an important mediator in inflammation, cardiovascular diseases, and 
neurological diseases, but very little studies have been focused on the effect of NSAIDs 
on COX-2-mediated lipid hydroperoxides.  Our recent studies on lipid peroxidation 
suggested that eicosanoids formed from COX-2- and 15-LO-1-mediated AA metabolism 
could modulate cell proliferation and might be involved in inflammatory pathways (Lee 
et al., 2007; Wei et al., 2009).  We hypothesized that aspirin as one of NSAIDs which 
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inhibited COX-2 activity would modulate the formation and metabolism of AA-derived 
15-oxo-ETE.  This could in principle confer a beneficial therapeutic effect because 15-
oxo-ETE is an anti-proliferative eicosanoid (Wei et al. 2009). 
AA-derived eicosanoids released from RIES cells with aspirin pretreatment 
followed with AA or with only AA treatment were analyzed by chiral LC-ECAPCI/MS 
methodology (Lee and Blair, 2007; Mesaros et al., 2009).  This revealed 15(R)-HETE 
and 15-oxo-ETE as the major products in aspirin-pretreated cells (Fig. 4.1 and 4.2).  
Aspirin caused a significant chirality switch of 15-HETE from 15(S)-HETE to 15(R)-
HETE (Fig. 4.1), with the enantiomeric access of 15(R)-HETE up to 61% compared to 
the 19% enantiomeric access of 15(S)-HETE in only AA-treated RIES cells (Fig. 4.2A 
and C).  In addition, 15-oxo-ETE levels released from aspirin-treated RIES cells were 3 
times higher than with only AA treatment (Fig. 4.2B and D).  Aspirin-pretreated RIES 
cells were found to significantly increase the rate of metabolism of 15(R)-HETE, 15-oxo-
ETE, 11(R)-HETE and 11-oxo-ETE by 12 times, 8 times, 6 times and 3 times, 
respectively. 
15(R)-HETE added to RIES cells was converted to 15-oxo-ETE as expected (Fig. 
4.4).  After addition of 15(R)-HETE (100 nM) to RIES cells, the half-life of 15(R)-HETE 
and 15-oxo-ETE was slightly longer than that of AA-derived 15(R)-HETE and 15-oxo-
ETE (Fig. 4.2 and 4.4).  That 15-PGDH inhibitor CAY10397 inhibited the conversion of 
15(S)-HETE to 15-oxo-ETE but did not inhibit the metabolism of 15(R)-HETE (Wei et 
al., 2009).  Therefore, 15-PGDH is not involved in the oxidation of 15(R)-HETE to 15-
oxo-ETE. 
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The present study demonstrated that 11β-HSD inhibitor carbenoxolone caused a 
decreased in the formation of 15-oxo-ETE (Fig. 4.5B) and a simultaneous increase of 
15(R)-HETE in a dose-dependent manner in RIES cells (Fig. 4.5).  In human, There are 
two isoforms of 11β-HSD, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD I) and 
11β-hydroxysteroid dehydrogenase type 2 (11β-HSD II) (Seckl, 1997).  Both types of 
11β-HSD catalyzes the conversion of inert 11-oxo-steroids (cortisone) to active 11-oxo-
steroids (cortisol), or vice versa (Seckl and Walker, 2001), thus regulating the access of 
glucocorticoids to their steroid receptors.  It was observed that human renal 11β-HSDI 
appears to function as a dehydrogenase with no significant "reverse" reductase activity 
(Gong et al., 2008).  The study in kidney by using immuno-histochemistry and Western 
blot analysis showed that 11β-HSDI was found to co-localize with COX-2 in proximal 
tubule cells, while COX-2 was not observed co-localizing with 11β-HSDII in cortical 
collecting duct (Gong et al., 2008).  The COX-2 mRNA response to IL-1α was associated 
with an approximate 18-fold increase in mRNA levels of 11β-HSDI in human ovarian 
surface epithelial cells which was considered as a compensatory anti-inflammatory 
component to the process of COX-2-mediated inflammation (Rae et al., 2004).  
Interestingly, the expression of 11β-HSD II was up-regulated in human colonic and 
Apc+/min mouse intestinal adenomas, and inhibition of 11β-HSD II suppressed colon 
carcinogenesis in mice and humans (Zhang et al., 2009).  Further studies need to be 
performed in order to confirm which specific type of 11β-HSD (I or II) involved in 
conversion of 15(R)-HETE to 15-oxo-ETE. 
Our studies have demonstrated that aspirin-mediated conversion of COX-2 into a 
15(R)-lipoxygenase results in increased formation of 15-oxo-ETE (Fig. 4.8).   In contrast 
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to 15(S)-HETE, 15(R)-HETE is converted to 15-oxo-ETE through a pathway that does 
not involved 15-PGDH.  Most likely the oxidation 15(R)-HETE is mediated through an 
11β-HSD.  The formation of 11(R)-HETE and 11-oxo-ETE was much lower than that 
observed before aspirin treatment.  The oxo-ETEs are conjugated to form OEGs, which 
are secreted and hydrolyzed by γ-glutamyltranspeptidase to OECs.  15-oxo-ETE and 11-
oxo-ETE are reduced back to HETEs in the human epithelial cells (most likely by AKRs) 
and re-oxidized by DHs.  Secreted 15-oxo-ETE is potentially anti-angiogenic through 
inhibition of EC proliferation.  11-oxo-ETE could have similar activity as 15-oxo-ETE, 
although additional studies will be required to test this possibility.  Therefore, down-
regulation of 15-PGDH would result in decreased anti-proliferative 15-oxo-ETE, 
increased pro-proliferative PGE2 and so the potential for concomitant increased tumor 
and EC proliferation.  The formation of 15-oxo-ETE from 15(R)-HETE after aspirin 
treatment, through a pathway that does not involve 15-PGDH, could potentially help 
counteract the increased pro-proliferative activity of PGE2. 
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Figure 4.8 Formation of eicosanoids and inhibition of endothelial proliferation by 
aspirin-treated COX-2 in epithelial cell models.  AA is released from membrane 
phospholipids by calcium-dependent cPLA2.  Aspirin acetylates COX-2 enzyme and 
inhibits PGs and 15(S)-HPETE formation which are derived from the released AA by 
COX-2 mediated metabolism, and this only leaves the LOX products 15(R)-HPETE and 
11(R)-HPETE as the major AA metabolits, which are reduced to the corresponding 
HETEs.  In contrast 15(S)-HETE, 15(R)-HETE is activated by 11-HSD (most likely 11-
HSD I) -mediated oxidation to 15-oxo-ETE.  11(R)-HETE is activated by 15-PGDH-
mediated oxidation to 11-oxo-ETE.  The oxo-ETEs are conjugated to form OEGs, which 
are secreted and hydrolyzed by γ-glutamyltranspeptidase to OECs.  15-oxo-ETE and 11-
oxo-ETE are reduced back to HETEs in the human epithelial cells (most likely by AKRs) 
and re-oxidized by DHs.  Secreted 15-oxo-ETE is potentially anti-angiogenic through 
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inhibition of EC proliferation.  11-oxo-ETE could also be able to inhibit EC proliferation, 
which needs to be confirmed.  Therefore, down-regulation of 15-PGDH would result in 
increased tumor cell proliferation and increased angiogenesis. 
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                                              CHAPTER 5 
General Discussion and Conclusions 
5.1 Conclusions 
The research reported in this thesis leads to a number of conclusions: 
1. From 15-LO-1-expressing mouse macrophages and primary human monocytes, 
15-oxo-ETE and 15-OEG were identified and quantified.  15-oxo-ETE was 
characterized as a metabolite of 15-PGDH.  The novel bioactivity of 15-oxo-ETE 
was identified as inhibiting HUVEC proliferation. 
2. A novel metabolite of COX-2 and 15-PGDH, 11-oxo-ETE, as well as its further 
metabolite 11-OEG were identified by LC-MS/MS analysis and targeted 
lipidomics studies.  11-oxo-ETE was quantified as AA-derived metabolite in both 
rat and human epithelial cells that expressed COX-2.   
3. Aspirin was observed to significantly stimulate the production of 15(R)-HETE 
instead of 15(S)-HETE, as well as the production of 15-oxo-ETE in COX-2 
expressing rat intestinal epithelial cells.  Aspirin was also found to accelerate the 
metabolism of 11(R)-HETE, 15(R)-HETE, 11-oxo-ETE and 15-oxo-ETE.  It was 
observed that an 11β-HSD inhibitor reduced the conversion of 15(R)-HETE to 15-
oxo-ETE in COX-2 expressing rat intestinal epithelial cells.  This suggested that 
an 11β-HSD isoform is responsible for the conversion of 15(R)-HETE to 11-oxo-
ETE.  The formation of 15-oxo-ETE from 15(R)-HETE after aspirin treatment, 
through a pathway that does not involve 15-PGDH, could potentially help 
counteract the increased pro-proliferative activity of PGE2 when 15-PGDH is 
down-regulated during tumor progression and carcinogenesis. 
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5.2 Discussion and Future Directions 
15-Oxo-ETE was shown to arise from rabbit lung 15-PGDH-mediated oxidation 
of 15(S)-HETE over twenty years ago (Bergholte et al., 1987).  Recently, our group 
identified 15-oxo-ETE as a metabolite of COX-2-mediated AA metabolism in mouse 
epithelial cell model (Lee et al., 2007).  The current study by employing targeted 
lipidomic analysis revealed the formation of 15-oxo-ETE as a 15-LO-1-mediated 
metabolite from endogenous AA in primary human monocytes and mouse macrophages 
(R15L cells).  R15L cells are a mouse macrophage cell line RAW264.7 stably transfected 
with human 15-LO-1.  It showed stable expression of 15-LO level over several passages 
with Western blot analysis (data not shown).  Stable isotope-labeled internal standards 
were added in the followed cellular experiments to facilitate the quantification of 15-oxo-
ETE as well as its upstream 15(S)-HETE metabolite.  The targeted lipidomics studies of 
cell culture medium showed a greater than 100 fold increase in the production of 15(S)-
HETE and 15-oxo-ETE.  However, this interesting AA metabolite has remained a 
pharmacological curiosity for years.  
The endothelium lining the vascular lumen plays a crucial role in cancer 
angiogenesis as well as controlling thrombosis and inflammation.  HUVECs form a 
spindle monolayer, which is characteristic of endothelial cells.  The cells stably express 
endothelial-specific markers, such as platelet-endothelial cell adhesion molecule-1 
(PECAM-1) and intracellular adhesion molecule-1 (ICAM-1).  Therefore, they have been 
widely used as model of ECs that can readily be maintained in culture (Muro et al., 
2003).  This thesis study demonstrated for the first time that 15-oxo-ETE which is 
released from macrophages can inhibit HUVEC proliferation, which could further 
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prevent endothelial growth and that in turn could lead to the inhibition of angiogenesis.  
Rapid 15-oxo-ETE uptake in these cells was verified to confirm that these biological 
effects are indeed due to 15-oxo-ETE.  It was demonstrated that the expression of 15-
PGDH is down-regulated in colon cancer (Backlund et al., 2005).  In the absence of 15-
PGDH, no 15-oxo-ETE would be formed from 15(S)-HETE and therefore its anti-
proliferative activity on endothelial cells would be lost. This could then in turn lead to 
increased tumor growth and metastasis.  Moreover, it is known that GSTs are up-
regulated in cancer so that 15-oxo-ETE-GSH-adduct formation would increase with a 
concomitant loss of macrophage-derived 15-oxo-ETE, reducing a factor that could be 
involved in preventing EC proliferation.  Therefore, identification of 15-oxo-ETE as a 
biologically active mediator in the macrophage-HUVEC model suggests that it could be a 
potential endogenous inhibitor of EC proliferation and serve to modulate tumor cell-
mediated angiogenesis.    
Both PGD2 and its dehydration end product 15d-PGJ2 are involved in the 
regulation of inflammation, via both receptor-dependent (PGD2 receptors DP1 and DP2) 
and receptor-independent mechanisms (Scher and Pillinger, 2009).  Intracellular effects 
of PGD2 and 15d-PGJ2 that may suppress inflammation include inhibition of nuclear 
factor-kappaB (NF-κB) by multiple mechanisms (IkappaB kinase inhibition and blockade 
of NF-κB nuclear binding) and activation of peroxisome proliferator-activated receptor-
gamma (PPARγ) (Scher and Pillinger, 2009).  Based on the similar chemical structure 
characteristics, we hypothesize that the biological activity of 15-oxo-ETE on endothelial 
cell inhibition could also be mediated by NF- κB and PPARγ (Scheme 5.1).  In addition, 
it was recently demonstrated that the synthetic oxo-ETE family including 5-, 9-, 11-, 12-, 
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and 15-oxo-ETE induced PPARγ activation by covalent modification (Waku et al., 2009) 
(Scheme 5.2).  And very recently, it was reported that the reduction in 15-LO activity 
with decreased levels of 15(S)-HETE and 13(S)-HODE resulting in the decreased PPARγ 
activity were observed in human lung cancer tissue and also contributed to the 
development of lung tumors induced by tobacco smoking (Yuan et al., 2010).  This could 
be attributed to the decrease of 15(S)-HETE metabolite 15-oxo-ETE which inhibits 
endothelial cell proliferation further leading to inhibition of new vessel formation. 
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Scheme 5.1 Further proposed mechanisms of oxo-ETEs on the inhibition of EC 
proliferation (Modified from Scher JU and Pillinger MH. J Investig Med. 2009;57:703). 
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Scheme 5.2 Oxo-ETE family and their GSH-adducts.  (Z)-ETEs are produced from 
enzyme-mediated lipid peroxidation which may have potential bioactivities, while (E)-
ETEs are from the ROS (reactive oxygen species). 
 
A novel metabolite of COX-2 and 15-PGDH, 11-oxo-ETE, was identified as 
secreted eicosanoids of rat and human colorectal adenocarcinoma epithelial cells (RIES 
cells and Caco-2 cells) in this study.  Quantitative studies demonstrated that 11-oxo-ETE 
was a metabolite of AA-derived 11(R)-HETE and that it was secreted into the cell media 
at nM concentrations.  It will be very intriguing to study the biological activity of 11-oxo-
ETE because of its structural similarity to 15-oxo-ETE and 15d-PGJ2.  Preliminary 
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studies have suggested that it can bind to PPARγ and that it can induce transcriptional 
regulation.  15-oxo-ETE and 11-oxo-ETE are rapidly cleared from the cells, indicating 
that 15-oxo-ETE and 11-oxo-ETE undergo further metabolism.  LC-ESI/MS analysis 
revealed the formation of 15-OEG and 15-OEC adducts as the further metabolites of 15-
oxo-ETE in R15L cells.  Similarly, 11-OEG and 11-OEC adducts were identified derived 
from 11-oxo-ETE.  However, whether 11-/15-OEG adducts and/or 11-/15-OEC adducts 
have any biological activity is not known yet.  Previous studies have shown that GSH 
adducts of AA-derived metabolites can arise and some of these GSH-adducts such as 
LTC4 and 5-oxo-7-glutathionyl-8,11,14-eicosatrienoic acid (FOG7) have potent 
biological effects (Murphy and Zarini, 2002; Blair, 2006).  These GSH-adducts can 
interact with cysteinyl LT receptors CysLT1 and CysLT2, and thus, LTC4 can stimulate 
pro-inflammatory activities including endothelial cell adherence and chemokine 
production (Bowers et al., 2000).  Similarly, FOG7 is a highly potent stimulator of 
eosinophil and neutrophil chemotaxis, which is also capable of initiating actin 
polymerization (Zarini and Murphy, 2003).  Therefore, it is plausible to speculate that 
GSH-adducts of 15-oxo-ETE and 11-oxo-ETE could have significant biological 
activities.  Further work will also be conducted to quantify 11-/15-OEG and 11-/15-OEC 
derived from 15-LO-1-expressing macrophages as well as COX-2-expressing epithelial 
cells (Scheme 5.2).  In addition, OEGs could be used as a read-out of increased lipid 
peroxidation in both 15-LO-1- and COX-2- expressing cells.   
Studies on 5-oxo-ETE indicated its receptor is coupled by a Gi/o-protein (Grant et 
al., 2009).  The oxo-ETE analog 15d-PGJ2 can engage DP1 and DP2 as its receptors, but 
its main receptors seem to be active transporters (Scher and Pillinger, 2009).  It will be 
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important to identify the receptors and/or active transporters for the oxo-ETE family and 
to reveal endogenous or exogenous agonists or antagonists of oxo-ETE receptors, which 
would shed light on its intracellular mechanism.  Oxo-ETEs could also be tested for their 
anti-angiogenic effects on the capillary endothelial cells which could be induced to form 
three-dimensional networks in vitro.  Furthermore, animal models could be employed to 
investigate the in vivo anti-angiogenic effect of oxo-ETEs including studying endothelial 
tube formation.  
Aspirin switched the chirality of the 15(S)-LO activity of COX-2 to 15(R)-LO 
activity, giving significantly high production of 15(R)-HETE and 15-oxo-ETE, and 
accelerated the metabolism of AA and its metabolites.  A more complete study on the 
effects of aspirin mechanism as well as the acceleration of PUFA metabolism could lead 
to more in depth understanding of aspirin some 100 years after it was discovered. 
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APPENDIX 
HPETE-Mediated DNA Damage by Forming DNA-Adducts 
A.1 Background 
PUFAs can be converted into lipid hydroperoxides by the action of LOs (Brash 
1999), COXs (Laneuville, Breuer et al. 1995) or ROS (Porter et al., 1995).  Lipid 
hydroperoxides undergo homolytic decomposition into bifunctional electrophiles, which 
react with DNA bases to form DNA-adducts such as heptanone-1,N6-etheno-2’-
deoxyadenosine (H-εdAdo), heptanone-3,N4-etheno-2’-deoxycytidine (H-εdCyd) and  
heptanone-1,N2-etheno-2’-deoxyguanosine (H-εdGuo) (Fig. A.1A) (Blair, 2010) (Jian 
2009).  These DNA modifications are proposed to be involved in the etiology of cancer, 
cardiovascular disease, and neurodegeneration (Spiteller, 2001; Blair, 2010).  In previous 
studies, the homolytic decomposition of 13(S)-HPODE and 5(S)-HPETE were examined 
(Jian 2009) (Fig. A.1A).  The major decomposition products were identified as HPNE, 
ONE, HNE, and EDE (Lee et al., 2000; Lee et al., 2001).  ONE was responsible for the 
formation of and H-εdGuo (Lee et al., 2000; Rindgen et al., 2000; Lee et al., 2002).  
HPNE and EDE were the precursors in the formation of E-dAdo and E-dGuo adducts 
(Lee et al., 2002; Lee et al., 2005).  On the basis of structure similarities of the HPETEs, 
11(R,S)-HPETE, 12(R,S)-HPETE and/or 15(R,S)-HPETE could also under go hemolytic 
decomposition leading to DNA-adduct formtion(Figs. A.1A and A.1B).  As mentioned in 
Chapter 2 and 3, AA is an essential fatty acid and a precursor of HETEs and oxo-ETEs, 
which are potential potent inhibitors in angiogenesis.  The first step of biosynthesis of 
HETEs and oxo-ETEs is conversion of AA into 11-HPETE and/or 15-HPETE by COX-2 
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and 15-LO.  In this study, the H-εdAdo, H-εdCyd, and H-εdGuo adducts produced from 
the reaction between calf thymus DNA and 11-HPETE, 12-HPETE or 15-HPETE in the 
presence of vitamin C were identified and analyzed by LC-MS. 
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Figure A.1 HPETE-mediated DNA damage. 
 
 
A.2 Experimental Procedure 
A.2.1 Vitamin C-Mediated Decomposition of 11-HPETE, 12-HPETE, and 15-
HPETE in the Presence of Calf Thymus DNA –A solution of 11-HPETE, 12-HPETE 
or 15-HPETE (each 50 μg, 149 nmol) in ethanol (10 μL) and vitamin C (157.4 μg, 894 
nmol) in water (10 μL) were added to calf thymus DNA (295 μg, 894 nmol) in Chelex-
treated 100 mM MOPS containing 150 mM NaCl (pH 7.4, 180 μL).  The reaction 
mixture was sonicated for 15 min at room temperature, incubated at 60 oC for 24 h.  
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DNA-adducts from the reaction mixture was precipitated and DNA hydrolysis was 
performed.  DNA was dissolved in 300 μL of 10 mM MOPS and 100 mM MgCl2, pH 7.4 
(chelex-treated).  DNase I (2.5 μg) was added, the samples were incubated at 37 oC for 
1.5 h.  At the end of the incubation, 45 μL chelex-treated 0.2 M glycine buffer (pH 10) 
and phosphodiesterase (0.5 units) were added, and the samples were incubated at 37 °C 
for 2 h.  Then 45 μL Tris-HCl (50 mM, pH 7.4) and shrimp alkaline phosphatase (15 
units) were added, and the samples were incubated for 2 h.  An aliquot (100 μL) of the 
hydrolyzed DNA was taken for LC-UV base analysis.  DNA hydrolysis products were 
analyzed with LC gradient system A.1 by monitoring the UV absorbance at 260 nm. The 
quantitation of DNA bases was achieved through constructing standard curves of known 
amounts of H-εdGuo, H-εdAde and H-εdCyd in the range of 0.005 mg/mL to 0.25 
mg/mL.  Blank reaction solution (pH 7.4, 200 μL) was prepared, spiked with the 
following amounts of authentic DNA-adducts standards (H-εdAdo, H-εdCyd and H-
εdGuo): 10, 20, 50, 100, 200, 500 and 1000 pg.  A mix of internal standards [15N5]-H-
εdAdo, [15N3]-H-εdCyd and [15N5]-H-εdGuo, 2 ng each, was added to each reaction and 
blank sample.  The samples were then loaded onto Supelclean LC-18 SPE columns (0.5 g) 
that had been preconditioned with ACN (7.5 mL) followed by water (7.5 mL). The 
columns were then washed with water (2.5 mL) and methanol/water mixture (0.5 mL, 
5:95 v/v).  Adducts were eluted with ACN/water mixture (3 mL, 1:1 v/v).  The eluted 
samples were evaporated to dryness under nitrogen and reconstituted in 100 μL 
water/acetonitrile (94:6).  An aliquot of the sample (20 μL) was injected into LC-
MRM/MS system for analysis.  
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A.2.2 LC-MS Analysis of HPETE-Mediated DNA-adducts – LC-UV DNA base 
analysis and LC-ESI/MRM/MS analysis for DNA adduct were conducted on Hitachi L-
2200 Autosamplers equipped with Hitachi L-2130 Pump (Hitachi, San Jose, CA).  For 
LC gradient system A.1 for DNA base analysis, solvent A was water and solvent B was 
ACN.  The gradient condition was as follows: 0 % B at 0 min, 0 % B at 3 min, 13% B at 
15 min, 100 % B at 20 min, 100 % B at 22 min, 0 % B at 25 min, followed by 
equilibration for 5 min, employing a Phenomenex Luna C8 column (250 mm × 4.6 mm 
i.d., 5 μm; Phenomenex, Inc., Torrance, CA) with a flow rate of 1 mL/min.  The 
separation for LC-MS analysis employed a Luna C18 column (150 × 4.6 mm i.d., 3 μm; 
Phenomenex, Torrance, CA).  For LC-ESI/MRM/MS analysis for DNA adduct, solvent 
A was 5 mM ammonium acetate in water and solvent B was 5 mM ammonium acetate in 
acetonitrile.  The flow rate was 0.3 mL/min and the gradient was as follows: 6 % B at 0 
min, 6 % B at 2 min, 9% B at 12 min, 55 % B at 22 min, 80 % B at 30 min, 80 % B at 35 
min, 6 % B at 37 min, and 6 % B at 47 min.  Gradient elution was conducted in linear 
mode and the separation was performed at ambient temperature.  For DNA adduct 
analysis, mass spectrometry was conducted with a Thermo Finnigan TSQ Quantum Ultra 
AM Triple Quadrupole mass spectrometer (Thermo Electron, San Jose, CA) equipped 
with ESI source in positive mode.  Operating conditions for the instrument was as 
follows: vaporizer temperature at 550 oC, heated capillary temperature at 180 oC, with the 
corona discharge needle set at 18 μA.  The sheath gas (nitrogen), auxiliary gas (nitrogen) 
and ion sweep gas (nitrogen) were 30, 3 and 0 (arbitrary units), respectively.  Source CID 
collision energy was -5 eV.  CID was performed using argon as the collision gas in the 
RF-only quadrupole.  LC-ESI/MRM/MS analysis was conducted and the following 
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MRM transitions were monitored: H-εdAdo m/z 388 → 272 (collision energy, 20 eV); 
[15N5]-H-εdAdo, m/z 393 → 277 (collision energy, 20 eV); H-εdCyd m/z 364 → 248 
(collision energy, 20 eV); [15N3]-H-εdCyd, m/z 367 → 251 (collision energy, 20 eV); H-
εdGuo, m/z 404 → 288 (collision energy, 20 eV); and [15N5]-H-εdGuo, m/z 409 → 293 
(collision energy, 20 eV). 
A.3 Result and Discussion 
LC-MS analysis of the reaction of calf thymus DNA and 11-HPETE, 12-HPETE 
or 15-HPETE in the presence of vitamin C showed three types formation of hepatonone-
etheno adduct  (H-εdAdo, H-εdCyd, and H-εdGuo) for each reaction (Fig. A.2).  The 
chromatograms from LC-ESI/MRM/MS analyses demonstrated the formation of H-
εdAdo (rt, 28.7 min), H-εdCyd (rt, 29.0 min) and H-εdGuo (rt, 27.8 min) from the 
reactions between 11-HPETE with DNA (Figs. A.2Aa, A.2Ac and A.2Ae), 12-HPETE 
with DNA (Figs. A.1Ba, c and e), and 15-HPETE with DNA (Figs. A.2Ca, A.2Cc and 
A.2Ce).   The signal intensities of 11-HPETE- and 15-HPETE-mediated H-εdAdo was 
approximately 3-fold higher (1.10 x 105 and 9.30 x 104) (Figs. A.2Aa and A.2Ca) than 
the intensity of 12-HPETE-mediated H-εdAdo (3.24 x 104) (Fig. A.2Ba).  Similarly, the 
signal intensities of 11-HPETE- and 15-HPETE-mediated H-εdCyd were higher (9.90 x 
105 and 7.51 x 105) (Figs. A.2Ac and A.2Cc) than that of 12-HPETE-mediated H-εdCyd 
(2.57 x 105) (Fig. A.2Bc), while the intensities of 11-HPETE- and 15-HPETE-mediated 
H-εdGuo (6.41 x 103 and 5.15 x 103) (Figs. A.2Ae and A.2Ce) were lower than that of 
12-HPETE-mediated H-εdCyd (8.56 x 103) (Fig. A.2Be). 
The quantitative analyses revealed that 11-HPETE, 12-HPETE and 15-HPETE led 
to H-εdAdo formation of 2.6 adducts/105 bases, 0.4 adducts/105 bases and 3.4 
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adducts/105 bases respectively, H-εdCyd formation up to 7.5 adducts/105 bases, 2 
adducts/105 bases and 12.1 adducts/105 bases respectively, and H-εdGuo formation of 0.6 
adducts/105 bases, 0.6 adducts/105 bases and 1.6 adducts/105 bases respectively (Fig. A.3). 
These observations combined with the data from previous chapters indicated 
HPETE metabolism could generate DNA-adducts leading to further mutagenesis or 
undergo reduction and further oxidation to form oxo-ETEs inhibiting endothelial cell 
proliferation resulting in anti-angiogenesis (Wei et al. 2009) (Fig. A.4). 
The preliminary conclusion of this study needs to be further confirmed by 
analyzing the DNA-adduct formation of 11-HPETE, 12-HPETE and 15-HPETE reacted 
with individual DNA nucleotides (dAdo, dCyd and dGuo).  And the levels of DNA-
adduct formation of specific 11(R)-HPETE, 15(R)-HPETE and 15(S)-HPETE should also 
be determined, since they could play very important role in COX-2-mediated DNA 
damage.  In addition, the formation of the heptanone-etheno-DNA-adducts can server as 
biomarkers for oxidative stress.  A quantitative LC-MS method is being developed and 
will be employed to analyze the heptanone-etheno-DNA-adducts in human urine and 
plasma with high sensitivity and high specificity. 
 
 
 
 
 
 
 
147 
 
R
el
at
iv
e 
A
bu
nd
an
ce
(%
)
11-HPETE-mediated DNA-adducts 
A
24 26 28 30 32
retention time (min)
50
100
50
100
50
100
50
100
50
100
50
100 28.68
28.68
29.05
29.05
27.84
27.84
1.10E5
2.59E5
9.90E5
1.49E6
6.14E3
4.38E4
m/z 404 →288
m/z 388 →272
m/z 393 →277
m/z 367 →251
m/z 364 →248
m/z 409 →293
H-εdGuo
H-εdCyd
H-εdAdo
[15N5]H-εdGuo
[15N3]H-εdCyd
[15N5]H-εdAdo
(a)
(b)
(c)
(d)
(e)
(f)
12-HPETE-mediated DNA-adducts 
B
24 26 28 30
retention time (min)
50
100
50
100
50
100
50
100
50
100
50
100 28.68
28.68
29.02
29.03
27.82
27.82
3.24E4
2.81E5
2.57E5
1.55E6
8.56E3
4.74E4
H-εdGuo
[15N5]H-εdGuo
H-εdCyd
[15N3]H-εdCyd
H-εdAdo
[15N5]H-εdAdo
m/z 404 →288
m/z 388 →272
m/z 393 →277
m/z 367 →251
m/z 364 →248
m/z 409 →293
(a)
(b)
(c)
(d)
(e)
(f)
15-HPETE-mediated DNA-adducts 
C
24 26 28 30 32
retention time (min)
50
100
50
100
50
100
50
100
50
100
50
100 28.68
28.68
29.05
29.03
27.84
27.84
9.30E4
2.74E5
7.51E5
1.50E6
5.15E3
4.75E4
H-εdGuo
H-εdCyd
H-εdAdo
m/z 404 →288
m/z 388 →272
m/z 393 →277
m/z 367 →251
m/z 364 →248
m/z 409 →293
[15N5]H-εdGuo
[15N3]H-εdCyd
[15N5]H-εdAdo
(a)
(b)
(c)
(d)
(e)
(f)
R
el
at
iv
e 
A
bu
nd
an
ce
(%
)
 
 
Figure A.2 Quantitative analysis of DNA-adducts formed from 11-HPETE (A), 12-
HEPTE (B) and 15-HPETE (C). 
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Figure A.3 Quantitative analysis of DNA-adducts formed from 11-, 12- and 15-
HPETE. 
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   Figure A.4 The potential role of COX-2-derived eicosanoids in mutagenesisis and 
proliferation.   
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